var title_f18_21_18768="MUAP morphology";
var content_f18_21_18768=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F65788&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F65788&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 544px\">",
"   <div class=\"ttl\">",
"    Motor unit action potential (MUAP) morphology and needle electromyography (EMG) position",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 524px; height: 350px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The position of the EMG needle influences the morphology of the recorded MUAP. To properly assess MUAP parameters, the major spike must be as steep as possible, indicating the proximity of the needle to the motor unit. Note that needle electrode position E3 has the shortest major spike rise time and is the preferable position in which to assess the MUAP. Also note that although MUAP amplitude changes markedly with needle position (compare position E1 with E3), duration is relatively unaffected. (From D Dimitru, JA DeLisa. AAEM minimonograph #10: volume conduction. Muscle Nerve 1991;14:605. Reprinted by permission of Wiley.)",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Preston, DC, Shapiro, BE. Electromyography and neuromuscular disorders, Butterworth-Heinemann, Boston 1998. Copyright &copy; 1998 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_21_18768=[""].join("\n");
var outline_f18_21_18768=null;
var title_f18_21_18769="Joint infection";
var content_f18_21_18769=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Joint infection (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?18/21/18769/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/21/18769/contributors\" id=\"au4387\">",
"       Don L Goldenberg, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?18/21/18769/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/21/18769/contributors\" id=\"se2060\">",
"       Daniel J Sexton, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?18/21/18769/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/21/18769/contributors\" id=\"de1811\">",
"       Elinor L Baron, MD, DTMH",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?18/21/18769?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      JOINT INFECTION OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     A bacterial infection of a joint can cause a severe and potentially destructive form of arthritis, often referred to as septic arthritis. Bacterial joint infections can be caused by a number of different organisms and can occur in both natural and artificial joints (eg, after a knee replacement).",
"    </p>",
"    <p>",
"     The most common type of joint infection is caused by N. gonorrhoeae, the sexually transmitted bacteria that cause gonorrhea; this is called a gonococcal joint infection. Joint infection with other types of bacteria is called nongonococcal bacterial (septic) arthritis. Infection of an artificial joint is known as prosthetic joint infection.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      GONOCOCCAL JOINT INFECTION",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Gonococcal joint infection symptoms",
"     </span>",
"     &nbsp;&mdash;&nbsp;A person who becomes infected with gonorrhea but does not receive early treatment can develop joint pain, especially in the wrist, fingers, ankles, and toes. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/44/1730?source=see_link\">",
"      \"Patient information: Gonorrhea (Beyond the Basics)\"",
"     </a>",
"     .) This is called disseminated gonococcal infection, or DGI.",
"    </p>",
"    <p>",
"     Symptoms can also include fever (temperature &gt;100.4&ordm;F or 38&ordm;C), chills, and feeling ill. A skin rash can develop and may be mild (",
"     <a class=\"graphic graphic_picture graphicRef67183 \" href=\"UTD.htm?16/49/17171\">",
"      picture 1",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     In other people, the knees, wrists,",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     ankles become painful and swollen due to collections of pus inside the joint; this is called purulent arthritis. More than one joint may be affected at the same time.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Gonococcal joint infection diagnosis",
"     </span>",
"     &nbsp;&mdash;&nbsp;Your healthcare provider may use a syringe and needle to remove fluid from the joint to analyze it for signs of infection and bacteria. Blood tests and a test for gonorrhea are also usually recommended.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Gonococcal joint infection treatment",
"     </span>",
"     &nbsp;&mdash;&nbsp;Treatment of gonococcal joint infections generally requires intravenous (IV) or intramuscular (IM) antibiotics. Oral antibiotics may be used in selected situations. The duration of treatment depends upon the severity of the infection and varies from three days to two weeks.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H6\">",
"     <span class=\"h1\">",
"      BACTERIAL (NONGONOCOCCAL) ARTHRITIS",
"     </span>",
"    </p>",
"    <p>",
"     Nongonococcal arthritis is an infection of a joint caused by bacteria other than N. gonorrhoeae (the bacteria that causes gonorrhea). (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/50/11049?source=see_link\">",
"      \"Septic arthritis in adults\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Nongonococcal bacterial arthritis, also called septic arthritis, is a potentially dangerous form of arthritis that can destroy a joint if not treated promptly.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Bacterial arthritis symptoms",
"     </span>",
"     &nbsp;&mdash;&nbsp;Symptoms of nongonococcal arthritis usually include sudden pain and swelling in one or more joints. A fever may or may not be present.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Bacterial arthritis diagnosis",
"     </span>",
"     &nbsp;&mdash;&nbsp;A healthcare provider may use a needle and syringe to withdraw fluid from the joint. The fluid will be analyzed in a laboratory for bacteria and white blood cells. In some cases, this procedure will be done in the operating room.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Bacterial arthritis treatment",
"     </span>",
"     &nbsp;&mdash;&nbsp;Treatment of bacterial arthritis includes antibiotics, drainage of the joint fluid, and physical therapy to maintain joint motion.",
"    </p>",
"    <p>",
"     In most cases, antibiotics are given into a vein initially and then by mouth. Intravenous therapy is usually started in a healthcare provider's office or hospital. Treatment can be continued at home and monitored by a visiting or home health nurse. During home IV therapy, it is important to monitor yourself for signs of infection or inflammation at the site of the IV line (pain, redness, and swelling) and signs of a blood clot in the vein (pain and swelling in the arm or armpit). Drainage of the joint fluid may require repeated needle aspiration or, for some deep joints (eg, hip, shoulder), surgical placement of a drainage tube.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H10\">",
"     <span class=\"h1\">",
"      ARTIFICIAL JOINT INFECTION",
"     </span>",
"    </p>",
"    <p>",
"     People who have artificial joints are at risk of developing a joint infection. Approximately 0.5 to 1 percent of people with replacement joints will develop such an infection. Infections can occur early in the course of recovery from joint replacement surgery (within the first two months) or much later. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/13/21717?source=see_link\">",
"      \"Patient information: Total knee replacement (arthroplasty) (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/30/21987?source=see_link\">",
"      \"Patient information: Total hip replacement (arthroplasty) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Unfortunately, artificial joint infections are hard to treat. This is due, at least in part, to the development of a structure called a biofilm within the joint. A biofilm develops when bacteria adhere to the solid surface of the artificial joint. The biofilm can act as a kind of shield to some of the bacteria, making it difficult for the bacteria to be found and destroyed by the body's defenses or by antibiotic medications.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Artificial joint infection symptoms",
"     </span>",
"     &nbsp;&mdash;&nbsp;People who develop infections immediately after joint replacement surgery typically have pain, redness, and swelling at the joint or drainage from the wound. Those who develop infections later usually notice a gradual onset of joint pain, often without fever or other obvious signs of joint infection.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Artificial joint infection diagnosis",
"     </span>",
"     &nbsp;&mdash;&nbsp;Artificial joint infections can be difficult to diagnose because the pain is similar to that of other complications of joint replacement surgery. Analysis of the joint fluid is helpful to rule out infection.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Artificial joint infection treatment",
"     </span>",
"     &nbsp;&mdash;&nbsp;As noted above, treatment of artificial joint infections is difficult. Treatment usually includes a long course of intravenous (IV) antibiotics and surgery to remove infected tissue. In many cases, the artificial joint must be removed, at least temporarily.",
"    </p>",
"    <p>",
"     After a period of antibiotic treatment and once the infection is controlled, a new prosthesis may be placed. However, in some cases, it is not possible to replace the prosthetic joint, and surgery to fuse the bones is recommended instead. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/19/6457?source=see_link\">",
"      \"Treatment of prosthetic joint infections\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H14\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1784976653\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H2878298\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?42/3/43058?source=see_link\">",
"      Patient information: Osteoarthritis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/34/23075?source=see_link\">",
"      Patient information: Hip replacement (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?28/50/29474?source=see_link\">",
"      Patient information: Knee replacement (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/21/338?source=see_link\">",
"      Patient information: Ganglion cyst (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/63/17393?source=see_link\">",
"      Patient information: Septic arthritis (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H2878306\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/44/1730?source=see_link\">",
"      Patient information: Gonorrhea (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/13/21717?source=see_link\">",
"      Patient information: Total knee replacement (arthroplasty) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/30/21987?source=see_link\">",
"      Patient information: Total hip replacement (arthroplasty) (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/56/3976?source=see_link\">",
"      Disseminated gonococcal infection",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/14/28904?source=see_link\">",
"      Evaluation of the adult with monoarticular pain",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/57/28564?source=see_link\">",
"      Joint aspiration or injection in adults: Complications",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/43/42680?source=see_link\">",
"      Clinical manifestations and diagnosis of prosthetic joint infections",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/8/43142?source=see_link\">",
"      Pseudomonas aeruginosa skin, soft tissue, and bone infections",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/50/11049?source=see_link\">",
"      Septic arthritis in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/56/20360?source=see_link\">",
"      Synovial fluid analysis and the diagnosis of septic arthritis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/19/6457?source=see_link\">",
"      Treatment of prosthetic joint infections",
"     </a>",
"     <br/>",
"    </p>",
"    <p>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"        www.nlm.nih.gov/medlineplus/healthtopics.html",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       National Institute of Arthritis and Musculoskeletal and Skin Diseases",
"       <br/>",
"       Phone: 301-495-4484",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.niams.nih.gov/\">",
"        www.niams.nih.gov",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       American College of Rheumatology",
"       <br/>",
"       Phone: 404-633-3777",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.rheumatology.org/\">",
"        www.rheumatology.org",
"       </a>",
"       )",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?18/21/18769/abstract/1-5\">",
"      1-5",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 19, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?18/21/18769?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18769/abstract/1\">",
"      Rice PA. Gonococcal arthritis (disseminated gonococcal infection). Infect Dis Clin North Am 2005; 19:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18769/abstract/2\">",
"      Zimmerli W, Trampuz A, Ochsner PE. Prosthetic-joint infections. N Engl J Med 2004; 351:1645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18769/abstract/3\">",
"      Mathews CJ, Kingsley G, Field M, et al. Management of septic arthritis: a systematic review. Ann Rheum Dis 2007; 66:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18769/abstract/4\">",
"      Tarkowski A. Infection and musculoskeletal conditions: Infectious arthritis. Best Pract Res Clin Rheumatol 2006; 20:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18769/abstract/5\">",
"      Margaretten ME, Kohlwes J, Moore D, Bent S. Does this adult patient have septic arthritis? JAMA 2007; 297:1478.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f18_21_18769=[""].join("\n");
var outline_f18_21_18769=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           JOINT INFECTION OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           GONOCOCCAL JOINT INFECTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H6\">",
"           BACTERIAL (NONGONOCOCCAL) ARTHRITIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H10\">",
"           ARTIFICIAL JOINT INFECTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H14\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          PICTURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/49/17171\" title=\"picture 1\">",
"           Gonococcal skin lesion PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f18_21_18770="Patient information: Asthma and pregnancy (The Basics)";
var content_f18_21_18770=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?4/11/4275\">",
"         Patient information: Asthma in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?16/2/16419\">",
"         Patient information: Avoiding asthma triggers (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?9/47/9970\">",
"         Patient information: How to use your dry powder inhaler (adults) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?40/34/41506\">",
"         Patient information: How to use your metered dose inhaler (adults) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?29/43/30386\">",
"         Patient information: Inhalers (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?29/22/30052\">",
"         Patient information: Medicines for asthma (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?14/20/14660\">",
"         Patient information: Asthma and pregnancy (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?38/63/39925\">",
"         Patient information: Asthma treatment in adolescents and adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Asthma and pregnancy (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/asthma-and-pregnancy-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H18846637\">",
"      <span class=\"h1\">",
"       What is asthma?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Asthma is a lung condition that can make it hard to breathe. It can also cause wheezing (noisy breathing), coughing, or a tight feeling in the chest.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H18846644\">",
"      <span class=\"h1\">",
"       Do asthma symptoms change during pregnancy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Sometimes. During pregnancy, a woman&rsquo;s asthma symptoms can get better, worse, or stay the same.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H18846651\">",
"      <span class=\"h1\">",
"       How is asthma treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Asthma is treated with different types of medicines. These can be inhalers, liquids, or pills. Asthma medicines work in different ways. They can:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Stop symptoms quickly",
"       </li>",
"       <li>",
"        Control symptoms over time and prevent future symptoms",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Your doctor will work with you to make an asthma action plan. This is a list of instructions that tells you which medicines to take and when to take them. It also tells you when to get help or call 9-1-1 for your asthma.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H18846658\">",
"      <span class=\"h1\">",
"       Are asthma medicines safe to take during pregnancy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Many asthma medicines are safe to take during pregnancy. If your asthma medicines are not safe to take during pregnancy, your doctor will change them.",
"     </p>",
"     <p>",
"      It&rsquo;s important to take all the asthma medicines your doctor prescribes so that your asthma is well-controlled. Having asthma that is not well-controlled can lead to serious health problems for you and your baby.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H18846665\">",
"      <span class=\"h1\">",
"       Which doctors will take care of me during pregnancy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You might need more than 1 doctor to take care of you during pregnancy. One doctor will take care of your pregnancy. This doctor might also be able to take care of your asthma. If not, you will see another doctor who can take care of your asthma.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H18846672\">",
"      <span class=\"h1\">",
"       Will I have tests during pregnancy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Your doctor or nurse will probably do a breathing test to check how your lungs are working. He or she might also recommend that you use a &ldquo;peak flow meter&rdquo; at home. A peak flow meter is a device that you breathe into that can show how well your lungs are working.",
"     </p>",
"     <p>",
"      Your doctor will also do different tests to check your baby&rsquo;s health. These include blood tests and an imaging test called an ultrasound. Imaging tests create pictures of the inside of the body.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H18846679\">",
"      <span class=\"h1\">",
"       What else can I do to prevent asthma symptoms during pregnancy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;To help prevent asthma symptoms, you can:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Avoid your asthma triggers &mdash; Triggers are things that cause asthma symptoms or make symptoms worse. Common triggers are dust, mold, dogs, cats, pollen, plants, and cigarette smoke.",
"       </li>",
"       <li>",
"        Stop smoking, and avoid being near people who smoke",
"       </li>",
"       <li>",
"        Get a flu shot &mdash; A flu shot can help keep you from getting the flu. Getting the flu can cause asthma symptoms to get worse.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H18846686\">",
"      <span class=\"h1\">",
"       Will my baby be healthy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If your asthma is well-controlled during pregnancy, chances are good that it will not hurt your baby.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H18846693\">",
"      <span class=\"h1\">",
"       Can I breastfeed if I have asthma?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you have asthma, it can be especially healthy to breastfeed your baby. That&rsquo;s because babies who breastfeed have a lower chance of having episodes of wheezing during their first 2 years.",
"     </p>",
"     <p>",
"      If you plan to breastfeed your baby, let your doctor or nurse know. He or she will make sure that your asthma medicines are safe to take if you breastfeed.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H18846700\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?4/11/4275?source=see_link\">",
"       Patient information: Asthma in adults (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?29/43/30386?source=see_link\">",
"       Patient information: Inhalers (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?40/34/41506?source=see_link\">",
"       Patient information: How to use your metered dose inhaler (adults) (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?9/47/9970?source=see_link\">",
"       Patient information: How to use your dry powder inhaler (adults) (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?16/2/16419?source=see_link\">",
"       Patient information: Avoiding asthma triggers (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?29/22/30052?source=see_link\">",
"       Patient information: Medicines for asthma (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?14/20/14660?source=see_link\">",
"       Patient information: Asthma and pregnancy (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?38/63/39925?source=see_link\">",
"       Patient information: Asthma treatment in adolescents and adults (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?18/21/18770?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16119 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-D4C8FA2A70-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_21_18770=[""].join("\n");
var outline_f18_21_18770=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18846637\">",
"      What is asthma?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18846644\">",
"      Do asthma symptoms change during pregnancy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18846651\">",
"      How is asthma treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18846658\">",
"      Are asthma medicines safe to take during pregnancy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18846665\">",
"      Which doctors will take care of me during pregnancy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18846672\">",
"      Will I have tests during pregnancy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18846679\">",
"      What else can I do to prevent asthma symptoms during pregnancy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18846686\">",
"      Will my baby be healthy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18846693\">",
"      Can I breastfeed if I have asthma?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18846700\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/20/14660?source=related_link\">",
"      Patient information: Asthma and pregnancy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?4/11/4275?source=related_link\">",
"      Patient information: Asthma in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/63/39925?source=related_link\">",
"      Patient information: Asthma treatment in adolescents and adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/2/16419?source=related_link\">",
"      Patient information: Avoiding asthma triggers (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/47/9970?source=related_link\">",
"      Patient information: How to use your dry powder inhaler (adults) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?40/34/41506?source=related_link\">",
"      Patient information: How to use your metered dose inhaler (adults) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?29/43/30386?source=related_link\">",
"      Patient information: Inhalers (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?29/22/30052?source=related_link\">",
"      Patient information: Medicines for asthma (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_21_18771="Location colonic diverticula";
var content_f18_21_18771=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F62942&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F62942&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Location of colonic diverticula within the bowel wall",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 417px; height: 312px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAE4AaEDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiqemapZaoLk6fcxT/ZZ3tZwh5ilQ4ZGHUHoeeoII4INAFtjtGTn8BmlqvHe28t9PZpMpuoESSSL+JVbO1voSrDP+yfSrFABRRRQAUUUUAFFFFABRQc44AP1ooAKKKKACgCiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA57wv4j/tfUtd0u6gW21PR7oQTRLJuDxOoeKYeiup6HoysuTjJ+d9B8Rap8O/jhd2WqXs1zaz3kWnapNcMks1zC+/7DdM+1cbFkWNzkgYxySoHtXjXd4f8eeF/E0QP2e8k/sDUQqM2UmO63fhgF2TDbkg8TtXk37XGlWUWo2GqzxOZ77SLqwWQqpjV4njnjBLMACQZ8YyxOAAelAHq/xJs59N8R+E/FumBFuLW/i0q+ywQS2V1IsRDcZYpKYnUZAHzeteg15vDCnxU+AkUUstrc3Ws6OoMjEiNbwIOTtyRsmXJHP3e/StL4P+Kk8U+CdPa6nY67ZRLa6rbzFRcQ3KZjfzEBym5kZgCBweg6UAdtRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUVymr+L10fXdRsdRtxHBBp5v4Jg/+uC8MmOzZqKXxzbabbacdetbi0nuoo5H2ruSIueBkkE474BxWftYrdnYsvxEknGN77efX/h+2x2FFc1Z+MtOvdRu7O0ivJ2tTIskkcOV3Rg7l65zxgcYJ6VN4a8Vaf4hnu4LITR3FrtMscqgEBs4OQSD0PfimqkW7JkTwdeEXKUGkrN+V9jformJfG+kRLqTyfbFi0+R4ppTbP5fmK4TYrYwWJYYAOcc8Co4fHekTWnmxLdtcG5+yC0WLMzSbd2AAcYxznOPej2sO5X1DE2v7N/cdXRXJaf40S88STaV/ZWoxCO2FwZJImDA/NlSuOPu4BycngVd8N+LNO1+7urW0WeK5tlDPHMoB2nvwSPw60KpF7MVTA16acpR0STfo9joKKKKs5QooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKQsAQCQCxwMnqaWgAooooAKKKKAOd+IfhweLPBWsaIHEc11AfIlLsojnUh4nJXn5XVDx6VxXiuyuPip8GbO9s7JV16EpexWVx5kIW9hZkmt3BKMASJoeSOuc969Xry7xBb6n8NL/AFfxNoy/b/Cl3N9v1fTCpM9q5/1txbHOCDkO6N/dYgjOAAeSfAL4oxeD54fC2vw3Fr4ZuruWHTLq5+/YT78vbTnA7uDuwNpfJG1sp6R8Q4j8Pvido3jy1kkg0PVpE0vxCin93yMQXLjGFCnAZiRgAAcuc8/+054J0jVvBNz480Zla7iigkn+z5eDU7dmVUZ9pGSivuWQH7owcjaVqfAe7i+JXwg8UeAtVujcrpw+xW91JFu2wOCbdyN3LI8ZIGRgKgoA+j6K85/Z/wDEd14k+F2lyarIX1ewL6deht29ZIm2jfuJO8psZiepYmvRqACiiqkOpWM9wYIb22knGQY0lUtx14BzQBbooooAKKKKACiiigAooooAKKKKAOe8V+EdM8US2EmpibNnIXXy2A3g4yjZBypwPT61U8QeBdN1vUbq8uLm+he6WJJkhdNreW2V+8pI/AgH611lAAHTiodOLvdHVTx2IpKKhNrl28ru/wCaucfP8P8ASbrU7m+u5ryeaeOWP5mRdgkBVsMqhm4JA3FsVe8MeE7Pw7dXFxbXN3PLNFHC3nlMBUztwFVfWuiooVOKd0hzx+InB05TbW1vI5qXwppL6ZqWkzySvHqd1JfOrSAOHLBiUwBgKdvr15zmoV8E2Yt40N9qBuIZhPDdK0aSRMAV42oFwQTkFTmtHxRZzzWkV5YJu1Gwf7RAveQYw8f/AAJcj64PatLTryDUbC3vLV98E6CRG9QRn86nki3Zo0+tV401OM3ZvX1/4K++zXQwD4NtGu2uJr/U5ZJbRrK43zKftEbbvvfLkEbzjbjGBxTvDHg+y8O3b3NrdXk8jW6W378pgIpyMBVXnmuloqlTinexlLG15RcHLRhRRRVnKFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVyGp+PtL03Vtb0+7SdJtLgWdjgYmyFIVOeuXUc46119che+BbG/1rVNSvXE0t1JHLANhH2d0i8vOc/N2OOOQPrWdTnsuQ7cF9W5pfWr2tpbe91+l/wDhyzb+NtFOkWGoXl0LNb2Lzo45RlwucZYLnAz3PFXv+El0c6kLBb+JrokLtQFgCRkAsBtBxzjNcpJ8Nl+y6akWooZrWy+wyGa2LxzR7i33A4IOWPcip4fh8E1qK9/tLyoVADx2sBhaVQmzaxD7Sv8AwHPvWalW7HZOjlru1UfW2j76dO39I3oPF+gTrctFqkDLbRmWRuQAgONwOPmXPGRkVSvvH/h21sJbuO+F1HFNHA6wDLBn+6cHHGATn0B61iQ/DPytNurEanEY5LVrWKU2f71FJB+Zt+GxjoAua0tZ8D/2jNqMq6j5Ml1Haoh8jcI2gbcCfm+YH04+tHNWtt/X3jVHLFP+I2r/AIXX93td/I2X8VaIl3b2rajCJ5whjXn+MZTJxhSw6A4JqveeMNJjWZbO9tLm4hkWOSLzthTMgQ54OOT071kXngJrnWZNQfUIXe4MUlyktpvDSIANyfONuducHdirT+C93h250v7fjztQN/5vk9P3ok2Y3c9MZz+FO9XXQhUsvXK+dva++nfp0NoeItKOr/2Wt7G19u2GNQThsZ2k4wDgZxnNa1c1pfh270vVrqay1MLp11dvey2r2wZy7j5gJM8LnB+7njGa6WtYOT+I4MRGlFr2Lurfj9y/X1CkZQylWAKkYIPIIpaKo5zxrR9KuNR+DfjTwHJDNd6joi3elWsdxKhkmTZ5tk/GABseEDOOUPoa82/Zq8XadpfxD1qG+T7DbeKkt5rGaWfzVadd2YTIFUeYxkfggfMu0ZJGfZ/GSjwZ42s/GkaxxaPfrFpevEyJGEBcLbXTZKg7GcozEkhHGBha8q/aS+Gul2moSeJobAJpuqFLfUJICqfYrppV2XmGKoQwLI4LIpLBickmgD0X4ayr4d+K/j3wjJHKi31wPEtnI4yZkmCLOcjgBZQFGeTz6Zr1evl3wnLrXxM8CWOtaNLFH8SfA115MUlwzCW/gCfcmycgyDcvzEgsj8qHYj6A8BeK7Pxn4at9WsVaFyTFdWsh/eWk68PDIOCGU+oGQQcYIoA6KvK/hV4D8IX3wz8K3V74U0C4uptLtpJZpdOhd5GMakszFckk9zXqlcf8Hf8Akk/g/wD7BNr/AOiloAm/4Vx4H/6E3w3/AOCuD/4mj/hXHgf/AKE3w3/4K4P/AImotb+IGjafqUulWAu9b1uPAfT9JhNxJGSwX96w+SLk8mRl45rH1G88dXVg91qeo+G/BGntCMtKTf3ET8k5kYxwqcdsOMjqQeADorbwD4OtZC9t4T8PwuRtLR6bCpx6cLVn/hEPDX/QvaP/AOAUX/xNcTa6bY+LF+xwfFvV9Smi2mWPSb6xhb158iIOoO0/xZxnnrV7/hVdt/0N/jr/AMH8/wDjQBtTfDnwVPK0k3hHw+8jHLM2nQkk/wDfNM/4Vp4G/wChO8O/+C2H/wCJrm9LvfCnw8u5rbWviVfX04PNtrWrRzSRH/dChvzyK0bX4t+B9Ws5TpXjLQ7efB2PfP5Sgg4yUdkJ/AigDT/4Vp4G/wChO8O/+C2H/wCJrC8Q+Avhlol9pGsaloul6XcxX1vHYyWytblrkv8AulCxEbju55B4XJ4XiSz17x1HBJeW9h4Z8W6Y8ieRNo181rK0ZxubZLvjJGSQPOGQPevOvjp48sNQtPCEGoabrWh3Fn4ptZ5k1WyaJfKi8wO6yjdE6jIOVc5BBHFAH0XRVDRda0vXbVrrRNSstRtlcxtLZzpMgYAEqSpIzgjj3q/QAUUUUAFFFFABXO6X/wASfxBcaWxxaXu+7s/RWyPNjH4kOP8Aeb0roqyvEmny3+nA2ZCX9s4uLVz0Ei9AfZhlT7MamS6rob0JK7hPaX4dn8vyuatFUtH1CLVdMt72EMqzLko33kboyn3BBB9xV2mnfVGUouEnGW6CiiimSFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV5Xqeu6zpHiHxt9nvWup7eOCW0sZIyw2FV3SIM/dQE5x1I5r1SioqQctnY68JiY4dyc4KSaWj9U+z7W+Z5RZ+Ldcns7WKHUrGZ7jVYLRLpY1kKxyRuSGVcLuBUYx+NP07xFqEmvabHqZjup7S41W2aeODDuIVTBVQcZOenfivVKKz9lL+Y7HmVHW1FK9+3VNdvPbY83+G/izUdb16a0u7uK6tmsVu42CqHRi+0q23gH1HJHrXpFFFaU4uKs3c4sZXhXq89OHIuy/4ZFXU71NO065vJY5ZEgjaQpCm52wM4UdzWL4c8aaB4gYLp2oR/aTwbeUmOTPoFPX8M10lc94j8G6D4hy2pafE056XEfySA/7w5P45FEufeIYd4Zpxrpp91bT1T3+9HQ0V53/AMI34u8ODPhnXBqVmvSx1UbiB6LIP/sRUtt8R47GZLXxfpN7odwx2iV0MkDH2cf4Ee9R7ZL41b+u50PLZ1FfDSVReXxf+AvX7rrzO/oqrp9/aalbLcafdQXMB6PC4cfmKtVsnc86UXF2krMgvrS3v7K4s72FJ7W4jaKWKQZV0YYZSO4IJFed+Ckjii1f4YeJg119jsj9mkluAz3+mSs8aE7QrKyAeU3A5CsD8wr0uvOfHC/Z/i58N7q3uBHcTvf2csKkAzwG3Mhz3Ko8aHHTJ9+QR83eCtWuvgx8U759SvC+mpqLaPqkcoMbmAgNBd+WAdx2gvkBjjcDgyAt9LeMPA89xqX/AAlPgO8h0rxUQm92Y/Y9RQH7lyig7xtLAOBvGRg8DHzb4z8KSfFn9o/xTp+gXi20kPmefPIpKp5EEUJGMgkGUbDgcA5+bGK9C/Zvj+I+jaBqVu1nYXehWbXMEVhdXwFxFdx7gYo2UMFQyLgh8Y3bhkZ3AHq1l4p8ZSXUNtd/D24hYzrHLcJq1tJAkZk2mUHIdgFy23YD2wOteX22tX0ngvwloWsXNwLSTR7KSLQvC4luNR1CLYoLTzYQW8RGNwGCQHAkOMU3wN+0DfX/AMTBoPijSzY29/Kltb26Rv59jcZx5coZQWySOQBj6ZNdJ4i1jw/4R1Tw14+sdSktbC+0VbC38PwW26S+hwZYfKRSNjIX5YgqAdvyk8gFO28L/EbUfD8eleHbHQfhxobbd1vZSma9YbcNumVdoY/L8wG/I5Y98nV/hb8M/h4Ydc+JGp3l/Ldu0TS3Uc0sc0hU5Zgodt5BJyW6jIAxxVl/aN1fUCYtC8N6QLuWV7SC3n1cSzGXzI40cxqo3KS+NisSeSDtUmtDxh4YXxR5CeKte1PWJ55Eljt4wkMDh/OVFtrcsViO1uJZvMdgo2cngA9D0jxZ8O/D8NxD4bfT47ZdrTtolg00IJHy73gRlye2TmuJ8Y+MPD3iqWCS68SeOtAsivyJprRQxyIePMbarSEH+63P+yMjPnPg7TbPwH46uvA/jiykv7a7tjcaLbtfRIYjKSDE8uUAY4OPmADKSilpBXrF5pviCaADQ7TWFfykuLcxahdyIhJPDyz3UW/OwfL5Z2g9wQSAeXQeCPg3Bdpc2/jXxpHcq25ZI4ZQ4bPUEWuc59K1bjwV8ItXaSzh17xrNdRRpEywW95NJHGFAVSpt2wu1QAMdBxwK6XVLa7tYpNG1D4i2mk3glbfE/i0mdflBRAXhDjLdcknB4JHynC8Q6VYzWO+/wDFvh3WLqD95apq/i0SqXDLlcLFFnIGPmY4IXoM0AcG/gLT7TWPM+GfxPs9LuIUZGj1Yy6RdJGOSC+xTKC2c5UYAA5xVnx34q+LVnp3gyLxroFvdxWmsW99ZXUKLK97Om4xxM8Lsh3BiAAoJxkZwa6iLTNWucanJot2okdp86JHFPHMojOIxdQSvKinIbcw5JU7Vwa4TXYLS3k8PQeF7i5sVOv2gtBDveISAEmTJQNJKrOvSAgAgAkMoIBrz/E/SNc1Oy1qDwHe+FrlrpYG13R9US0ZiwEjK7PCsMuVCnZKeQRyASa9N8BfGLV77Tg0ENv4zihAec6eBaatFFsUl3sWysh3MBmGQqcjpXm3wI8WXXhG/wDFvhPVdNttX0g3xjuYvliwxZo5CImXbsKpkiQoqhMEgkKez8QfCrw94v8AM8Q/BrWV0HxFbhXa1gka3VN4PO0DfAWQnBX5GAwBglqAPoLw9rWneItGtNW0S7ivNPuk3xTR9GHQgg8gg5BBwQQQQCK0K+Wfhd4j1W/13UNLS8tfDvxPsnlS8tbiNBY68wd2bzI4wqiYHH7xDuZcn5hkL7/4F8X23iq0uUe3k07W7B/I1LS52BltJfTI4dG6pIOGHIwQQADp6KKKACvH/BniD4o+LfD1vrdg3gu3tLl5Vjint7rzFCSvHyRIRzsz+NewV5p+zczP8FPDLuSXdJmYnuTPISaAOV0TUfH/AId8WXvhS4vvDcms6o51a0mninNsYiXEkSgENvUqp5J+Xkks1eiWlt8QWTN3qvhRH9ItMuGH5m4HtUXxV8LTeIdEgvNI+TxFo8v23TZFC7mkA5iy3RXAA5IAYIxztxWx4H8SW3izwxZavaEATLiWPPMUg+8p7jnpnBwQe9QtHY6av72mqvVaP9H81p8vMpC18bkZ/tjw3/4KZ/8A5Jpfsvjj/oMeG/8AwUz/APyTXVUc59qs5jlfsvjj/oMeG/8AwUz/APyTTXtPHRxs1rwyPrpE5/8AbqusooA48Wfj7POu+Fsf9gW4/wDkupILPx15q/aNd8M+X3CaLPn9bqusooA5F7Px7vbZrvhfbnjOi3Gcf+BdMa08fKpY674WwBn/AJAtx/8AJddjTZv9S/8AumgDivgt4r1Hxv8ADfSvEGsQWkF3dmbK2u4JhJXQHDEkH5emT698Dt68q/Zc/wCSE+Gf+3r/ANKpa9VoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAqK5t4bqB4bqKOaFxho5FDKw9wetS0UDTad0cLqHw100XLXnh26u9Bvj/AB2bnYfqmensCBVX+0/HPhvjVdOg8Q2K9bix+ScD3THP0A/GvRKr6jfW2mafc31/MkFpbRtNNK5wqIoySfoBWTopax0/rsehHMqkly4hKov72/ykve/G3kebeIfjBpVro6zaTFJLqRlVGtLmNozGP4i3boMcE8kVGnjLwHNqNr401fVWhv4LOSCG2uHL/Y1yDKyRqDhmygMnORtXI6V5Z8ZPE8er6fB4yurV9L0WVUt9LhumAu9TXOWmSIcqnzdXIyoUj74WuQ1HS/s/gS28V+I7CK20mWRHtLXUComvRnIKRg5K/UrlTn7pzXP7SvGpqro9p4PKa+DTp1OSpvq7/J6LT5fefWHw6vdK1bwzb6toWlTabZXxaaNbiARSzKWY+awySd5LMCTyG3d60dL8O6XpWpatf6fa+RcarIst5iRykrhdu7YTtViOpUAt1OTXz1eftX6bBaWa2Xhe6musbblJ7lbdIz/sYVyw69QpHHWuL1z46+MvFdlqk9hPc6JZIqRLFp6whPL3BZZGuJfnEmZIgNm3AYE4xk9p8q1Z2PbPF3jHwV4P8RyaL4a0Sxn8T36iK6k0uCKM2qPIqFriVRkEbshOSSADt3Ka+VNDun8QX7w3/iy40uyXSbbT/NuohcS7F8oCCKNcOE3biAgJIXLZLHNy3C6bqWnakI2g0t5oLkfarvfJNKSFaaKDczF9sqSKXGPkyQQdp3/hhoFxrOr2drHpEps7O1hlW2iMZmWSSCN2nIbITefLIlchVU4AY/KAR0Hwz8C3N7eXOoagml213b2wCWsMZnNuXULIksacqxLNmBtoO1lwUMuPT9S1P+ylFl4TT+3fFuowzNHLaOZWRGKhpI2Y7Uj3Ng3EjfMybcEAKmHptxqOsXlvpmlw3GoakkUkcMFrdFbGzWTO+W4mJLSAtzgBlfaQrONyDvbPRP8AhG7m30W71HU7xrky3SpaXLrearOIxvkkcMvkwoPLjRd4X7gZumQDzjxr8KLnXpIrf+1dnjH7Qtxb21hK8sVizSB5Zridl3DK5K4CMSFH70qWrZs7WwM1npurXnhzxTqsCCI38k99rTuisfnaxG9Y3OMEiQANnsQtYmqeIY9V1rUfBfhDw22t6/CGSVYp3i0/TriOSYebIsoIuHRimZJBiXC4Cn5T2OifCTxfcpYy+KfiTqsL2sCxw2egRpYwW5XIAAUBXABI/wBWpxx0GKAG6bperaZbFfB2n60t2pBaddC06wtJ2JBJ8qTy5lA3EDJzkdW6nWste8SXVs3h/wASeHb59RW2E7m01HTLm5miLEMXhkCKI2xtyFOcEcEZM9n8G7G2kkuD4v8AHEl/MR513/bLrJKo+6rbQAVXLYGONxrPm+DN/Y6ymueGviF4ltvEAiNq17qoi1EG3J3GIIyrgbsN1IBzxk5oA5TVtH8HW0cDanYxaRM0zxsniLQU08PKGVgV1C0jRIjhGIcM/wB7ocYriPjzpNxb6XoV5b6XqizajqNvJb3NpqZ1m0uv3bBcSSATPMRs2ocoVDbTktXrtzH8ZfDd/ZMZNJ8baSkjCeKJY9PupVKMBu3Dy1UMVPy5J2gdCTXlPj/X/Cy+IPClrpOgax4F1WLxDZXckOp25trLyVZ1+0CESeV8hC5YBcgsNxGSADl/gzqVz4f065Os6ddG2utT2M80IUSTpG+YhMcNFcDkqQ6uCeFkJwPWZPC/hXxKn9t+C9U1mG/t2eWS0t7lv7RgYgo7xsZA7Y35cbnLgFVIOBV/xBp02geI4bbxBoMU9j4l1B4dUt7Hyv7O1RjHIYpFSdwbe63rESob5zkqzuMDJ8e+ErvwlPaX2mTfbPCNoqrFcy3L+bpsscmESRw4dkBOxeQIwCpMXMpAPO/irq9nfaFDqXiaaCHxzCTdaTrGnTgtdxx3G0RzLGqFHCEMkmxc7cHYysld14I8UXPj/wAFReK9LhuJ/iP4R8lLlbV2ibVLLfuML43BvMRXO3BIkXIChgD5t4yEmoeNfC1trrWk1pItykTTx/8ALw24M1wdsbZE/LMQYxgnDkSg3Nfs7/wh47TX/AC38OpxNI8lrI6lblIW/wBKt3xJukaMqu5eWZGDn7nnSgH194N8Tab4u8OWWs6PPHLb3MauyrIrtCxUMY32kgOuQCOxrar5t0Dxvpeh+L7bxz4euN3gjxTNHba7bbkH9laiRxKwONqnnc3IPzNk/uxX0lQAVw/wOijh+EHhFYkVFOnRMQowMkZJ+pJJPua7ivCfhb8S4F8AeH9A8JaNqPifXrLS4RcQ2e2K3tn8sFUmuJCEQkbsY3HKsMZGKAPdq+dfFfi688IeN/Edv4WEtnDdyiS4juF3AT8l5Y1PCh9wJyDnr0wBa8b6lJp8SS/GPxm9pLKu+38L+FnePz0IYFZWH72QPgryyICpweePJfGfxB8D6fpDaH4K8GwabHBsnW7nuw88hZgWj/dmTcdrH78mF2kYBAU4V4TnH3HZnrZPicNh8RfFw5oPT01ve3U+ibH4keINXsIj4a+H+u6hMhRZZ7+SLT7dwRzJE7kmRc9ML0/KtG3/AOFoahdO0x8I6HYunyIEnv7iMn1O6JCR7ZFfMOn/ABD8a+L7iw8LeB9W1N1NplLKOa3sGV0VvljmOHcD5WI3AnDqBgbquXHw31KHWJv+E68W+H9N1i8jjnazNs+s3wZhsCsrhm7n7ruM8jgAjWDbimzz8RGMas4wd0m7elz2yW9vrXUZotY+Ouj28wLH7LDaWEBjyMqMSM7cEjqeR+day6B4u1RRP4d+LjS25VHUtpNlcqVK9coF4J5B9PXrXhx+HGmm3tFXxiFbSy3A8AzbdzYcmXKYY7Sv3hwMepJ5ax+G9nqCNaaR4w+H9yZbhWje/klsbxmG9UTyXTgEsGKgfMdvJGKoxPqq+tfihZi3Gmar4Q1UbiZvttjcWbbf9kpJID+Kj8abL4r8b6ZdMur+AGvLKKPe93ouqRXBJHZYZRE5PsM+2a+frfSPjX4Gt4ZdJtdZXTYYI7VUsLxNTiK8fPHbuXKg47KMZPIHFa8/x8+ImgqkniDwrEIFZgVudMubOSRAPv7izKMH7wxxxjOTgA9u034ueDbmf7LqOqHQtRVFaWy1uJrGWLcCQD5gCnp/CSOnPIrtrC9tNStEubC5gu7WQZSWCQSIw9iODXzja/tJaDrVgbTxX4SFzYzYR0t54rtHIznfHKI9o6EZyME85BFUodT+Dmt6272f9tfDrXi/lJe2zGwx1UrmNnhRSVbOdudp5oA9O/Zc/wCSE+Gf+3r/ANKpa9Vryr9lz/khPhn/ALev/SqWvVaACiiigAooooAKKKKACiiigAooooAKKKKACkyN2MjJ5xS0mBuzgZHGaAFooooAKKKKAEJCgliABySe1fOXxB8caP4htj4j8TYl8E2V1JBoujrLtbxBdxtgzSdhbIRxnjqW7I3WfFHVZvFV3qmgWt7PY+D9GgefxTqVuCHZQm/7FE3divMm0HCkKTklG8p8A6Bb+PZ774i/EiU6Z4H0ZzFpemOgWBYkcbYtoUB41+WPCrmR+OqlSAT/AAi0Z/ix4h1L4mfEW7R9L0qUiO2LEQgxqsm0qSQsMYIbb/GxJYnkHyT4ieLtS+I3iq2v9T1EoZd32a1gPmpZxsRsjUKAWfJwxALHg4OABoaZqGveF9H/AOEW1W41XQ/A+pX5lkvJNKV2uMmMDzAScALEC0asx++pDdB6BpXhXwrceFhqiawsGjvPsjkjcSsTHKF2IXAkiiIYKWaSEgshJbcMgHlFh4d1K8/0iXTGhj8tbG4tVljsXykKBWaLLSuNwDsdmGKk9c7dfw18O/Fms615OjRSQWdvdiRLuGSaKOw2tuLr5hV0K8gF1ydrYORk+x6fBpdlZNNBYXQ0wOY1uLmOBI5gJCoQzSmG3dmYAj/j5A28HgZ6G1u7rV7a1trWTQ7+6aRQ9sL06wLVGxGB9lt0ht1CnaxZmwPmOTgUAef2vwst9M8O61rH9pXOsahZWlxdNd6aiiDzhGCzyXUnzS9CxSPIByD1Oex+G9pHqfgrw3pnhi30rU7g2VtJqCRBYtOsWaMHzbtEbddXJMePLJ4Iy3l5Bbrdd0q8l8DG38VeLNSTWZ9OaN9NVoTGJ5ozCAUtoRJIgeZRgblzt68E8bep8V/Cnw00+G51rwNoGiabaRxNck3KXBiWPaFbcjfO3HCKH3Yx6UAenweR4M0jUbLTJ11HxCY1vr67vnEcY3ZX7RO/CxxKIzhF6JHhRxmvMtJh8RfEe81W18Ga42m6PbSCx1TxIZfMudQuUdZGa1KOxiiHJVBIECzHC8nHN6Vp3xL+LHgm3s4/D2haH4c+0RXrfaZbqBtVAXgO25pJEYFSXbG7CkNlePRvDmkfFbw1pMOmaDonw5sLGIYWKF7sAnAGSerMcDLHJPcmgD0jwP4P0XwRoMOkeHbNba2Tl3PMkz93kbqzH9BgDAAA6CvKvP8AjX/z5+AP+/t3VW01740wzSrfeDvDd0g4Q2+oGL8fmZsj8BQB6/RXlX/CSfFn/oQdH/8AByv+FNk8TfFpY2Zfh/pDkAkKuspk+wyMUAer14v+0vZW+rJ8PtJ1CPzdPvvE9pDcRZK70bcpG4YI4ZhwR1qX/hMfjD/0S6z/APB3B/8AFVh+JIfiV431zwSNX8Ax6Ra6TrltqFzdJq9vMNiOM4QEHhSTwSTjgUAReKPh+PhmdR1PSrO48QfD++tvL13RLhxLNbxxBmimgdiDtj9M7l6jPDRy6Jqc1xBFBpXiW11Ow1RZbXTNS1GJprHU8q2LK/i+UxXI3D94AplUfMGbKn3+vnrxJplh8J/HF5LcRXNt8MvEULG5W23tFpV+CCsyIqkoSUTaVwQ2MYEaigDxHXLdIPGPhqzhs1DWt9NJ9muLoTNZwQysskM43PjyfKcbzuV4kjbauHU+36lbX11ZxxWiAXtmLO80wzSNLsubbf5Lz7WX5pUWS0l/uvGvXcAvN+K/hz/a0javNCl1rAuv+Efv7nyTayw3fnr9jvyDlW8xXtvNwDlZCV5yBorf3E3he+eKe5sda03c5M7s7R3UDLPOrBgQRJ9m85S3BlilGdr/ADgHIawdE0LxHZ67a2Hk/DvxrEbHXLJZPNgsrsOwk2kDCmJgJEOMkCTZtGAPoD4E3monwfdaHrZle/8ADd/LozTyJsM8cYVopNvYGN0A65xnJzmvKLbQYvF3hrxd4Tm+d73Totc0S2UAC3mhQRFFdhkBP3Nuck5CP90lqg/Zn1+UeLdNluLqSSLxFpDWshYKS93YNsReBlcWrRk88liTnIwAfUlfHtj8a00fwL4b0nw4reHtGtYkt7y4gt4pr6eVVUytDG7CNVLMfncliXyF+VsfYVfJGn6j4M+E3hnR7jwzoMOveOJ9Ng1G8uryTemmLKikO5xhPmkUBFCsVI3Nyu4Ay/BfwT8U/EPVLjVvEAvPD2i3JDl9QP2i+ueQDkvh84jBLvtGWyibWKj0m7vfh38D3utJ8L6JJrXioWm+6TzA0oiwD++mYbYg3HyIMsSnyfMufJfG2s+IbAWOoeK/EWpXPi9Wju7e2+0qkdpMCojZYAvlrgKCwK5fewwCrtW3ZW91HNcx6TqEkupXRn1HUtWjiSeSF4oy0spKgITG0m2MByC7bxtDQGMAT4rfDrTjodl8UPhHGRZHZezW1qQTZMCH85FUkLsYYaMZCc4AAONS/wDHPhv4veE4rq4sra1+Iem24ZbGV5I4tWjVwXt4yh3yBiNyRZ3rJjBI3MdH9naabwr4s8S/a76Cy8IzW8M8r3l0oEN5KwMMZdgimRoiWbYMcpnacINbxh8MfhJ4u8RSz2M2pQ3SoHuF8NW7zwEk4Bby4ZEVvlPC47kjPNAHK+FNY0GO/iTT7HR4bnU1W1aC4dIZrSaMgGNopVupR8yDB2qvA4zW9a6rBe2i6TJqtpqauY90Et+srvCThU8q8kVdwCDdi3OWYAKpya56/wDhZ5wksPDvxC0u7uGYWdtpfizTlW4hjBOEjM6tInBYgxxqDjI6ZGEml3vhOaLRPFo1bwNLcyxvbTiX7fok7owZVkRizLzHHyZH25yVUUAd5Z6XFodytx4cbU9Au7l/tTR2sjWqzFk+RRB5bJKvLDi1X7v3hg57Pwj478SuFguJNM11FthKZEjkjuR8wGXFqtxG3JH/ADzPX5flOPJtd07xJ4ctri+1Owhi0W4SO6+16FGs2m3KooO/aiGJWdpAS80GMKdrYAFbFtqXhbVY4L1dSvLJoXeHDQQ6pYREupKxIgQbiMBlVMYJwCCrEA39a1/wt4njvbrxf4B0C8gePdJf2Oq2pucKoJDed9nnRhlVxwefpnkNZ+Hfw11iCFNO1zW/BTXRBitNdt5BZsI87lVpdoLAyMMrMer4yDmuo+zNp1rHANR1mSCSJ0a30PWre3eGZUUMPscsUGOP4csRjOATmsPxJ4aGl6PqFxp97cWELhplS90Gfa0LRMWEk8QlaVCCNyudoIXjAKMAepfsuf8AJCfDP/b1/wClUteq15V+y5/yQnwz/wBvX/pVLXqtABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFcl8SPEFzpOkxadoUtv/AMJTrDm00qGVv+Wh+/MRtb5IkJkYkEfKB1YA9bXz/wCLfHaaNp3iP4nlUl80DQPCyOWKyKGYy3BCsylXkVmBIUlIEGRv5AOd+M0trYadpPwg8KTGe9vZBPq9zO5Z5JTiTzZ5Crnlj9okb+FIwOFIwuky2Wp6h4Y0TR7e4n8O6Q4+x2qM8ckcW4A38ybA3my+ZvQhRtD/ACYeTdFm+BfB994f0ovrscr+KvFCebqKXMhWZbVpRstz8wPm3MgJkLN8sccmQChrtrbVZNP0+3Glxw6p4h1NyumwzrG7zXOWlEjNubYIopPNbOVD3LAEYCgAo+O73S/Duia3p1wr3+uaik9qLeOXfbaXbuUGzMpEaAsU3ykYRm9FRD554F8FXyeLBquha0+k+H7zTDNqWswaVLHbqTMD5VmZ41Jc7ImDoBtOSoGAtekyaZBplldQw20uqRW+qQJdzTsom8T6oJGcW0bu+IreKYhmyrD5ZP7kjPA/ibVH8cRabodp/wAJX8T4GkW7uryKWDS9Fjc4kSFGKnaAEHmAFpFOdzbtlAHe6L4X8NeEES90Xwxo+mxadGVfW9XxDKh+UF9zLuOUdyWLLz8vGTjmb/4m+DPEFu40258W+M7xQQ1jodtdw7EP8bKvljaCFGSWILcDHTT8NfBDTp9RfXfiNcnxPr8svn7ZWf7JbEsXMccZPzIGZuG+UjHyjmvXbS2gs7WG2tIY4LaFBHFFEoVEUDAVQOAAOMCgDwey13xpqWj3dr4Q+Er+H0u47iynlkuY7GSMlVEU6PhXO0tKSAp6KVfORW94a+D897e2eqfFTXG8X6hawottazR7LS1bA3kJnEpOANzKN2MsCcY9fooAAMDA6UUUUAFFFFABRRRQAUUUUAFc18SfDQ8YeA9c0HMYkvbZkhaQkKso+aNmIBOA4UnAPArpaKAPCvDNzN8RfDMcWqzSWr+JdGaDMuQV1CykwbmJUYqBvfOCVJ8hTjB4x4nvfDfi29a90m2bU9TWx1orbt5Z+0y+Uhj2sATunhk64ZVLnJ3Mp2fhPply1/HHbzAaXoPjHWLWC3dh8kJik2hflySGZurfxMcngDl/iBqlpHodrqk93O3iCzfWbOWYuGVY1vkiZJMkElFnVkAI+vSgDT8OXMlj8YPCkdpayWlktxqFth7fYBY3EQntUHHH7xJDz82SQe4HHeAbOy8IeKNNtIknN9oHjubTQjqV/wBFvoPJjkbgg7vIBB/+KzWJ4i8b+HdJ8UyXVjcLcWlnrlnqEUNs7M7wxSTZiDH5RtwmB02kYZutc9Jfa/aeLfE2ueKba5t9Wlgt/EEFq7yIA63sBQ7WIOFiMqqCcqDjgjgA+9WYKpZjgAZJr4M8Ax22l+B9bsbqyu21LV4V+ySW1tI8kuUDCPlDG0YBMjZYH90/oC33ZqX/ACDrr/rk/wDI18ZeDri98Q2mkaXpa2ZFhpIa7muEzHZrsG2TG4k4HmMxYFBuXhyViIBSttL06w8V6db6FaxQ3mhaYY571fNHmXTNuL/IocSRROzEkHaY8YGAD1/jG8Xw54UvLSSO3tbiaKObUoVgaIKDGzWllIvm7mZySZFXkKwxlImI6HwdpljoNhdandWz2+laTGlw0UsOJtQBd/IDMrEjzJlEjB1b/VxncyMaxdP0+fx94/jtr+HzkS5msp7tAN0lyYlN5ISUdNsCYgRSNpeYMjDJ2gG18LL/AMJeEZrm78ZagY/E+n7PKsLyF3vt91tdrgptLSXM5ZS23c0cflxuQVbOzoXj34qa94Wns7bwSYPED28jNdz3MVmbRmd1iYW8u5mACg5YKDg8YwTo/By31bxb4v1vxj440jSV1TT8aLYT2u5lUwyziZ4w5JXJdVz1IB6AkHB8aeMrzw78YNR1GwUTpAqW727PsWZRGuVJwcfNyDg4x0PIrGtVVJJvuellmWzzGU6dPeMW15tNafMtTeOvE2maM0Hxj+HstzoscNqJLqOGC8j8xRiaecKxRQX2soVRjnrxXQ2J8JeJZ49I8H+JbTUbRbSLzNCuAL3T2gSQgBlYExuM/KA4PyISpVcV6rZ3MN5aQ3Vs6yQTIJI3XoykZBrznxj8H9E1fV49f0Dy9B8UQ3Ed1HfxQCaJnXPMkDHYx5PzDDA4Oex2POaadmca/gDQtHvDaxHx94GiZBLL/YF/NNp8rn7zGRVcpt6EyCMYGQMc1Vl8KajdXGqwmy8I/EiOHaPMaZNP1uHB2rHJMi8FdhG5irEhs46DrofE3xM8MX11ceM/DNtruktEhR/CmZHgYMwIMMpEkhbcudpwoXPc4ZoPj3wD470xJ/F0eiaRrkFw8Emn6rOkd3ayJIyqAzhGDd/l+6WIzkUCOPn8N6ZHpYXTtd+IWgRlmL6Xf6Ve3ltExU/IPLQb9p6HzHDAYO4GodD8P6zFqbaVENFvri5+e3nu9GOkzTQouWhInsZA3IU43kgDpgcehWmoeHrjxZqfhjSPFWuaPqukxQFg98syzRvGXUxi480OAJBuOMj5RnAFaek3PiufSI9Q0LXtA8T2okMYEts9oZhGzpJiZGdd28AZEe35TjrmgDI/Zc/5IT4Z/wC3r/0qlr1WvKv2XP8AkhPhn/t6/wDSqWvVaACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA4n4x393aeBbi10q/isNV1W4t9KtJnYgq9xMkZKYIO5UZ2GORtz2rxfTbOy8bfHK00obj4P+HULQJFNEwRDCqIC0mfmYyqTggApbjrlq9P8AFt1Hq3xs8LaJcTLFZaJp9x4iuElRWjlbP2eI5J+UoWkfd9PqPJPgjJZf8Kb8VX0cpXUte1JNLlmuHJknHkRtKEBdQXxJdMvIJJHXgUAdZZmbxHrc2suqiPU5GknWV8sLTYqiBVyoSUh47cYJIea5xnANbHw7hnm0bxR4v1DxBZ/b2ivksJo2D21hbCaQtcBAAGWWaJpNx3blRBk7TWFqN0LzSm0ma5b7fqVzHbxXMdyi/MZ2QbmG1m3StcyjGQuYSByBXQaTp1vMsOnwXdvJo125tpLd5wY4dG0/fEqj5gzh5SCzHcCspU5UYIBydxpniG2s/DVlo1rJH4g8RwSW9iv2YJF4c0sKvmy4UrtuW82Nnfjc/wAigYUN6/8ADL4e6H8OtCOn6FB++l2tdXb8y3LgYBY9gOcKOBk9ySeN+Az6h4v1DXPiLrLl01J3sNGSSKNXg0+OaRgpKHkl2KnPP7vOSCK9ioAKKKKACiiigAooooAKKKKACiiigAooooAKbI2xGchiFBOFGSfoO9Orm/iJ4tsvBHhDUdcv2Q+RGRBCzEG4mI+SIYBOWbAzg4GSeAaAPH/grZX2q3+i63OtnBb6xrOr+Ko4opxOyI8cduIiwwNwadieMjaAdpyK8VN5qHj3xDDpuq+RZ6Cuo3d2b2ztplTUftV2GIJ3fMpaA7e4EJ+8y17R8PLbUfBXhJ4LFIL3xGAnh3TIgGKC7Z5Li5Y7V2iON5mDFeCLXGQcAc34Ftrez1Qarmy1KPQ4BJby20jM0sFqpgWQk/KiP9mmkCgnm6X7wIoA5j4m6B4c8IXccfhvTVtru1uWggld/mlu4ruMqFkZmwRBICTwvIJGVAWx8bvEek+JfiBY65AH+w3fg+52JdRbXilBu02MpBw6yDbweGGQcVznjzXJZ9Y0yzsBBPa6ZHE17DFcblnvLhShkWTL5by/KDEn76tkda5y+03U7s3trK0YltbfbbPb5kjupLm7VfLj5OPvS4VRuBjYFQwYAA+6LrWZD8MZtbhjfzTo5vFS5XDZ8neA4B6+oB9ea8E+Gmlw6T4C0lEjvorScW2qXEVtHNm6kAVYhuD8F5WKooBJZPNyEVUHvfxIK2Xwy8UGMbUg0e6KjGcBYW7ZGenrXz3ZeOoND8KeF7HTPtlxrDWkSwxRuPNkkkSNBKwz8zZLQwRlWIRfMJ2haAN7XrvUta8V2vg/w7tj1ONzNc38IP2e0cKI3nIJBIhVVih4Us67iwwQ1240Cw0z4I+J9Y0me50i3g002ui3cUnkXH2WFy6OWKqQbmbc7AYDq8Y4NamgeDbjT7M+Fp5ZbjXNfiim8RXsCbYbOzRSq20fb5sPEDkud0sp6YrL8dmL4n/EXT/AVpoUn9neGdSjudSvEuP9FFoIlIhKrgb3Ysm3qvl5HBfYAet/D7wxbeCfCOm6DFdNcvFuMlzLw9xMxZ3fGT1JY4ySAMZOM18x+Mbo33i7WbgciW8lK/Tecfpivr9kVihZVJQ5UkdDgjI/An865D4u6b/afgDVFUZkt0Fyh9Nhyf8Ax3dXLi6TqQ0ex9Dw5mUcDieWUb89le+2u+2v4GJ8DV1620Cay1mxngso232kkw2tg8ldp5xnkHHc16ZWP4Q1Iav4X0u/yS09ujPk5+bGG/UGtitqUVGCSdzy8yrSr4qpUlFRbeqXfqFUNZ0bS9cthba1ptlqNuG3CK7gWZQfXDAjNX6K0OI5O2+G3gm3s0tU8JaE0CO8irLYxyYZzljlgTzgD6ADoAByPin4X3WlwrffDW6+wzW1z9vXQ7mVzp00wEmCqBgYmzJkKrCMlV3LgZHrVFAHlX7Ln/JCfDP/AG9f+lUteq15V+y5/wAkJ8M/9vX/AKVS16rQAUUUUAJzntj6UtFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHmp8698f/Em3TfLIuiWEMSAcjcLs7R9S361478NJZbD9n/TLu3gcXVhrU12wD+W8Q+yySBhu4IMbKcHAKN1wefafBshm+MnxGIdWWKDS4CAMFWEUrkHnniRTngc46g18jw634g8GjWvCWlx2N7p+ka9M0ks9urCSTyZrd9wd8bXjRyVIPT7w6EA+ixNp+k+KdL1HU7hjo2jJcalc6pcKSqjy/s8SMSgPmGMQMoHzMdxBPRuZ8TakdE+FniSXU4dRgv5ND02xjksLdoJEuHSadt7AAqN7kyA7Rg7cZbnjPCPgXVfHXxHtE+J91ILGS0vLmKwglb9yYHFsyAAkRkFAeCxPljdkmuh8Wajda58Bpor67S3l1jWNMsLi8u03hMWttulnkyPLG+MsXw3Hy4+bcAD6T8K6VbaH4a0vTLGKKG2tbaOJEiBC8KMkZJPJyeSSc8knmtWiigAooooAKKKKACiiigAooooAKKKKACiiigArwf423ltr3jez028R7rQPCVo2varErReVJc4P2W3lL5wW2t8uCWWXpg5HuGpXKWWnXV1LLFDHBE8rSTHCIFBJZj2Axk186/DW2jsfhr4Uaa4v5LvxDqcviLVJLuNPMkS1UzEluTsMsUHzHLESE8ZwACzrNuZdPsNJu7hVaGOfR5bttpZrucedqt2ryOP3cUQmUELnfIwxgDOLqOrra+Adb8QzW9vLps7BrfTQHiSK2jlhjaDfs2jhbeMbcHAznI21embWNTknE13aW2pToum2sEq4Xzb2WK5vcIdxUqbq2iwS3yxSHFcV8Ur+5iv/DOjaG7TxJeQvFFPGxuAsZUwBlwNytFJajDElmQAYIIoA4HTb7XItKu2uhbQxajfLJfNLKyNdPHLKzMVQ4MSFmbKqRuUAbsMo7r4Z6RbXHxE8L+HI3le7/tddZ1UBMGKS3s4pEUkAgKtxLdR4/Dg1xUd1d6pe6ZY3WnvOFuJLxoYY5o59SSeUOqTBGbaJHjt1UrwDKDljyPpb4FeEbiw8aeLNZ1bULfUtQtCmkmeBuBM4W7vBgKo2+fPheAQEIIHcA9nvLaG8tJ7W6jWW3nRo5I26MrDBB+oNeNp+zd4Lt7p7jTbzxBp8hYtGbW+2mLJyNpKk8YGMk9BnNe1UUAeVL8EtKAAPivxsSO51luf/HazLP8AZ70ay8/7H4w8c2/nytNL5WponmSN1dsRcscDJPNe0UUAeP8A/CiLD/oefH//AIN1/wDjdIfgPp5GG8b+PXU8FW1ZSCPQjy+RXsNFA02ndHlEfwWghQR2njzx/aQLnbDa6ssMa85OFWMAc5PSnf8ACm/+qj/En/wef/YV6rRSSSVkOc5Tk5yd29zylvg2Sp2/Ef4kBscE65kZ/wC+Kg/4Uxd/9FN+IX/g2P8AhXrtFMk8i/4Uxd/9FN+IX/g2P+FNb4MXu5dvxP8AiAF/iB1ViT9PSvX6KAOd+H3hS08D+ELDw9p089xa2fmbJJyC7b5Gc5wAOrkdK6KiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPNPA9s1v8bvidIwYC5h0mVc45AhlTIwTxlT1wfbGCfDPCNhY+IfD/iLxStnHd3d34wu7kHyQVeOKznuNmG5UNvYDkHJXkEZHu9rJJZftDX9siMttqfhuK5dj0aWC5ZMD6LKOB6815B+zzb2tv8ACrxEup25mn0HX3vLm3cnEcXlJHM2R94iMT8AnOMchiCAS+B7hI/E3hS28WfazcyItk+9ZC6+dFcK/nSE5PnSzxEEYXIUgk5Na93oV7r3wQ8eaFpVvZyXiXQnit1kaXz4oki+eLYSx3PBKqZyCybSTgmsXxHZf2J/ZptLRbW7t7owTXMlwpAkBka2lXGB5a3NuSyvzgxr8wwB6V4M1G1gaPWNNs7a2srdil3AjBGS1vDHdRTk/dKxNLIpGdoBlZWyuxgDv/BXiK08W+E9L13Tmzb30CygZyUboyH3Vgyn3Brbrx/4aQ6n4L+KWueCbvUJtT0m+tW16wnurlZJ4mMoSZXARfvyMzjGFGD1LNj2CgAooooAKKKKACiiigAooooAKKTIzjueaWgAooooA4P476nHpPwe8W3ExYK9g9sNqgndN+6XuOMuPp79Kh8EJdQXHgqxu4bkNa+Gf3jOjRhZf9GUh0YZV/lOMkEfOMdcJ+0Jph1b4MeK7YOyFLT7VlV3f6l1lxj32Yz2zmtTT5YL7xX4f1GSezlvptHukf7HMZYSVltvM8tto3KHOMnB6cdcAHnPhVYF8c6zqcVspttFuNTvLqZVBb7QJ7kFMAFyWimgORx+5UD0rxfxdPd3PjabTr22ntpo7W2trtndgIUimXJR1QSFmW3h2swJA34U5BHtmkCGCTx7ptzBDHqFzqOoJHiMyO8d1JbJkKp3EfNETjA5XdggmuB+K8FrH8RNTa0G0qPLlQJgBzLLKSPXPnZJ9Saxr1fZQckepk2AWYYuNCW2rfp/w9h37NvhqTWvGseo6kbOa00TTYJLJoGG8ea58sPgfwrFJwdp53EbmJr139nhFufBmq69Gw2+Idcv9UCA5EYaYx7Qe/8Aqs59685+Am3wto/xK1pLcJbW9jb3CeWnlqfJinJGQPvcZJ5PIJ5PPqX7PWly6P8ABfwpbTEFpLU3QIP8MztMv6SCtIyUkpLqcOIoSw9WVGe8XY9EoooqjEKKKKACiiigApCcAkAkjsO9LRQAUUVyvxB8bad4K02Ca7jnvNQvJPIsNNtF33F3Lx8qL6DIJboOOpIBAOqrN1PXtH0p0XVNVsLJnztFxcpGTjGcbiPUfnXz7481WJQH+MmpXd9dTQh08FeG5HEUKEg7rp1cFyGMZyWChlO3cOnG6p8TfCS2LnS/h58PLeWOQwpHdILl5NqqWI2QAY+bG4vhirbS/BoA+xI5EkQPG6up6MpyDTq+QbHxZ4F1qfztW8KXfgC+jhBh1zw1OV+zIwVt0qxKpVWEkKhij7vNAyvb3HwJ4u1LTtUsPDHjS7tL2a7t2udJ8QwzxiDWI9/ChABtkCSRHau8MNxz3IB6bRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAec/FeNdJ13wb4ykl222i37Wl2GkCILe8CwtIxx/A/lNj0B9q86+G0cXhX9orx94OvoVjsPEMRvLUOCvm/ek8uPAA27Zpxx08ojJIr3nxNo9v4h8O6no16XW2v7aS2kZMblDqV3LkEZGcjjqBXzj421HWLPw/4Z8fTWvmeL/AupnRtcACp9piOEL73XJWRXQqQpx9pYgcZoA3pNKaHSLi0ZkhntI302VTbNKUkhWNS5V4vnTaltdgHcW2yj5gxIvfCB5te0y80e8A03UrCa7glt541uIrqN7gm5glU4EhSQsNyHAWWMk/Oy10Ot3WnayujeJtE+zS6Trkaob5IA7W92vNpNIVQsAreZE4ZgBvCnjcK86un1Pw7rOkeIvCWjGRrK4m0q9slYtPLNHncjlOH3xLu3KGUOu4jCk0AdZqqR+IdR0+yimtLTxvp0jXXhrVLlpVS8iik/e28pXDb1UNFNFktyXxgkDs/C3j8ahr7eHfEmj3fh/xAWl8iCcl7e9VOWa2n2qJcKVYjAIyeOCRzHjC00Pxp4VTxh4dF9dv59rJNFZKGmVo5VUyhMFluYUaQqVwTgKwkTCm1q+iweMdFsLDxrp6+KtEWGO4ttc0qQx732hS7Qxvu3HlgU3Lg4wO4B6tRXhWheKPF/gvSNVuJGtvHPhHTbl1N5BfD+07GBSS4uEdQHkRQMqdrZPJx930TwZ8TPCHjO6e18O63Bc3aKGNvIjwykEZyqSBSwx1K5A49RQB2NFFFABRRRQAUUUUAFFFFABRRRQBw/wAbrx7L4T+JvJgkuJrq0NhFFGMsz3BEC45HeQf/AF+lO8H6CulL4QS3tYLGCy0SaB7aNkfbI7WzHDqoVuUfLADcTnFc/wDtD2z6xoPhrw2t0ttDrmvWtncklQTCA8hxu4J3ImAc5OBg5xXXacw0/wAU6b4fsoibGw0fLMIQgj+dEiGVwvIjk+VVGNnYECgDiLa1P/CzfGF15UUjx6nYxRLLu2qjjTmkYDO0nKgg4yGXrzx5P8U7Z7XydftIxGmo3t4s6Ssz4lEt0QV6cYg5B/vcV6j4lsYp/j3YefJbGKaG33qV3SIYnMsecYZQzquDnadjBgTtxxPxolNxouh6hJDbobrUVby9p8wRynUTGWJwSCrEgbRg7uuayrwUoO6PSynEVaGLh7KVrtJ+ja0MzwdrK2f7NPxG1p5IryeaeTSi9vvSMowjiRlDgHH79m5GcEA4IwPpD4f2cmneA/DdlMnlyW2mW0LJkHaViUEZHXpXz94702KH9nP4Z+FtGMdvJ4iudPjdCeZDMnmO3P8A01ZD7ZAr6fRVRFRFCoowABgAVpGKirI4a1apXm6lV3k+rFooopmYUUUUAFFFFABRXH/FrU9T0nwJeXOhXgsdSa4tLeK5MSy+V5tzFEW2Nw2A54NZt74P8bOsX2H4nahCQP3nnaPZSbj7YRcd/WgDsfEes2Xh3Qr/AFjVZhDY2ULTStxnAHQepPQDuSBXztrviy/0OyXx1qdqn/Cda9asbCznzJD4f0sNgTOFDE53ISSAWZ9oUYZTu+NfDni288VeDPB/iPxa+v6Pq91JdX0R0qK3VoLXZKUkMZ6MxRewyR1ryj4t6pqXjL4j6zpiT3UNne6tHpoVkEi29vaCVGnCAbpF3NcycHau1s5YqUAMr4eeBtX+JdwLia1dLCWVZZJY5GS4vWDFZLmSWQvtBbeS2H+cMsSHEpX3TS/hH4U1TQriDR9I8JXDWt/JFcwn7TM6SxuytCbrzRIpClc5TGedpBGKWraXqltc+D/BngDWG0fxDlrzU/KnSUadapbxxBZ4ud7BGiCE4DOC3y7srL4H+Emg3k+vvb+LPF51WOZrW9votUMUkso+9JgLyDyBuL8FvQGk2k7FxpylFzS0W/zOL+LPw1vPDOL7w3YxafZTabKb63XVXuBJHAozFBLLHuWQ2/m8ZIMYlULgEPh+ALzVtS8Ma18N9V+zJqUFsfEPhqe0ljMkVwp85Ui2nC7wS6/dYI7HkMMej/CO58QXXwq0XUL+ewTw+l7ptppVtaRvBLtS/WCSSfDEFnySVyyknPB6+V/sxWkWo/GbTX0+e7a10i1u7pzO2QykGFSo4x8jxZOP4cYAApkH1v8ADrxND4y8D6Nr8G0fbrdXkVAQElHyyIM84V1Zc98Zro6+fP2ctF8ZSfCnQrvSvFtha6bIs4isLnRhP5X+kSZPmLMjMSQTz03Y7A16h/ZPjz/obdC/8EEn/wAlUAdnRXI2+m+OI3zN4n0CZfQ6DKP5XVc58VPEXjLwJ4C1TxGmoeHr5rLyv9HOkzRh98qR/e+0nGN+enagD1GiqOg3supaFp19cQLbzXNtHNJCr7xGzKCVDYGcE4zgZq9QAUUUUAFFFFABRRRQAUUUUAFFFFABXlHxT0vTvD+tJ4svE2+H9TQaP4ohXhZreUeXDO/zrzG7KhYAtskOPu16vUF/Z2+oWNxZX0KT2lxG0UsUgyrowwVI9CDQB816tDrnwSl1CG+tbvxD8MNQk8t1WQsbWOZm3ZJbKON2MjCSblO5HznYnutPu4JdTttV+36TNa+bfrBPLJJdab5pEV9GSoxcW7DbMhVsgMH5IB1oL26+GE174b8b251D4a3TGLTdTZTMlhE+QLO5DFmMYGFVzkYwM4OI/M9T0rVvgp4h/tiwWTV/hdfXUdxDJZXGXtN7B18tt27OEVSc7Jk2qxBI2gHZ2y3vgG8a+0vUUNvcQedDPLIzWN7EsIInb5goLLtBYtuDhRny3Bj4CTxJefEnXXuvh14NGi6utx/pWs6fqC2d1LA8rNhY/MjWV2EZJLF8kN04Iw/EPiDVPGHhW9tPCWjaja/Dyxmjl1WSOCNlEhkDPLbxOT5HL7jFHIVA5O0FidXS/FOh6pKmnJZXtiI7dFhgjjjv4wU8xBiAzIdwb5VEnnH7uDjaSAegy6XqHijWIiuuajp+shZEsI/FekvY3wdAwKxXlo0IkRtxJQF8AbtpxWtqum2niLTNJi8eaBJqF/FcCJotXuBY3scoRRstbiFEjuVYh2A3qCzLk5wF5LwzrD3elL/ZWrxNFGJSyx3UflrLhSp8oiO2hDqScAu6ktj5gcbr6l4m07SprbU7f+1o5I2FzoF9tZJ4ht3vFuZps/LIw8rzYwBhUHBABrWFh4h0y2HiH4W+LNQ8Yad9pVLvQtYuxKxGfmRJpMNA6K6nY+Dxlt3Cn0jwJ4007xlY3ElnFdWV/ZyeTe6dex+Vc2j9g6ehHII4I9wQPO9JGg6r5eteE55bfxBqdp9psbW4uyv2x40AUxzHmQKEAaJmO0YEiJyK5xvtDeJdQHh2xt9A+K1o7XCRqWgtNfi8xnkSRCShkYMzEbiRlGWTaCUAPo6iuQ8F/EDSfFWqanpMUN9pmuaa2LnTNRjWK4VTjEgAZgyHI+ZSeqnoy56+gAooooAKKKKACiis3xHren+HNCvdY1m5S2sLOMyyyOcYHYD1YnAAHJJAHJoA8x8RWt54z+PGkR6LqEVjH4HjW4vpTF5jyvdgZtwrYADQxn5wTjfwMjjs/BbHU9a8Ra+srSW11cLY2hyhUw225SwKk8GZrjr2xwK8r+HdlqKeFLjxu8UrfEHxvcSWts0nmRJZo27YNr5BjjjhMoJUkqoUEggn1nxHqn/CG+ErWKziuNT1DEWn6fbu4Mt3ORtQMxIHYu7dlV27YoA82Es//CZeIfE0NtaPcC9aGNPMcbUh86M+a/3QC1iCFx8vmnBy2Dj+MtIOpXsGjxS/aYtB06S8vAyP5ai3tmtoPL6qMzSXTcnd+6bPQVdsJLPw/wCF7GOaWK7isDJqN5crcO0czRsuXMhLZM7LKwDEDFz3zz0XgbR7w/DHxJretJNHqviG2nuXSU5eGDy2EUfUjoWkIAXDTP8AKOgmavFo6MJLlrwl2a/M8/8ADkq+Kfil8JtBihintfCvh2HUbwNjMcj28ezgjkqfszAjpuzxivpqvDf2YdLnuLTXvFV9Esct+8GmW6gA/uLOIQhwc5G4qcg45TPpXuVNO6MqseWbj2YUUUUyAooooAKKKKAOG+NRC/D+YsQANR00knt/p0FdwTjoCfpXmv7R08lr8HtauISFlimsnQlQQCLuEjg8H8a9LoA8m8Y65qGlfFPWNQVUk03QPBdxeAYB2zyT7sEZBO5bUce3UZrw/wCEnhsXnxI0+0VbydLbS4rWea5ZojbXFyhknEeTlw8QuwrD5fm3DPBPT/FfWUNh8XtQN0w07UNR0zw/BLCAziSBd9yu1iM4DSDqAeeRyaX4GWeszWt147s9Huru71nV7jURZRXEAE6RxyxDDSOu3Mt1KSfSPpyuQC7p3ibxDf8Ajuy1PVLSWPVPB8Or2+vX0Mfl2d0Hb/RreNxy4BMbBXAI+8QTk1zXh3xbdeG7HxPLHcvE93pV0FlB5WcRO0Tj33cf8CrsvCtpr3jT4W+IdR0izjA8Q+IrjUFhE65EChYwpY4UnfD1Bxx17V57rmgalpNprkmo2ZVNIjV75A6MUVyAOAfm6jpmvPxUpqrFxWx9tw/Rwk8vrxrzSc97taJbP73+Rsa1YX3gD9nuLUj4i1XUbPX7bTTaWk1wyNpsnkPLmFg4483Y2FUYVADuxurN/Z8Fz/wj/wAVb2yvru81HSNF+xaZcZYuiFbhlWMHJUbo0IUY57Zra+PenL4P+H+i6NrMt5rty1tLJJd3l2ZZI2N1Zs4jLL90hWUEjIDd8kHm/gd40m8AfF/V7Hx5eXNr/aKC0vZbkkqt0r/upJGYArHs3AHkAOCcL930D4pqzsfSvwOubK6+EHhGTTGDQLp0UbEAj96g2yjn0kVx/Liu4rxo/DHxF4H1ufU/hNq1rBp1zJ5tz4d1TebRmIO54nXJRuIwBgdOWKgLXSaR4x8Y+TO/iD4a6palPuf2fqdnd7x3OGkjI+gBoEeg15z+0TbxXPwV8VJMu5BbLIBkj5lkRlPHoQDUmn/Fzw00sMHiBdS8LXcxbyofEFm1nvUAfMJDmPHP9/PHSovjrdQXvwQ8T3NnPFcW0tjvjlicOjqWXBBHBHvQB2nhb/kWNI/684f/AEAVp1meFv8AkWNI/wCvOH/0AVp0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUARXdtBeWk1reQxT20yNHLFKgZJEIwVYHgggkEGvINW+HmveFXvW8CtZav4Xuldrvwlq5zByxdltWwRGWyQFYbQSSc8AeyUUAfJnhaOKzg1ey+Hl1eT2t0rx6x8O9cc290qOHEotpCQdwTnj5toBYs21a821uxRdZFjqAv/s0csbSPMiWV7bKVYRidZQPLw7wksG8psr86HBX7O8f/Dzw746tkXWrPZexbTBqNtiO6gKkkbJMZwCSdpyuTnGcGuA8Z/C3xbPHp66Z4itvEdpY4MNt4kj23MLBg3mRXsCrMr5VB1GcckjigD5w0eFpNNSaTSrnVbxpnSPWI3Ij+0OF2ObnHmM6NhdgIUlU24MhL3dG8ZeJPCt/JZXskF9BCtvJHp92RGk2VVRLESFBbdtywG8gNh+rnYudAsor7VNH1681jw/rN1ADJomsSwJHqMiK6pLFfCLytx2gb2jUszODIxYkZGqeA7zw3YnV9Y0i8vNNtp1tRqchePyMsFVZ4JCWTHOWXdGS6hX/ALybsrl04c81G6V+r2Osg8V22sqX0nVLzT9RbIu7G+3u1xjJ3yJAoZyAseZlCzIjsfMm27V62a8/tSCKx8XXdxFLbInkazNMU2qsh8t3nQfK0ZkxHehFRzvDjD4fx6Lw5pn2e9kiWSWe5TEEolAEIZtxC4B49MY4LA5BxXTfDjxDLqWqR6bq+pR31laxzzQGa4WYyWxUB7clgiv8qoHBIARixAUMRnSrQq/CduPyvE5e17dWT2d07nrXifwbqGta1YS6rq/9jfErTk8rRdfgk22+qxpvYK8J4V8F/MjAI+Ykb0+Qd/8AC3xrN4sstTtNXt7ez8R6NdNZalawSb03jpInOfLbnGecqw5xk+b6Xex6dZ/2D4lupNT8GupWK8EAB0lt7+TKkka7Y4hgqp3M0RQZKgFU1PHPw8u0eHWFvrhdcsbhZbDxFp1gGvY8gh1u4YwBcIVVVyq5+bBXbvzqeee10V4hYfETx14fki/trw8vjTw/JtFvr3hdPMeVBuG54QSC5K/MAVVTkZPFdFYfGbQpZreLVNG8V6NLdBmtUv8ARpt1yqruYxiMPuCryfQc9KAPTaK4DU/i74Q0o2i6rcatYy3mfs0Vzot7G02MZCAxfN1HT1HrWDJ8YL7Xbu6tPh14K1jX3tWdJrq6xYWysoXKh5BkuCwBQhW79OaAPWLu5gs7Sa6vJooLaFGklllcKkaAZLMTwAACSTXgHjPUNR+J+kvrF1e23hr4X6bcJdG6vrUvc6gIxkSCJ1ZGiLlQqEEt3BJCDX1jQdV1vwLLdfGPxlNpNlqQiL6RpcMUEcLH5hBuZHllc7R8oPXcBuGDXVeEfD11q1lpk2s2Z0rQdPeGbRtDBbzIURB5bXZJO6QHlYx8qFVyXYAqAX9Dg/tC9fxn4khewSOA/YbW+IT+z4BuLTOCcJLIpy3QqoCHo2cGLUIdfvpvFd5crbWEdtJFpe+J1ltbV8h7wrjdvmMYWPodgGMlmFT+KtRk8VX/ANksoEvPDenzqJ0xn+1rwFglqh6CON1V5Hww+Xb0V653xp4ixJfzxubdG8lvPtFeSa/maJkhgt/9tmdWhIDqpV5GGRwAc7ZaTH498Z/8I8LH7PpltcfadUTy5A0VvGFSO0Z8BQSVEe1cZWJyclFZ/afiHr9voHh9DcbDJqF1BpkEbPtLyTyCPjg5KqWfHcIenWmfDTw7L4Z8JW1perB/aUzyXd60O4gzSMWK7mZmYICEDMxJVFrzjQnk+LnxU/tuRJT4F8Lu0enKzqY7+/DEG4AA+ZFHQ7uCEI+860nqVF8skz0j4X2drY/D/Q4rGHyYmthMy7icySEu7c+rsxx78V1Fcv8ADAk+AdGDZ3JDsOfVWI/pXUVNN3gvQ6MauXE1F/ef5hRRRVnKFFFFABRRRQB5h+0wQPgp4gJ6b7T/ANK4aXx148v7zUJfCfwzWHUvFDHy7m8yHtdIXJVnmbkeYCGxHycgkg4CtY/aIVW+C/igPjHkIee2JU5r5x8Y/FXTtJ8LyeFvhXLNo2gWgjik1OGNFu9RlYAFiDsZBtV2MgG4kIvyA0AVfjjqWkWE2jeBtK1O6mh8OiafULyN2d9R1KQjdxkjzA27Lsx2B3AyVCt9A6PpV/8ADDwl4RsoFGp3dnp9/E9pFI268umjN0Y4/lOctE4DEZwehJrxT4M/D2DwhHD8QPiasml6bYzY03TLmEme5uGG1WMRGcgjKgAMSu/5VUbvXLP4kat4nmtLmPQm0+xkE11pNwkv2mYywrIxiuIVHy+ZCH4UkqSBkllwAdl8EfEVr4p+GekalY6fBplufNhjsYJN626RyMiJnA52qp6DrnFecfE+Rl8QePdMit4rm61u2s9OtklLKiyTNFCrMwB27S27PTKgd6i8G654b+Ffj5vC2j65qGpeHb9EuLppbfz/ALDezeV5MjTqqgxzRso/iwwU5AY1n/HeG2uviE2japqaaPomtLbQajeum4RxKfMUgnhcvFGu48DPNY1d4+v+Z6eXawrr+4//AEqL/QwPjV4U8RXd74Z8P+JPEbaxcte2Nl9taFYOLyW5XG1RyALWMktuOeldh8Zvh54V+K2tXh8I6zpEfjrTm8m8t/PA+0Iu1WEgXJ3JkASAHBGxug2YHxItFvPh54L8QeENUm1KKxswsOoSL5CvcaaskqStGw352R3oAJIyV9dxxpdKsPFOpzT3tmumyyag+oJcyTR2uba6la4gnWYoFTMbN82ZJd0RXYApA2PMKdp8SPH3wZaz0jWbaaewiSNE03VUJKKANwt7lMqyjoBlwgKrgkNj1Tw9+0XpdyjjxD4a1jS5IriS3me323cUBQZYuRtcYGTwh6HGcHGHZ+IfHPhgwWl5qcuqRIpQ2GvWuBOi4LlZwgY7drgOTLv3phSScT+V8P8AWYrSLXvhhLpl3MzqDoioxCgHDBbdkuCrKwPzQjIYZGMUAemaZ8Xfh7rMUix+KNMjTADJfsbXcGGekwXII/Dn3rhvjf4B8O2vwv17XfCR/sci1EjppMnl2l7HnGJIV/dsMMSGABBwcnGK5qT4U/CmXWYrSbxF4n0i4bLW9vqKGzQqcLtQ3NuN4wAuMkkdc5rgfiX8KNS8FeDdU8QeEvFS6t4UuyiXX2S48kEGTau9UJjmQEheMEEj5cA0AfY/hb/kWNI/684f/QBWnWZ4W/5FjSP+vOH/ANAFadABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAZPifw3o3inS307xDpttqFm2cJMgYoSpXch6q2CcMpBGeDXgl1beI/gdfQWV5NP4l+FV43k3X2uHzW02N22EHG7KBSuRgIxLAKrNk/SNRXNvDd20tvdRRzW8yGOSKRQyupGCpB4IIOMGgD5f+I/gFLXQYfE/wANrdNS8K3cSzm2iLu1sG53qmN7RdNyZ3plsDAwvi97L5H9kagk8cWutBi0mi/dAGKUqkkbjIdSF25b+4yfKEUn6Xk8F+Ivg5c3+sfDgNrPhaYma88Nzs7SxnKjfbOASWAyDnnaozvOCtW28NeBfjFpNzrHgK4t9Mvd5/tCymtRsdnU8TRKwKk9fMicBmUEl2jXbn7OK1jozseOq1EoVnzRSsk+i8u39XutDgfBHiiz1Pw/BZXbC21S1t5/Os3tyyfLC+S8a/6yJo1YBwG2ZMbq0ZQ16B4K8eXngJDpevadqLeFhPHFpkwikmktonyAFbDLNAuBtKu7qGCjzRhhmJ+z5rFrYy6hL4hh1HX7ebz7VvJaIsMcqZd+4MTg7vXcSSWDLVh8SHQr2bSH0uTSZpmLSaTqto0sJO9I0EPln94SYjtIVA5OfMkIJLUraSM5UVJc9F3Xbqv815r52PatKbw94wtl1fwjrbQN5vmS3GlyKrO5UZWeJlKltuOJE3DjGKsLp/jC1tSlvr+lXsisSrXumMrsD2Zo5VXj1Cen1rwdbWz1XU7bVbG7vNC1IKsQSa/kgYRLJuaCC5XC7cBVMcigLuGCc89fB4i8e6FaJJql2GCYVpdTt1eGTKDaqGBBuckj5i+089CMVZznofleMJ7i1eWz8L291HE0R1DzJrhkDEFgkWxDtbYmV80YIBy20Zt/2R4huZ0e+8T+RGiYCaZp8cO9u5YzGY+mAu3vnPbjI/GHi59Ke+kl8P20ced5uYd24ZAXaILmZiWZlXGM5PfjOTZ+N/F2tW8kVvqWlGRZcO+i6dLKkaK4Vv38zYXPzAO0BT5W+Y7SQAehpoGheHXfX9bvpLi5tt7/ANp6xdbvswckN5e7EcIIIU+Wq5GAc15p4q+JEHiqZbaxutU0vwqsXnS3FtE0d7quSQIocjMEWMOzttdgQFABJNLUbB9WvrXUNVneSVJQYJri8LpFIWQvtdmaJXOBte1yV5/djoLulwWXh4I6xS218iqyQiNJLySTqRb2gAwxDfK8+WAI+ULQBTn1m4KWdtNHFo+kQHyLSxjtN/lxSDZHGISDukkUkbmBDAsqbfnNdn8LfD15Mw1fXNOk0+3t5M6Rp1w7vLbfuykk8jM2WdwdoBA2IvAG9hT/AAj4dvLdI9c8ZNHpdjYIbiDTZLpZVhcAl7u7nIHmTYJHXYgBIyTkcdqniq/+N+q3PhfwPc3Gn+DIh/xN9dEbK90pA/0eEEAjdnknqM5GPlkAIPHvibXfi9rEvgn4btLB4ZDtDrPiMI3kMFxvhiYYDDDAYBzJntHuZvb/AAvoVh4Y8PafoukRCKxsohFGuACcdWbAALMcsT3JJ71B4L8M6d4O8MWGg6Kki2NmhVDK+92JJZmY+pYknGBzwAMCtugDlvhl8vg62jPWKe5jIPUYnkAB/DFdTXLfDz5dL1OLtDqt5GD6/vmOf1rqail8COvH/wC81H3bf3sKKKKs5AooooAKKKKAPOf2igT8FvFQHX7Ov/oxK8U8P+CtK+GGhafq+v6dZ6z8StbkRtK0iaNjDZsxGCUAJJTduZiM5UKhBy59t/aFIHwa8TknAECZP/bVK8c8G31/4y1TWfFE9za3HiS8n8u10yS6GbBEkUwROQodY1Bkdtu1XbZk7ydgB514nttU1jxRoh1O7vtS8bT6pNBJM8igLHDIR5caZCL6hVOCxYA56+trf6dpN34VOj2wgew1yOM3l2ZC/wBkL3RkJc4UYguYX5P3ZenyADj/AIfeHpNP+LGp3s0luNE8ORtbQK7yXUS3UYgTahOXXbK8RYjHAI6ZFdHdSjxBqWn2pvrfVp0WSUvNKzSR/aESztVyF2R5W5SQ4DHdA3OfugEvx01u+tfghoGi2N34fS1utJsjcWd1cuuoP80XltBHnJAZeS2TwfQ13HxC8PReJviLf6FOyquq+HZIVkYEiJ9zbHwCM7WUNjI6Vy/jLVtE8WfFXRdLt/CF2vjKHVobeSa/hZVTTLa4EzXEe4hMPtYKQMlS655UN6Jrn7v43eHG+75unyx5/vYEhx/Wsa2y9Uenlmsqq/uT/K/6HJ3nibxBq3iODw1480q00HU3WGXQlht5b5L6+jdi0yyxgiOEBQHjYBxHMSXUc1554etrHUJpvAtz5ng7xfo15cxaBdSqxEkEzO7Wkr5+cEO21gQSCjJzkN778TPDN9qv9ka94bEY8UaDO09iJpNsc0bgLPA+QQA6DAbGQwXBXk15cTb/ABO8JWmuavZ6NqHjK1tpotW8MKWWSW3juWXaIi/mwzoN+x/70rL0fjY8wwNZm8T+G54oda0K+0mKxdJpbixgkvNOyr7UnQuXXhFXCSmPYNpG09YhqFiuk3EOn63b6rbxXipHLG5kRMEsJJYwhUr5g8zYgIVWcNhiC3pnhPWfEWm276Jo+teGtb8q8kNq2s6pPBqAttxPkzQmJn8xSHXeT0UHbxV28/sDxOJV8d/D68tdaGIZnXTHvCq8FWiu4UJK8jkFWUg5AwaAOC0jxEbGa8kus4tpgZFtUmtdrv8AfQrbMiBt6kfvAG65AORXGfGi+0bUPAN9dWOiTQXEphZ7oSRvHHKzoxjMskYmkfYVO1WIA6HCNXtVx8F/Dt/5d1peo69p8QYzQ28jieNJSMFyl1G75IAyCcEAcdK8/wDjz4BvNC+Dd9NcXlnffYzAXlhtks1BMyICkCqyg/NyVZOp45IIB9DeFv8AkWNI/wCvOH/0AVp1meFv+RY0j/rzh/8AQBWnQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV554x+FWka3ra+IdFurrw54pjBKanppC+Y3JHnR/dlXJ+YHBYAAnHFeh0UAeQXXjTx54EZh438ODxBosS/8hrw+h8xVUH5prdjwSF3MykIucDNdBMngf4v+Hmazu7PUkCFI7q3IW6tNxHTcN0ZJUfKwwwAyCOK7+uA8S/CLwdrupvqp019N1s5ZNS0ud7WeOQknzRsIUvkk7mUn1oavuOMnF80XZnmOv8Ag+fwPd28es+be+EDMgfUVhaUwRYdfKlVZA0ShSMOhEeQMpkqo6LR/B3iS2iN54G8QWMlnchXFxHeGKNzhQ2IPJkiVsqeecdCM5J04/CnxP8ADkfl+HPGmm6/a5KR23iW0YNEmcgmeI75H7fMAK5C00L4peHvFKXnhzwxpNhatb/6VaWF8n9n3Ei5xshfa0RKgDjIzjJXc7CLOO2x089Ot8fuy79H6rp6r7upry6Z8TPJMWraTo+pAOA09tZ2r3Eyn725pZEjww6sEB7becrbuNB8ca1D5B0y2s0QkxvqlxEREMjCxxRebGABwpCqw5+YcEun+JvjsalBYQfDBjcTR+ZGJ9aigLjuAHQAsO4BOKSLVvjfrNzcpb+HPCvhy22/u21G6a5fJJ6NCxBIGOqgfyqk09jGpSlTdpL+vLubmj+Btcdnl1bWIbIzFfOj00PJKQqBBi5lO/nauQVxjPGTuGdrHjj4Z/CiOS0t5LY6kSwaz09ftN3IxYEq7Z4OWyBIw749Kq6l8LvGviaJbbxf8Tb6TS5C32ix0qwjs96kEbPNByy4PIZWB9O9dj4A+GfhTwHAo8PaXEl3sCPfTfvLiTgA5c9AcAlVwuewpmZ55eaH4y+M0oj8T28vhXwCs/mppxyt/qAUjaJxnCLkFsY4OOGwrj2Xw/ouneHtGtNK0S0is9PtU8uKGMcKPUnqSTkknJJJJJJrQooAKKKKAOV8BjbJ4ljwMrrM+ce6o3/s1dVXK+EP3ev+LYOm3UFl2/78EZz+OK6qop/CdeO/jN90n96TCiiirOQKKKKACkVQowM4yTyc9TmlooA81/aRlEPwT8UMxQAxRId5IHM0Y7d+ePf0r5juFvPAn2c+GAZbvU7SVZ7iViIoCHhmWTA+VZI/kOFOOYhgkOrfUH7RX/JFvFXGf9HX/wBGJXgHw40m68Q65H4hk8qBZgvkrHvlW1jY7lLyNjy9rLLMSu0Fo5ARtdcAHUWFlaeBvAtjLpccwmvIWae5hRo5isbhI8OsYYid2lCl1yd8Zz8gzX8PT+JJND1zxhp01re3Wlxf20zaskxjdESbyIlUEYJiluLnA4BuIANoGaPEkdn428RxWglW20EQTybrfa32fSoFjQuQ+fvcqse3cjusgIwQdD4o+HdYtPCHg2yh1ufRZ/FepR6dq9hFGNh+1FCcKWyBCsUcIAONgCjaCwYA9M+COj3jaJceMdfnt7nxB4rWHUJngVkjhg8seRAoJ6IpPPUlsEtgMdTxFo1/cfEnwvqtrbmS0tY5kuJNwAjDKQO+Tnd2rrrG0t7Cyt7OyhSC1t41iiijGFRFGFUDsAABU9TKKkrM3w+Ilh5OUeqa+TTT/MK85u/AOoaP4q1jxJ4GutEtNQ1MFp4NR0tZFMh2bis0RSVFbYGZSXBYlsAmvRgcjI6UVRgeUeI/EWqnwcZPGPwyvNSu7a2LyCOO0u7bz1QksqGZpBGSCfu7gOOTUvheT4feI7BL7Q9UsLDUJ7Bbm6i0XUmtHjUAEs8Ubr90nGXXI6H0r1KsrXfDmieIBCNe0bTdTEG7yvttqk3l5xnbuBxnAzj0FAHKrcCPwnp/iHSfH3k6KI1lW61iKGW3kifhfMbEUgbLKBlwcjDAnNcX+0o3iaH4N+JIdRj0e7sGe2zd27yW8iL9ojIHksHDfMFGfMHBzjjB7TU/g94E1BbtW0CO1iu0WOeGwnltIpQpyu6KJlRiDyCVPNeW/tE+E/Emg/C3UJbfxbfaxoMUEVvd2usFXmANxAUkjkjRd7h1AJkz8rNg5oA+irG1isbK3tLcEQwRrEgJyQqjA/QVPRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFIAFACgADgAdqWigAooooAqapp1rqlo1tfQpNCSDhh0I6EHqCPUYI7Vi79U8Pf64z6tpI/5aAbrqAe4H+tUeo+b2brXS0VLjfVbm1Os4rkkrx7f5dn/TuV7C9ttQtI7mxnjnt3GVdGyD/9f2qxWFfaCUu5NQ0ScWGoOd0o27obg/8ATRO5/wBoYb3PSn6ZrolulsNVgOn6oRkRO2Um94n6OPbhh3ApKVtJFSoqS56Luu3Vf5rzXzsbVFFFWc4UUUUAcr4c+Xxv4uQHq1pJj3MO38vl/nXVVzul2lxB44124eF/s1zbWuyUjClk8wFR6nkH8a6Kop7fN/mdWMadRNfyx/8ASUFFFFWcoUUUUAFFFFAHnP7RX/JFfFX/AF7L/wCjErz+8KaD4ASWeW4mvLhEswzSAxs00UchJyqvtW3jgiLKBgM2FGDn1z4p+G7nxf8AD7W9BsJoYbq9h2RPNkIGDBhuwCQOMZANeI6z8J/ivqmgR6P/AGn4QtbRY2idrea6EkqMEUqzshbGyNEwCAVGDmgDS+EXhlNSvrK5vo18rVz/AG7c2zK7j7NEdlijHcAA7vNPypzsAIG2ofgrolv4v+KOt+Mm0c6ZYaXc3EaWw1E3kMmqSN/pFxGeAAY/LHTacqQflGNk+G/jZ/ZetWQ1HwJH/afmbriEXMUsAZAgEbIgxsUAKW3MMDJOBUvhLw38YfCnhuw0PRx8Oo7Gyj8uMMbwseSWZjjkliSfcmgD26ivKNnxx/56fDn/AMnf8KNnxx/56fDn/wAnf8KAPVYlCoNucHnn35p1eUbPjj/z0+HP/k7/AIUbPjj/AM9Phz/5O/4UAer0V5Rs+OP/AD0+HP8A5O/4VT1W/wDjJpNmbvU734aWtsHSMyym8VQzuEUE44yzAfjQB7HXlX7Uf/JCfE3/AG6/+lUVcxF43+I8t1NbJ4j+E/nQgtIrTXa7AJvIySf+muE+pHqKxfE9x46+Jmh3PhE+K/hRcjUdv7vTr+dp28thL8n3s/cyeDxk+9AH0tRTY93lr5m3fgbtvTPtTqACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACsdvEmlr4lTQTc/8AE0aPzRFtPTBPXpnAzitivM7jwJrcmqnW11K0Gq/2iLxYSD5flj5Qnmbd3+rAGMY/nWdSUlblVztwVGhVcvbz5dNPXp0enc9CGo2Rn8gXlsZsE+X5q7sDrxnt3rLtte0jWI9PktCt9DPMRE4QYjdM/MQ2CDkHBx79Oa5mz8BTQ3NjcMmn/aItWmvZpQDueB92EztyTyMg8cdaTw94I1DTG0NHGmrHpt7NO0sJYPOjh8ZG37w3AYyeB17VHPUb2/rQ6/q2DjFuNW7W3TpL9VG3qdu2raaoctqFmAi72zMvyrnGTzwM8fWpZr60glhimuoI5Jv9UjyAF/8AdB6/hXmtp8NJo7SySeLSnmjtb2KZ9pO+SViYmyU52ggZPI7Zpt78OdRmFtmWzuQbC1tZVknePyniUDKMEJKk84+U5pe0qfylfUcDzWVfv087d/n+B6Wt9ZG8a1W6tzdgZaISLvH1HWki1KxmjeSG9tpI0bYzLKpCt6E54Neff8IBqT6vqki3VpZ2V4t1uEbGVi0qkBgGQFDzk4c56DANVofh1qH9l3NrIumrJL9mRmWd2WVYpA3KlABxkAc9cZxR7Sp/KL6jg9P3/bp33/pX8/Lv7vxFo9pHbST6jbiO5nFtE6NvUyYztyM46ck4A71eF9aG7FoLqA3RXcIfMG8j129cV57qXw/uHurqaxh0ny/7Vhv4LaQFYzGse10bCHbuPPAIOBmpLXwLeweKzqDNaTW5v/tyyGZ0kiz1QKFwwA4HzAYxxT56l9YkvCYJxvGrrZvpvpp/n36HbXGrWsRtvLcXHnzLEDCytt3Zwx56fKemasR31pJdvax3UDXKDLQrIC6j3XrXB6T4Cm0/QPDdrGmnpf2OoRXd7NGCPPVPMwN23LEBxjOO9afhHw3e6HdCKaHSp7dJZpRfYb7VJvYn5uMA84J3HIA4pxnNtXRnWw2FjGTp1LtXt0vvr/wN9TsaKKK2PMCiiigAooooAKKKKACiiigAooooAK4X43aaur/DLWLJ7DUdQDiNhbadzO7LIrLtGDxuAzjnbnFd1RQB8f2XhA+H/DEU9x4U8Qy3Mtuun7jLIk06XKXsTwCF02KokSGRQFZkMiyNu+4e7+D8mpa54xs5bnSrzSrS3mbUPsagR2sbx2gsw8Z8kkgqwRUEuD5Mr8Dah+haKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAOV+JOqajo/hxbvSJYop/tMKM8gBARnAPUEdwPpnvWLdeONUi8QyafDp9tNHaNAl0Vc5bzFBZ0JwAozxnrjtXfXdrb3ts9veQRXFu4w8UqB1bvyDwaqSaHpMslu8ul2DvbqFhZrdCYgOgU44A7YrGcJt3iz0sNicNCmoVafM9dfW1u21n99zjIvGuqyXcDS2VkunT38+nApI/nBkDYbpgD5fes2Xx9e6f4a0qazjhuJ2sPts0VwzvJs3lclyQOxGeTntXpI0rTgqAWFphJTMo8lflkOcuOPvHJ5681DN4f0aeKCKfSNOkjgUpEj2yERqeoUEcD2FS6dT+Y3jjcEmr0dL/5/5r7i5ZTi6sre4C7RLGsm3OcZGcVPTURY0VI1CooACqMAD0FOroR48rX0CiiigQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABSMyqVDMAWOFBPU4zgfgDRRQAtFFFABRRRQAUUUUAFFFFAH/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Diverticula develop at four well-defined points around the circumference of the colon, the sites at which the vasa recta penetrate the circular muscle layer. These vessels enter the wall on each side of the mesenteric taenia and on the mesenteric border of the two antimesenteric taeniae. The insets represent the development of a diverticulum at one such point of weakness.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from Pemberton, JH, Armstrong, DN, Dietzen, CD. In: Textbook of Gastroenterology, 2d ed, Yamada, T (Ed), 1995. By permission of Mayo Foundation 1997.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_21_18771=[""].join("\n");
var outline_f18_21_18771=null;
var title_f18_21_18772="Defibulation 1";
var content_f18_21_18772=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F54998&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F54998&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Defibulation (reversal of female genital infibulation)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Step 1: Insert a Kelly clamp under the scar.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_21_18772=[""].join("\n");
var outline_f18_21_18772=null;
var title_f18_21_18773="Definition of transient ischemic attack";
var content_f18_21_18773=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"62\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Definition of transient ischemic attack",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/21/18773/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/21/18773/contributors\">",
"     Karen L Furie, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/21/18773/contributors\">",
"     Hakan Ay, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/21/18773/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/21/18773/contributors\">",
"     Scott E Kasner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/21/18773/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/21/18773/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/21/18773/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 15, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transient ischemic attack (TIA) is a brief episode of neurologic dysfunction resulting from focal temporary cerebral ischemia not associated with cerebral infarction.",
"   </p>",
"   <p>",
"    TIA was originally defined clinically by the temporary nature (&lt;24 hours) of the associated neurologic symptoms. However, the arbitrary nature of the 24-hour time limit and lack of specific pathophysiologic meaning hampered the clinical and research utility of the term \"TIA.\" Recognition of these problems led to a change to a tissue-based definition of TIA. The change was driven by advances in neuroimaging that enabled very early identification of ischemic brain injury.",
"   </p>",
"   <p>",
"    An overview of the classic and modern definitions of TIA is provided here. The etiology, clinical manifestations, diagnosis, treatment, and prevention of TIA are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/46/40678?source=see_link\">",
"     \"Etiology and clinical manifestations of transient ischemic attack\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/11/10426?source=see_link\">",
"     \"Initial evaluation and management of transient ischemic attack and minor stroke\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/33/32281?source=see_link\">",
"     \"Secondary prevention for specific causes of ischemic stroke and transient ischemic attack\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/61/30682?source=see_link\">",
"     \"Secondary prevention of stroke: Risk factor reduction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TISSUE-BASED DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;As endorsed by 2009 guidelines from the American Heart Association and American Stroke Association",
"    <span class=\"nowrap\">",
"     (AHA/ASA),",
"    </span>",
"    transient ischemic attack (TIA) is defined as a transient episode of neurologic dysfunction caused by focal brain, spinal cord, or retinal ischemia,",
"    <strong>",
"     without",
"    </strong>",
"    acute infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18773/abstract/1\">",
"     1",
"    </a>",
"    ]. Ischemic stroke is defined as infarction of central nervous system tissue.",
"   </p>",
"   <p>",
"    TIA was originally defined as a sudden onset of a focal neurologic symptom",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    sign lasting less than 24 hours, presumably brought on by a transient decrease in blood supply, which rendered the brain ischemic in the area producing the symptom. However, this classic definition of TIA was inadequate for several reasons. Most notably, there is risk of permanent tissue injury (ie, infarction) even when focal transient neurologic symptoms last less than one hour. Thus, the benign connotation of \"TIA\" has been replaced by an understanding that even relatively brief ischemia can cause permanent brain injury. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Relationship of symptom duration and infarction'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The advantages of modern tissue-based definitions of TIA and stroke include the following [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18773/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The defined end point is biologic (tissue injury, as confirmed or excluded by neuroimaging) rather than arbitrary (24 hours).",
"     </li>",
"     <li>",
"      The definition encourages use of neurodiagnostic tests to identify brain injury and its cause.",
"     </li>",
"     <li>",
"      The presence or absence of ischemic brain is more accurately reflected.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An earlier proposal for a tissue-based TIA definition noted that clinical symptoms of TIA typically last less than one hour [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18773/abstract/2\">",
"     2",
"    </a>",
"    ]. While this is true, the",
"    <span class=\"nowrap\">",
"     AHA/ASA",
"    </span>",
"    did not incorporate the phrase \"typically less than one hour\" in the new definition of TIA because there is no time cutoff that reliably distinguishes whether a symptomatic ischemic event will result in ischemic infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18773/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29656225\">",
"    <span class=\"h2\">",
"     Impact of tissue-based definition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of the new TIA definition in epidemiologic studies is likely to modestly alter the incidence and prevalence rates of TIA and stroke, but these changes are encouraged by the",
"    <span class=\"nowrap\">",
"     AHA/ASA",
"    </span>",
"    because they should reflect more accurate diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18773/abstract/1\">",
"     1",
"    </a>",
"    ]. One study estimated that switching from the classic to the tissue-based definition of TIA could reduce the annual incidence of TIA in the United States by 33 percent (range 19 to 44 percent) and increase the annual incidence of stroke by 7 percent (range 4 to 10 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18773/abstract/3\">",
"     3",
"    </a>",
"    ]. Subsequent reports have estimated that using the tissue-based definition will decrease the annual rate of TIA by approximately 28 percent, based upon the proportion of patients with classic TIA who have evidence of infarction on diffusion-weighted MRI [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18773/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another important clinical implication is that TIA, when using the new tissue-based definition, is a low-risk condition [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18773/abstract/6\">",
"     6",
"    </a>",
"    ]. It is not an emergency anymore. This is in clear contrast to the conventional time-based definition, in which TIA is regarded as a sign of an imminent stroke. According to a pooled analysis of 3206 patients with TIA who were evaluated with diffusion-weighted MRI, the risk of stroke at seven days was much lower in patients with no infarction compared with those with infarction (0.4 versus 7.1 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18773/abstract/4\">",
"     4",
"    </a>",
"    ]. Thus, prognostic models that incorporate information from acute diffusion-weighted MRI may improve the accuracy of stroke risk prediction after TIA. This issue is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/11/10426?source=see_link&amp;anchor=H16#H16\">",
"     \"Initial evaluation and management of transient ischemic attack and minor stroke\", section on 'ABCD2 score'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     OTHER TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The terms \"acute neurovascular syndrome\" and \"transient symptoms with infarction\" (or \"cerebral infarction with transient signs\") have been proposed to supplement TIA in the description of transient symptoms related to ischemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Acute neurovascular syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;With the new tissue-based definitions of stroke and TIA, there may be uncertainty regarding the diagnosis if immediate neuroimaging is not available to detect infarction when transient symptoms of brain ischemia occur [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18773/abstract/1\">",
"     1",
"    </a>",
"    ]. The",
"    <span class=\"nowrap\">",
"     AHA/ASA",
"    </span>",
"    has proposed (but not formally endorsed) consideration of a term such as \"acute neurovascular syndrome\" that can be used in this setting until the diagnostic evaluation is completed, or if a diagnostic evaluation is not performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Transient symptoms with infarction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The awareness that a classically defined TIA (&lt;24 hours in duration) can be associated with irreversible ischemic brain injury led to a proposal to label these events as \"transient symptoms associated with infarction\" (TSI) or \"cerebral infarction with transient signs\" and to distinguish them from transient symptoms without infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18773/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While TSI in general has smaller infarct volumes than classically defined ischemic stroke (where neurologic deficits persist for &ge;24 hours), there is no unique size that differentiates TSI from ischemic stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18773/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with TSI have a higher short-term risk of recurrent ischemic stroke than patients who have transient symptoms without infarction. This conclusion is supported by a number of head CT and diffusion-weighted MRI studies [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18773/abstract/4,7-11\">",
"     4,7-11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     RELATIONSHIP OF SYMPTOM DURATION AND INFARCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A classically defined TIA with symptoms lasting for as little as a few minutes can be associated with infarction, whereas a spell lasting for many hours may rarely cause no signal changes on diffusion-weighted MRI imaging (DWI).",
"   </p>",
"   <p>",
"    Some reports suggest that increased duration of classically defined TIA (&lt;24 hours in duration) is associated with a higher probability of infarction on DWI, but the association is not absolute [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18773/abstract/7,12-15\">",
"     7,12-15",
"    </a>",
"    ]. A systematic analysis of patients with classically defined TIA found that symptom duration was not a reliable predictor for the presence of infarction (",
"    <a class=\"graphic graphic_figure graphicRef82729 \" href=\"UTD.htm?32/61/33758\">",
"     figure 1",
"    </a>",
"    ), even though the mean duration tended to be significantly longer in patients with infarction than in those without infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18773/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One potential caveat is that abnormalities on initial imaging such as diffusion-weighted (DWI) MRI obtained during or soon after symptoms, may actually be reversible injuries. However, most patients with TIA seek medical attention after their symptoms fully resolve; a low proportion (&le;7 percent) of patients with classically defined TIA are admitted and scanned at the height of their symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18773/abstract/8,12-14\">",
"     8,12-14",
"    </a>",
"    ]. Therefore, infarcts observed in patients with classically defined TIA most likely represent permanent brain injury, as the probability of DWI reversibility decreases as the time from symptom onset to imaging increases.",
"   </p>",
"   <p>",
"    DWI is advantageous for evaluating patients who have transient symptoms because it is highly sensitive for detecting infarction, thereby confirming an ischemic cause. A systematic review found that DWI detects corresponding appropriate ischemic lesions in 16 to 67 percent of patients with classically defined TIA [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18773/abstract/16\">",
"     16",
"    </a>",
"    ]. Also, the combination of DWI with MRI and MRA often provides clues to the underlying pathophysiology.",
"   </p>",
"   <p>",
"    DWI also has an advantage in differentiating acute infarction from chronic lesions. One study estimated that the amount of error potentially imposed by the use of conventional MRI in identifying the clinically responsible infarct in patients with classically defined TIA could be as high as 50 percent when compared with DWI [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18773/abstract/8\">",
"     8",
"    </a>",
"    ]. This is, in large part, because infarctions associated with classically defined TIA are often very small. A volumetric study of TIA-related infarcts showed that 96 percent of all infarcts were smaller than 1 mL [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18773/abstract/7\">",
"     7",
"    </a>",
"    ]. The smallest single lesion that was associated with a classically defined TIA was 0.17 mL in volume. The mean infarct volume was 0.66 &plusmn; 1.20 mL.",
"   </p>",
"   <p>",
"    Perfusion-weighted MR imaging (PWI), when used in combination with DWI, may improve the accuracy of diagnosis in patients with transient ischemic symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18773/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. This is illustrated by a prospective series of 43 patients with classically defined TIA who had both studies performed within 48 hours of symptoms onset [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18773/abstract/18\">",
"     18",
"    </a>",
"    ]. Lesions on DWI only, PWI only, or both DWI and PWI were observed in 19, 16, and 16 percent of patients, respectively. Thus, objective evidence of brain ischemic with either DWI or PWI lesion was present in 51 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?34/22/35170?source=see_link\">",
"       \"Patient information: Transient ischemic attack (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?20/18/20772?source=see_link\">",
"       \"Patient information: Transient ischemic attack (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Transient ischemic attack (TIA) is defined as a transient episode of neurologic dysfunction caused by focal brain, spinal cord, or retinal ischemia, without acute infarction. This tissue-based definition of TIA relies on the absence of end-organ injury as assessed by imaging or other techniques. The proposed advantages of the tissue-based definition are that the defined end point is biological (tissue injury) rather than arbitrary (24 hours). In addition, a tissue based definition encourages the use of neurodiagnostic tests to identify brain injury and its cause. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Tissue-based definition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      TIA was originally defined as a sudden onset of a focal neurologic symptom",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      sign lasting less than 24 hours, caused by a transient decrease in blood supply. This \"classic\" definition of TIA is inadequate because even relatively brief ischemia can cause permanent brain injury. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Tissue-based definition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A substantial proportion of patients with classically defined TIA (&lt;24 hours in duration) have corresponding relevant ischemic lesions on diffusion-weighted or perfusion-weighted MRI. The associated infarctions associated are often very small. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Relationship of symptom duration and infarction'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3774341\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editorial staff at UpToDate, Inc. would like to acknowledge Dr. Philip Kistler for his contributions to an earlier version of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18773/abstract/1\">",
"      Easton JD, Saver JL, Albers GW, et al. Definition and evaluation of transient ischemic attack: a scientific statement for healthcare professionals from the American Heart Association/American Stroke Association Stroke Council; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing; and the Interdisciplinary Council on Peripheral Vascular Disease. The American Academy of Neurology affirms the value of this statement as an educational tool for neurologists. Stroke 2009; 40:2276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18773/abstract/2\">",
"      Albers GW, Caplan LR, Easton JD, et al. Transient ischemic attack--proposal for a new definition. N Engl J Med 2002; 347:1713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18773/abstract/3\">",
"      Ovbiagele B, Kidwell CS, Saver JL. Epidemiological impact in the United States of a tissue-based definition of transient ischemic attack. Stroke 2003; 34:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18773/abstract/4\">",
"      Giles MF, Albers GW, Amarenco P, et al. Addition of brain infarction to the ABCD2 Score (ABCD2I): a collaborative analysis of unpublished data on 4574 patients. Stroke 2010; 41:1907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18773/abstract/5\">",
"      Mullen MT, Cucchiara BL. Redefinition of transient ischemic attack improves prognosis of transient ischemic attack and ischemic stroke: an example of the will rogers phenomenon. Stroke 2011; 42:3612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18773/abstract/6\">",
"      Arsava EM, Furie KL, Schwamm LH, et al. Prediction of early stroke risk in transient symptoms with infarction: relevance to the new tissue-based definition. Stroke 2011; 42:2186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18773/abstract/7\">",
"      Ay H, Koroshetz WJ, Benner T, et al. Transient ischemic attack with infarction: a unique syndrome? Ann Neurol 2005; 57:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18773/abstract/8\">",
"      Ay H, Oliveira-Filho J, Buonanno FS, et al. 'Footprints' of transient ischemic attacks: a diffusion-weighted MRI study. Cerebrovasc Dis 2002; 14:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18773/abstract/9\">",
"      Douglas VC, Johnston CM, Elkins J, et al. Head computed tomography findings predict short-term stroke risk after transient ischemic attack. Stroke 2003; 34:2894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18773/abstract/10\">",
"      Purroy F, Montaner J, Rovira A, et al. Higher risk of further vascular events among transient ischemic attack patients with diffusion-weighted imaging acute ischemic lesions. Stroke 2004; 35:2313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18773/abstract/11\">",
"      Prabhakaran S, Chong JY, Sacco RL. Impact of abnormal diffusion-weighted imaging results on short-term outcome following transient ischemic attack. Arch Neurol 2007; 64:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18773/abstract/12\">",
"      Kidwell CS, Alger JR, Di Salle F, et al. Diffusion MRI in patients with transient ischemic attacks. Stroke 1999; 30:1174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18773/abstract/13\">",
"      Engelter ST, Provenzale JM, Petrella JR, Alberts MJ. Diffusion MR imaging and transient ischemic attacks. Stroke 1999; 30:2762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18773/abstract/14\">",
"      Crisostomo RA, Garcia MM, Tong DC. Detection of diffusion-weighted MRI abnormalities in patients with transient ischemic attack: correlation with clinical characteristics. Stroke 2003; 34:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18773/abstract/15\">",
"      Rovira A, Rovira-Gols A, Pedraza S, et al. Diffusion-weighted MR imaging in the acute phase of transient ischemic attacks. AJNR Am J Neuroradiol 2002; 23:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18773/abstract/16\">",
"      Redgrave JN, Coutts SB, Schulz UG, et al. Systematic review of associations between the presence of acute ischemic lesions on diffusion-weighted imaging and clinical predictors of early stroke risk after transient ischemic attack. Stroke 2007; 38:1482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18773/abstract/17\">",
"      Krol AL, Coutts SB, Simon JE, et al. Perfusion MRI abnormalities in speech or motor transient ischemic attack patients. Stroke 2005; 36:2487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18773/abstract/18\">",
"      Mlynash M, Olivot JM, Tong DC, et al. Yield of combined perfusion and diffusion MR imaging in hemispheric TIA. Neurology 2009; 72:1127.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1122 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-183.1.191.153-6CC31590FA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_21_18773=[""].join("\n");
var outline_f18_21_18773=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H8\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TISSUE-BASED DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29656225\">",
"      Impact of tissue-based definition",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      OTHER TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Acute neurovascular syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Transient symptoms with infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      RELATIONSHIP OF SYMPTOM DURATION AND INFARCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3774341\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/1122\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/1122|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/61/33758\" title=\"figure 1\">",
"      Duration symptoms TIA",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/46/40678?source=related_link\">",
"      Etiology and clinical manifestations of transient ischemic attack",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/11/10426?source=related_link\">",
"      Initial evaluation and management of transient ischemic attack and minor stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?20/18/20772?source=related_link\">",
"      Patient information: Transient ischemic attack (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?34/22/35170?source=related_link\">",
"      Patient information: Transient ischemic attack (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/33/32281?source=related_link\">",
"      Secondary prevention for specific causes of ischemic stroke and transient ischemic attack",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/61/30682?source=related_link\">",
"      Secondary prevention of stroke: Risk factor reduction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_21_18774="Doppler U-S choriocarcinoma";
var content_f18_21_18774=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F52443&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F52443&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Doppler ultrasound choriocarcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 497px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Choriocarcinoma: Ultrasound reveals a hyperechoic mass showing hypervascularity on color Doppler.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Department of Radiology, Santa Clara Valley Medical Center.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_21_18774=[""].join("\n");
var outline_f18_21_18774=null;
var title_f18_21_18775="Classification of interstitial lung disease in infants and children";
var content_f18_21_18775=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Classification of interstitial lung disease in infants and children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/21/18775/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/21/18775/contributors\">",
"     Cynthia E Epstein, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/21/18775/contributors\">",
"     Leland L Fan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/21/18775/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/21/18775/contributors\">",
"     George B Mallory, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/21/18775/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/21/18775/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/21/18775/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 14, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interstitial lung disease (ILD), also known as interstitial pneumonitis, consists of a diverse group of rare disorders that involve the pulmonary parenchyma and interfere with gas exchange. These disorders are classified together because of similar clinical, radiographic, physiologic, or pathologic manifestations. However, the term \"interstitial\" is misleading because most of these disorders are associated with extensive alteration of alveolar and airway architecture, in addition to changes in the interstitial compartment. For this reason, the terms \"diffuse infiltrative lung disease\" or \"diffuse parenchymal lung disease\" are sometimes used.",
"   </p>",
"   <p>",
"    There are several potential ways in which to classify ILD in children [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18775/abstract/1\">",
"     1",
"    </a>",
"    ]. It may be classified according to etiology, if the etiology is known. This classification can be further divided according to whether the ILD is primarily a pulmonary process or whether it occurs in association with a systemic disorder (",
"    <a class=\"graphic graphic_table graphicRef71704 \" href=\"UTD.htm?30/32/31245\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    However, many cases of ILD have no recognized cause and are not associated with a systemic disease. These idiopathic cases may be classified pathologically, as may other types of pediatric ILD. Finally, ILD may be classified according to age at presentation. This classification scheme is particularly helpful in infants in whom unique forms of ILD occur (",
"    <a class=\"graphic graphic_table graphicRef71704 \" href=\"UTD.htm?30/32/31245\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18775/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A two year prospective survey of all pediatric hospitals in Germany conducted from 2005 to 2006 reported an incidence of 1.32 new cases of pediatric",
"    <span class=\"nowrap\">",
"     ILD/million.",
"    </span>",
"    In this study, 38 cases of pediatric ILD were described, including 21 cases in infants (9 surfactant mutations, 2 neuroendocrine cell hyperplasia of infancy, 10 unknown) and 17 cases in older children (11 hypersensitivity pneumonitis, 2 idiopathic pulmonary hemosiderosis, 1 sarcoid, 3 unknown) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18775/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The classification of interstitial lung disease in infants and children will be discussed here. The approach to the infant and child with interstitial lung disease is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/22/26985?source=see_link\">",
"     \"Approach to the infant and child with interstitial lung disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ETIOLOGIC CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;ILD in children can be classified according to the etiology if the etiology is known. This categorization can be divided according to whether the ILD is primarily a pulmonary process or whether it occurs in association with a systemic disorder (",
"    <a class=\"graphic graphic_table graphicRef71704 \" href=\"UTD.htm?30/32/31245\">",
"     table 1",
"    </a>",
"    ). Known causes of ILD in children include aspiration syndromes, chronic infection, and hypersensitivity syndromes. These disorders are discussed in detail separately. (See appropriate topic reviews).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     IDIOPATHIC ILD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many cases of ILD have no recognized cause and are not associated with a systemic disease. Seven types of idiopathic interstitial pneumonia in adults have been defined on the basis of histopathology (",
"    <a class=\"graphic graphic_table graphicRef68251 \" href=\"UTD.htm?23/25/23963\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/23/4474?source=see_link\">",
"     \"Idiopathic interstitial pneumonias: Clinical manifestations and pathology\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Desquamative interstitial pneumonia (DIP)",
"     </li>",
"     <li>",
"      Acute interstitial pneumonia (AIP)",
"      <span class=\"nowrap\">",
"       /",
"      </span>",
"      Diffuse alveolar damage (DAD)",
"     </li>",
"     <li>",
"      Nonspecific interstitial pneumonia (NSIP)",
"     </li>",
"     <li>",
"      Organizing pneumonia",
"     </li>",
"     <li>",
"      Lymphocytic interstitial pneumonia (LIP)",
"     </li>",
"     <li>",
"      Idiopathic pulmonary fibrosis (IPF)",
"      <span class=\"nowrap\">",
"       /",
"      </span>",
"      Usual interstitial pneumonia (UIP)",
"     </li>",
"     <li>",
"      Respiratory bronchiolitis interstitial lung disease (RBILD)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Among these, the first five may be applicable to children (",
"    <a class=\"graphic graphic_table graphicRef71704 \" href=\"UTD.htm?30/32/31245\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18775/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. In adults, UIP is the histopathologic pattern of the clinical disease idiopathic pulmonary fibrosis (IPF, also called cryptogenic fibrosing alveolitis, CFA). IPF is the most common form of idiopathic ILD in adults and is associated with a poor prognosis, but probably does not exist in children, as outlined below. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Usual interstitial pneumonia (UIP)'",
"    </a>",
"    below.) RBILD is related to smoking in most cases and, therefore, usually is not seen in children.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Desquamative interstitial pneumonitis (DIP)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Desquamative interstitial pneumonitis was previously considered to be a distinct category of ILD, as it is in adults. It is now recognized that most cases of DIP in children are caused by an inborn error in surfactant metabolism, including mutations in the surfactant protein B, surfactant protein C, and ABCA3 genes. DIP is just one of many histologic expressions of these mutations (others include alveolar proteinosis, chronic pneumonitis of infancy, nonspecific interstitial pneumonitis, and, rarely, usual interstitial pneumonitis).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Acute interstitial pneumonia (AIP)",
"    </span>",
"    &nbsp;&mdash;&nbsp;AIP, also known as Hamman-Rich syndrome and accelerated interstitial pneumonia, is an acute, severe, and rapidly progressive process with a high fatality rate. Histologically, AIP is identical to the organizing or proliferative stage of diffuse alveolar damage (DAD). It is characterized by an active diffuse interstitial process consisting of multiplying fibroblasts and myofibroblasts within thickened alveolar septae. Honeycomb changes are the final result of this progressive process. The histologic features of AIP are described in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/23/4474?source=see_link&amp;anchor=H15#H15\">",
"     \"Idiopathic interstitial pneumonias: Clinical manifestations and pathology\", section on 'Acute interstitial pneumonia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Nonspecific interstitial pneumonia (NSIP)",
"    </span>",
"    &nbsp;&mdash;&nbsp;NSIP is the designation for a heterogeneous group of interstitial pneumonias that fit specific histological parameters. The main change in all cases is an interstitial pneumonia characterized by expansion of alveolar septa by a variably dense infiltrate of predominantly mononuclear inflammatory cells with or without associated fibrosis (",
"    <a class=\"graphic graphic_picture graphicRef68775 \" href=\"UTD.htm?21/6/21609\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18775/abstract/6\">",
"     6",
"    </a>",
"    ]. Although these changes may be patchy or diffuse, they appear to occur over a single time period. The temporal uniformity distinguishes NSIP from UIP [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18775/abstract/4\">",
"     4",
"    </a>",
"    ]. Focal areas of organizing pneumonia, patchy intraalveolar macrophages, lymphoid hyperplasia, and rare focal granulomas also may be seen in NSIP [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18775/abstract/6\">",
"     6",
"    </a>",
"    ]. The histologic features of NSIP are described in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/23/4474?source=see_link&amp;anchor=H18#H18\">",
"     \"Idiopathic interstitial pneumonias: Clinical manifestations and pathology\", section on 'Nonspecific interstitial pneumonia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The incidence of NSIP in children is unknown, although it does occur. In one review of 25 lung biopsies in children with interstitial pneumonitis, 7 were classified as NSIP [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18775/abstract/5\">",
"     5",
"    </a>",
"    ]. As in adults, NSIP occurs in children with immune-mediated disorders and hypersensitivity pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18775/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Organizing pneumonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cryptogenic organizing pneumonitis (COP), previously called bronchiolitis obliterans organizing pneumonia (BOOP), is a rare type of pediatric ILD characterized by patchy areas of inflammation and organizing pneumonia with obstruction of airways by intraluminal polyps of fibrous tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18775/abstract/7\">",
"     7",
"    </a>",
"    ]. The histopathologic lesions characteristic of COP include excessive proliferation of granulation tissue within small airways (proliferative bronchiolitis) and alveolar ducts, associated with chronic inflammation in the surrounding alveoli. COP may be idiopathic [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18775/abstract/8\">",
"     8",
"    </a>",
"    ], AIDS-related [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18775/abstract/9\">",
"     9",
"    </a>",
"    ], or a complication of chemotherapeutic regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18775/abstract/7\">",
"     7",
"    </a>",
"    ] or bone marrow transplantation with graft versus host disease [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18775/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Lymphocytic interstitial pneumonia (LIP)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lymphocytic interstitial pneumonitis in children is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/10/7335?source=see_link\">",
"     \"Lymphocytic interstitial pneumonitis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Usual interstitial pneumonia (UIP)",
"    </span>",
"    &nbsp;&mdash;&nbsp;UIP is characterized by an ongoing and progressive process with variable distribution of interstitial changes within the lung. The histologic hallmark and chief diagnostic criterion is a heterogeneous appearance with alternating areas of normal lung, interstitial inflammation, fibroblast foci, and honeycomb change. The histologic features of UIP are described in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/23/4474?source=see_link&amp;anchor=H3#H3\">",
"     \"Idiopathic interstitial pneumonias: Clinical manifestations and pathology\", section on 'Usual interstitial pneumonia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Whether UIP exists in children is controversial. In adults, UIP is the histopathologic pattern of the clinical disease idiopathic pulmonary fibrosis (IPF, also called cryptogenic fibrosing alveolitis), which is associated with a poor prognosis. In contrast, children with possible UIP follow a variable clinical course [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18775/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. Furthermore, many researchers consider fibroblast foci to be essential to the diagnosis of UIP [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18775/abstract/4\">",
"     4",
"    </a>",
"    ], and this finding is almost never seen in the pediatric age group. Fibroblast foci were described in one 15-year-old boy with mutations in the ABCA3 gene [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18775/abstract/14\">",
"     14",
"    </a>",
"    ]. However, this is not an actual case of UIP seen in the context of idiopathic pulmonary fibrosis, but rather it occurred in the setting of another disease process.",
"   </p>",
"   <p>",
"    The histologic pattern of UIP can also be found in secondary types of ILD, such as collagen vascular disorders and hypersensitivity pneumonitis (HP). However, these diseases are not IPF, and have distinct mechanisms and clinical courses. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/18/34087?source=see_link\">",
"     \"Epidemiology and causes of hypersensitivity pneumonitis (extrinsic allergic alveolitis)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/34/42534?source=see_link\">",
"     \"Pulmonary manifestations of systemic lupus erythematosus in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     ILD SYNDROMES UNIQUE TO INFANTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of unique forms of ILD have been described in infants and neonates (",
"    <a class=\"graphic graphic_table graphicRef71704 \" href=\"UTD.htm?30/32/31245\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18775/abstract/2\">",
"     2",
"    </a>",
"    ]. These entities likely represent more precise descriptions of previously misidentified disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18775/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Neuroendocrine cell hyperplasia of infancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuroendocrine cell hyperplasia of infancy (NEHI), also known as persistent tachypnea of infancy (PTI), was described in a group of infants who presented with tachypnea, crackles, and hypoxemia in the absence of an underlying disease to explain the symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18775/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Radiographic findings included hyperinflation on chest radiograph, and hyperinflation and ground-glass opacities on high-resolution computed tomography (HRCT), usually involving the right middle lobe, lingular, and central portions of the lung [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18775/abstract/15-19\">",
"     15-19",
"    </a>",
"    ]. Pulmonary function testing was consistent with air trapping (increased",
"    <span class=\"nowrap\">",
"     RV/TLC)",
"    </span>",
"    and restriction (low FEV 0.5 and normal FEV",
"    <span class=\"nowrap\">",
"     0.5/FVC).",
"    </span>",
"    In some cases, the clinical presentation of this disorder is indistinguishable from that of infants with more severe interstitial lung diseases, including inborn errors of surfactant metabolism.",
"   </p>",
"   <p>",
"    Lung biopsy showed only mild and nonspecific changes, but no known pathologic disease process, no interstitial involvement or inflammation, and no infectious organisms. The only consistent finding, demonstrated with bombesin immunohistochemistry, was hyperplasia of neuroendocrine cells in the distal airways and aggregates of neuroendocrine cells in the lobular parenchyma [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18775/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Hence, the more descriptive name, \"neuroendocrine cell hyperplasia of infancy\" [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18775/abstract/20\">",
"     20",
"    </a>",
"    ]. A striking feature of NEHI is the discrepancy between the infant's ill-appearance and the lack of significant abnormalities in radiographic studies and biopsies [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18775/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One report suggests that KL-6, a glycoprotein that is expressed in the normal lung, can be used to distinguish between infants with NEHI and those with inborn errors of surfactant metabolism [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18775/abstract/21\">",
"     21",
"    </a>",
"    ]. Infants with NEHI have normal levels of KL-6, while those with inborn errors of surfactant metabolism are elevated 5- to 10-fold (eg, &gt;500",
"    <span class=\"nowrap\">",
"     U/mL).",
"    </span>",
"    Thus, for infants whose clinical presentation is consistent with NEHI or other interstitial lung diseases, measurement of KL-6 may clarify the diagnosis and avoid the need for lung biopsy.",
"   </p>",
"   <p>",
"    The clinical course and treatment of NEHI have not been well-studied. Patients appear to improve with time, though symptoms may persist for months to years. Treatment with corticosteroids, bronchodilators, and other agents has been tried, with inconsistent results [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18775/abstract/16,17,20\">",
"     16,17,20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Follicular bronchitis/bronchiolitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Follicular",
"    <span class=\"nowrap\">",
"     bronchitis/bronchiolitis",
"    </span>",
"    was described in a small number of infants who presented in the first six weeks of life with tachypnea, fine crackles, and chronic cough [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18775/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. Biopsy findings, present in most, but not all infants, included follicular lymphocytic infiltration surrounding and locally infiltrating the bronchial walls; infectious organisms were not detected. The presence of airway inflammation appears to distinguish follicular",
"    <span class=\"nowrap\">",
"     bronchitis/bronchiolitis",
"    </span>",
"    from NEHI, although it is possible that follicular",
"    <span class=\"nowrap\">",
"     bronchitis/bronchiolitis",
"    </span>",
"    and NEHI are the same entity [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18775/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Pulmonary interstitial glycogenosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary interstitial glycogenosis, also known as cellular interstitial pneumonitis of infancy, was described in several infants who presented with tachypnea since birth and diffuse infiltrates of unknown etiology [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18775/abstract/24-28\">",
"     24-28",
"    </a>",
"    ]. Lung biopsy demonstrated interstitial proliferation of bland, nondescript histiocytic type cells and minimal or no inflammation. Electron microscopy demonstrated that these interstitial cells contained monoparticulate glycogen, called \"pulmonary interstitial glycogenosis\" by the authors [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18775/abstract/26\">",
"     26",
"    </a>",
"    ]. Most infants remained tachypneic for months but generally improved over time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Chronic pneumonitis of infancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic pneumonitis of infancy occurs in term or late preterm infants who appear well initially and then develop tachypnea or other respiratory symptoms and hypoxemia with diffuse interstitial infiltrates on imaging studies [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18775/abstract/2\">",
"     2",
"    </a>",
"    ]. Characteristic pathologic findings include alveolar septal thickening, pneumocyte hyperplasia, and an alveolar exudate containing numerous macrophages, occasional eosinophilic globules, and rare cholesterol clefts [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18775/abstract/27,29,30\">",
"     27,29,30",
"    </a>",
"    ]. Although this pattern has been associated with gastroesophageal reflux and lysinuric protein intolerance in the past [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18775/abstract/28\">",
"     28",
"    </a>",
"    ], it is now recognized that chronic pneumonitis of infancy mainly is a manifestation of genetic abnormalities of surfactant function, which are discussed in the next section.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Genetic abnormalities of surfactant function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genetic abnormalities of surfactant function have been described in infants with ILD [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18775/abstract/31-33\">",
"     31-33",
"    </a>",
"    ]. This group of disorders probably encompasses some infants who were previously diagnosed with idiopathic pulmonary fibrosis, familial desquamative interstitial pneumonitis, or congenital alveolar proteinosis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18775/abstract/34-37\">",
"     34-37",
"    </a>",
"    ]. These rare disorders may produce familial or sporadic lung disease, with clinical presentations ranging from neonatal respiratory failure to childhood- or adult-onset interstitial lung disease. An overview of these disorders is presented in the table (",
"    <a class=\"graphic graphic_table graphicRef71981 \" href=\"UTD.htm?15/47/16125\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/33/43545?source=see_link\">",
"     \"Genetic disorders of surfactant dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Mutations causing surfactant dysfunction should be considered in infants with the following clinical presentations [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18775/abstract/20,38\">",
"     20,38",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Severe unexplained lung disease in the newborn period",
"     </li>",
"     <li>",
"      Diffuse disease involving the entire lung on HRCT",
"     </li>",
"     <li>",
"      Histopathology that demonstrates findings of congenital alveolar proteinosis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/22/360?source=see_link\">",
"       \"Pulmonary alveolar proteinosis in children\"",
"      </a>",
"      ), desquamative interstitial pneumonia, nonspecific interstitial pneumonia, or chronic pneumonitis of infancy",
"     </li>",
"     <li>",
"      Electron microscopy demonstrating abnormal or absent lamellar bodies",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Genetic defects in surfactant function include mutations in the genes encoding surfactant proteins B or C (SP-B and SP-C), the ATP-binding cassette transporter A3 (ABCA3) gene, and NKX2.1 (also called thyroid transcription factor 1). The SP-B and SP-C proteins are essential components of surfactant, and ABCA3 and NKX2.1 are important for the production of functional surfactant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Interstitial lung disease (ILD) is also known as interstitial pneumonitis, diffuse infiltrative lung disease, or diffuse parenchymal lung disease, and consists of a diverse group of rare disorders that involve the pulmonary parenchyma and interfere with gas exchange. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      ILD in children can be classified according to the etiology if the etiology is known, and whether the ILD is primarily a pulmonary process or whether it occurs in association with a systemic disorder (",
"      <a class=\"graphic graphic_table graphicRef71704 \" href=\"UTD.htm?30/32/31245\">",
"       table 1",
"      </a>",
"      ). In addition, ILD can be caused by chronic aspiration, chronic infection, and hypersensitivity syndromes. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Etiologic classification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      ILD in which the specific cause is unknown is termed idiopathic ILD. Of the seven categories of idiopathic interstitial pneumonia that are classified in adults on the basis of histopathology (",
"      <a class=\"graphic graphic_table graphicRef68251 \" href=\"UTD.htm?23/25/23963\">",
"       table 2",
"      </a>",
"      ), five may be applicable to children. Idiopathic ILD patterns seen in children include desquamative interstitial pneumonia (DIP), acute interstitial pneumonia (AIP), nonspecific interstitial pneumonia (NSIP), organizing pneumonia, and lymphocytic interstitial pneumonia (LIP). Whether usual interstitial pneumonia (UIP) exists in children is controversial. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Idiopathic ILD'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most cases of desquamative interstitial pneumonitis (DIP) in children and chronic pneumonitis of infancy are now recognized to be caused by inborn errors of surfactant metabolism. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Desquamative interstitial pneumonitis (DIP)'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Chronic pneumonitis of infancy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Genetic abnormalities of surfactant function'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Neuroendocrine cell hyperplasia of infancy (NEHI) presents with tachypnea, crackles, and hypoxemia, with hyperinflation and ground-glass opacities in a characteristic distribution on high-resolution computed tomography (HRCT). Although classic cases are readily diagnosed based on HRCT and infant PFTs, the disorder can occasionally be difficult to distinguish from that of infants with more severe interstitial lung diseases, including inborn errors of surfactant metabolism, without a lung biopsy. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Neuroendocrine cell hyperplasia of infancy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18775/abstract/1\">",
"      Langston C, Fan LL. The spectrum of interstitial lung disease in childhood. Pediatr Pulmonol 2001; Suppl 23:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18775/abstract/2\">",
"      Langston C, Fan LL. Diffuse interstitial lung disease in infants. Pediatr Pulmonol 2001; Suppl 23:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18775/abstract/3\">",
"      Griese M, Haug M, Brasch F, et al. Incidence and classification of pediatric diffuse parenchymal lung diseases in Germany. Orphanet J Rare Dis 2009; 4:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18775/abstract/4\">",
"      Katzenstein AL, Myers JL. Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification. Am J Respir Crit Care Med 1998; 157:1301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18775/abstract/5\">",
"      Nicholson AG, Kim H, Corrin B, et al. The value of classifying interstitial pneumonitis in childhood according to defined histological patterns. Histopathology 1998; 33:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18775/abstract/6\">",
"      Katzenstein AL, Fiorelli RF. Nonspecific interstitial pneumonia/fibrosis. Histologic features and clinical significance. Am J Surg Pathol 1994; 18:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18775/abstract/7\">",
"      Battistini E, Dini G, Savioli C, et al. Bronchiolitis obliterans organizing pneumonia in three children with acute leukaemias treated with cytosine arabinoside and anthracyclines. Eur Respir J 1997; 10:1187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18775/abstract/8\">",
"      Inoue T, Toyoshima K, Kikui M. Idiopathic bronchiolitis obliterans organizing pneumonia (idiopathic BOOP) in childhood. Pediatr Pulmonol 1996; 22:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18775/abstract/9\">",
"      Zahraa J, Herold B, Abrahams C, Johnson D. Bronchiolitis obliterans organizing pneumonia in a child with acquired immunodeficiency syndrome. Pediatr Infect Dis J 1996; 15:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18775/abstract/10\">",
"      Kleinau I, Perez-Canto A, Schmid HJ, et al. Bronchiolitis obliterans organizing pneumonia and chronic graft-versus-host disease in a child after allogeneic bone marrow transplantation. Bone Marrow Transplant 1997; 19:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18775/abstract/11\">",
"      Zapletal A, Houst��k J, Sam&aacute;nek M, et al. Lung function in children and adolescents with idiopathic interstitial pulmonary fibrosis. Pediatr Pulmonol 1985; 1:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18775/abstract/12\">",
"      Chetty A, Bhuyan UN, Mitra DK, et al. Cryptogenic fibrosing alveolitis in children. Ann Allergy 1987; 58:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18775/abstract/13\">",
"      Steinkamp G, M&uuml;ller KM, Schirg E, von der Hardt H. Fibrosing alveolitis in childhood. A long-term follow-up. Acta Paediatr Scand 1990; 79:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18775/abstract/14\">",
"      Young LR, Nogee LM, Barnett B, et al. Usual interstitial pneumonia in an adolescent with ABCA3 mutations. Chest 2008; 134:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18775/abstract/15\">",
"      Fan LL, Langston C. Pediatric interstitial lung disease: children are not small adults. Am J Respir Crit Care Med 2002; 165:1466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18775/abstract/16\">",
"      Deterding RR, Fan LL, Morton R, et al. Persistent tachypnea of infancy (PTI)--a new entity. Pediatr Pulmonol 2001; Suppl 23:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18775/abstract/17\">",
"      Deterding RR, Pye C, Fan LL, Langston C. Persistent tachypnea of infancy is associated with neuroendocrine cell hyperplasia. Pediatr Pulmonol 2005; 40:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18775/abstract/18\">",
"      Brody AS, Guillerman RP, Hay TC, et al. Neuroendocrine cell hyperplasia of infancy: diagnosis with high-resolution CT. AJR Am J Roentgenol 2010; 194:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18775/abstract/19\">",
"      Kinane TB, Shailam R, Mark EJ. Case records of the Massachusetts General Hospital. Case 37-2011. A 9-month-old boy with recurrent tachypnea and respiratory distress. N Engl J Med 2011; 365:2221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18775/abstract/20\">",
"      Fan LL, Deterding RR, Langston C. Pediatric interstitial lung disease revisited. Pediatr Pulmonol 2004; 38:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18775/abstract/21\">",
"      Doan ML, Elidemir O, Dishop MK, et al. Serum KL-6 differentiates neuroendocrine cell hyperplasia of infancy from the inborn errors of surfactant metabolism. Thorax 2009; 64:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18775/abstract/22\">",
"      Kinane BT, Mansell AL, Zwerdling RG, et al. Follicular bronchitis in the pediatric population. Chest 1993; 104:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18775/abstract/23\">",
"      Hull J, Chow CW, Robertson CF. Chronic idiopathic bronchiolitis of infancy. Arch Dis Child 1997; 77:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18775/abstract/24\">",
"      Schroeder SA, Shannon DC, Mark EJ. Cellular interstitial pneumonitis in infants. A clinicopathologic study. Chest 1992; 101:1065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18775/abstract/25\">",
"      Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 40-1999. A four-month-old girl with chronic cyanosis and diffuse pulmonary infiltrates. N Engl J Med 1999; 341:2075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18775/abstract/26\">",
"      Canakis AM, Cutz E, Manson D, O'Brodovich H. Pulmonary interstitial glycogenosis: a new variant of neonatal interstitial lung disease. Am J Respir Crit Care Med 2002; 165:1557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18775/abstract/27\">",
"      Katzenstein AL, Gordon LP, Oliphant M, Swender PT. Chronic pneumonitis of infancy. A unique form of interstitial lung disease occurring in early childhood. Am J Surg Pathol 1995; 19:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18775/abstract/28\">",
"      Fisher M, Roggli V, Merten D, et al. Coexisting endogenous lipoid pneumonia, cholesterol granulomas, and pulmonary alveolar proteinosis in a pediatric population: a clinical, radiographic, and pathologic correlation. Pediatr Pathol 1992; 12:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18775/abstract/29\">",
"      Abe K, Kamata N, Okazaki E, et al. Chronic pneumonitis of infancy. Eur Radiol 2002; 12 Suppl 3:S155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18775/abstract/30\">",
"      Kavantzas N, Theocharis S, Agapitos E, Davaris P. Chronic pneumonitis of infancy. An autopsy study of 12 cases. Clin Exp Pathol 1999; 47:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18775/abstract/31\">",
"      Nogee LM, de Mello DE, Dehner LP, Colten HR. Brief report: deficiency of pulmonary surfactant protein B in congenital alveolar proteinosis. N Engl J Med 1993; 328:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18775/abstract/32\">",
"      Nogee LM, Dunbar AE 3rd, Wert SE, et al. A mutation in the surfactant protein C gene associated with familial interstitial lung disease. N Engl J Med 2001; 344:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18775/abstract/33\">",
"      Brasch F, Griese M, Tredano M, et al. Interstitial lung disease in a baby with a de novo mutation in the SFTPC gene. Eur Respir J 2004; 24:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18775/abstract/34\">",
"      Osika E, Muller MH, Boccon-Gibod L, et al. Idiopathic pulmonary fibrosis in infants. Pediatr Pulmonol 1997; 23:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18775/abstract/35\">",
"      Tal A, Maor E, Bar-Ziv J, Gorodischer R. Fatal desquamative interstitial pneumonia in three infants siblings. J Pediatr 1984; 104:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18775/abstract/36\">",
"      Buchino JJ, Keenan WJ, Algren JT, Bove KE. Familial desquamative interstitial pneumonitis occurring in infants. Am J Med Genet Suppl 1987; 3:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18775/abstract/37\">",
"      Balasubramanyan N, Murphy A, O'Sullivan J, O'Connell EJ. Familial interstitial lung disease in children: response to chloroquine treatment in one sibling with desquamative interstitial pneumonitis. Pediatr Pulmonol 1997; 23:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18775/abstract/38\">",
"      Kunig AM, Parker TA, Nogee LM, et al. ABCA3 deficiency presenting as persistent pulmonary hypertension of the newborn. J Pediatr 2007; 151:322.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6381 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-200.215.4.194-84581B2B62-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_21_18775=[""].join("\n");
var outline_f18_21_18775=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ETIOLOGIC CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      IDIOPATHIC ILD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Desquamative interstitial pneumonitis (DIP)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Acute interstitial pneumonia (AIP)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Nonspecific interstitial pneumonia (NSIP)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Organizing pneumonia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Lymphocytic interstitial pneumonia (LIP)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Usual interstitial pneumonia (UIP)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      ILD SYNDROMES UNIQUE TO INFANTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Neuroendocrine cell hyperplasia of infancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Follicular bronchitis/bronchiolitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Pulmonary interstitial glycogenosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Chronic pneumonitis of infancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Genetic abnormalities of surfactant function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6381\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6381|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/6/21609\" title=\"picture 1\">",
"      NSIP lung biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6381|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/32/31245\" title=\"table 1\">",
"      Classification pediatric ILD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/25/23963\" title=\"table 2\">",
"      Histologic clinical class idiopathic interstitial pneumonias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/47/16125\" title=\"table 3\">",
"      Genetic disorders surfactant dysfunction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/22/26985?source=related_link\">",
"      Approach to the infant and child with interstitial lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/18/34087?source=related_link\">",
"      Epidemiology and causes of hypersensitivity pneumonitis (extrinsic allergic alveolitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/33/43545?source=related_link\">",
"      Genetic disorders of surfactant dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/23/4474?source=related_link\">",
"      Idiopathic interstitial pneumonias: Clinical manifestations and pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/10/7335?source=related_link\">",
"      Lymphocytic interstitial pneumonitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/22/360?source=related_link\">",
"      Pulmonary alveolar proteinosis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/34/42534?source=related_link\">",
"      Pulmonary manifestations of systemic lupus erythematosus in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_21_18776="Stress ulcer prophylaxis in the intensive care unit";
var content_f18_21_18776=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Stress ulcer prophylaxis in the intensive care unit",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/21/18776/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/21/18776/contributors\">",
"     Gerald L Weinhouse, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/21/18776/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/21/18776/contributors\">",
"     Scott Manaker, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/21/18776/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/21/18776/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/21/18776/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 22, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stress ulcerations usually occur in the fundus and body of the stomach, but sometimes develop in the antrum, duodenum, or distal esophagus. They tend to be shallow and cause oozing of blood from superficial capillary beds. Deeper lesions may also occur, which can erode into the submucosa and cause massive hemorrhage or perforation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18776/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The epidemiology, pathophysiology, risk factors, and prognosis of stress ulceration in the intensive care unit (ICU) are discussed in this topic review. In addition, stress ulcer prophylaxis is reviewed. Diagnosis and treatment of bleeding peptic ulcers are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28538?source=see_link\">",
"     \"Approach to acute upper gastrointestinal bleeding in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/15/24826?source=see_link\">",
"     \"Overview of the treatment of bleeding peptic ulcers\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     STRESS ULCERATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Estimates of the incidence of overt GI bleeding range from 1.5 to 8.5 percent among all ICU patients, but may be as high as 15 percent among patients who do not receive stress ulcer prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18776/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]. Most episodes of overt GI bleeding in critically ill patients are due to gastric or esophageal ulceration, as determined by endoscopic studies [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18776/abstract/2,5\">",
"     2,5",
"    </a>",
"    ]. Stress ulceration can also cause perforation. However, this complication is rare, occurring in fewer than 1 percent of surgical ICU patients [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18776/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Pathophysiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stress ulceration generally begins in the proximal regions of the stomach within hours of major trauma or serious illness. Endoscopy performed within 72 hours of a major burn or cranial trauma reveals acute mucosal abnormalities in greater than 75 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18776/abstract/7\">",
"     7",
"    </a>",
"    ]. Up to 50 percent of such lesions have endoscopic evidence of recent or ongoing bleeding, although only a small percentage of patients experience hemodynamic compromise due to acute blood loss [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18776/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Stress ulcerations that develop after the first several days of hospitalization tend to be deeper and more distal [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18776/abstract/8\">",
"     8",
"    </a>",
"    ]. In a study of 67 patients with GI bleeding that occurred an average of 14 days after admission, duodenal ulceration was the most common source of bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18776/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is uncertain if early and late stress ulcerations have the same pathophysiology. However, both types probably result from an imbalance between mucosal protection and gastric acid production.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Impaired mucosal protection - The stomach is normally protected by a glycoprotein mucous layer that forms a physical barrier to hydrogen ion diffusion and traps bicarbonate. The bicarbonate neutralizes gastric acid adjacent to the stomach wall. This barrier may be denuded by increased concentrations of refluxed bile salts or uremic toxins, which are common in critically ill patients [",
"      <a class=\"abstract\" href=\"UTD.htm?18/21/18776/abstract/10,11\">",
"       10,11",
"      </a>",
"      ]. In addition, its synthesis may be decreased when there is poor gut perfusion caused by shock, sepsis, or trauma [",
"      <a class=\"abstract\" href=\"UTD.htm?18/21/18776/abstract/12,13\">",
"       12,13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hypersecretion of acid - Hypersecretion of acid due to excessive gastrin stimulation of parietal cells has been detected in patients with head trauma [",
"      <a class=\"abstract\" href=\"UTD.htm?18/21/18776/abstract/14-16\">",
"       14-16",
"      </a>",
"      ]. This abnormality is probably not a factor in all ICU patients, since acid secretion tends to be normal or subnormal in most other patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    H. pylori infection may also contribute to stress ulceration, but the evidence is of limited quality. A case-control study of 50 ICU patients found that patients with GI bleeding were more likely to have H. pylori infection than patients without acute GI bleeding (36 versus 16 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18776/abstract/17\">",
"     17",
"    </a>",
"    ]. Conversely, another observational study of 99 ICU patients found that patients with H. pylori infection were more likely to have GI bleeding than patients without H. pylori infection (23 versus 13 percent), although the difference did not reach statistical significance [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18776/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;A multicenter prospective cohort study of 2252 ICU patients identified two major risk factors for clinically important GI bleeding (defined as overt GI bleeding leading to hemodynamic deterioration or requiring blood transfusion) due to stress ulceration [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18776/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Mechanical ventilation for more than 48 hours (odds ratio 15.6)",
"     </li>",
"     <li>",
"      Coagulopathy (odds ratio 4.3)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The incidence of clinically important GI bleeding among patients with one or both of these risk factors was 3.7 percent, compared to 0.1 percent among patients with neither risk factor.",
"   </p>",
"   <p>",
"    Smaller studies have reported additional risk factors for stress ulceration, including shock, sepsis, hepatic failure, renal failure, multiple trauma, burns over 35 percent of total body surface area, organ transplantation, head trauma, spinal trauma, a history of peptic ulcer disease, and a history of upper GI bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18776/abstract/1,4,19-21\">",
"     1,4,19-21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Glucocorticoid therapy is commonly cited as an indication for stress ulcer prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18776/abstract/22\">",
"     22",
"    </a>",
"    ]. However, glucocorticoid therapy alone has not been conclusively shown to be a risk factor for stress ulceration [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18776/abstract/2\">",
"     2",
"    </a>",
"    ]. Glucocorticoid therapy may increase the risk of stress ulceration when combined with other risk factors for GI ulceration, such as nonsteroidal antiinflammatory drugs or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link&amp;anchor=H11#H11\">",
"     \"Major side effects of systemic glucocorticoids\", section on 'Gastrointestinal tract'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Overt GI bleeding due to stress ulceration is associated with increased mortality. In the prospective cohort study described above, mortality was higher among ICU patients with clinically important GI bleeding than among those without bleeding (49 versus 9 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18776/abstract/2\">",
"     2",
"    </a>",
"    ]. Another study used four different statistical models to adjust for confounders and found that overt GI bleeding was associated with increased mortality using three of the models (relative risk ranged from 1.8 to 4.9) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18776/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PROPHYLAXIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H929814\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is widely accepted that prophylaxis is indicated for ICU patients who are at high risk for stress ulceration, although there is disagreement about which clinical characteristics define high risk.",
"   </p>",
"   <p>",
"    The American Society of Health System Pharmacists developed clinical practice guidelines based upon studies that compared prophylaxis to no prophylaxis and used clinically important GI bleeding as an endpoint [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18776/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. The guidelines recommend stress ulcer prophylaxis for ICU patients with any of the following characteristics: coagulopathy, mechanical ventilation for more than 48 hours, history of GI ulceration or bleeding with the past year, and two or more minor risk factors. Minor risk factors included sepsis, ICU admission lasting &gt;1 week, occult GI bleeding lasting &ge;6 days, and glucocorticoid therapy.",
"   </p>",
"   <p>",
"    Many clinicians also provide stress ulcer prophylaxis to patients with traumatic brain injury, traumatic spinal cord injury, or thermal injury (&gt;35 percent of the body surface area) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18776/abstract/25\">",
"     25",
"    </a>",
"    ]. Their rationale is that such patients have been routinely excluded from studies of stress ulcer prophylaxis because of a presumed high risk of stress ulceration.",
"   </p>",
"   <p>",
"    It is frequently asked whether a patient who is receiving enteral nutrition also requires pharmacological stress ulcer prophylaxis. This question is based upon reports that enteral nutrition alone may reduce the risk of overt GI bleeding due to stress ulceration and that stress ulcer prophylaxis may be ineffective or harmful among patients who are receiving enteral nutrition:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Enteral nutrition alone may reduce the risk of overt GI bleeding due to stress ulceration [",
"      <a class=\"abstract\" href=\"UTD.htm?18/21/18776/abstract/26-28\">",
"       26-28",
"      </a>",
"      ]: In one observational study performed using data from a randomized trial, enteral nutrition independently reduced overt GI bleeding (relative risk 0.30, 95% CI, 0.13-0.67) in 1077 critically ill patients who were mechanically ventilated for more than 48 hours [",
"      <a class=\"abstract\" href=\"UTD.htm?18/21/18776/abstract/28\">",
"       28",
"      </a>",
"      ]. Another observational study of 526 patients in a burn intensive care unit found that the incidence of overt GI bleeding was lower among patients who received early enteral nutrition alone than among patients who received an H2 blocker without early enteral nutrition (3 versus 8 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/21/18776/abstract/27\">",
"       27",
"      </a>",
"      ]. While these observational data suggest that enteral nutrition may be an adequate substitute for pharmacologic stress ulcer prophylaxis in ICU patients, controlled clinical trials are necessary for confirmation.",
"     </li>",
"     <li>",
"      Pharmacological stress ulcer prophylaxis may be ineffective or harmful among patients who are receiving enteral nutrition: A quantitative systematic review of randomized trials comparing H2 blockers to placebo for the prevention of stress ulceration found that the effect of the H2 blockers varied according to whether the patients were receiving early enteral nutrition [",
"      <a class=\"abstract\" href=\"UTD.htm?18/21/18776/abstract/29\">",
"       29",
"      </a>",
"      ]. Among patients not receiving early enteral nutrition, H2 blockers reduced the incidence of GI bleeding and had no significant effect on mortality or the rate of hospital-acquired pneumonia. Among patients receiving early enteral nutrition, however, H2 blockers increased mortality and the incidence of hospital-acquired pneumonia, without reducing the rate of GI bleeding. This systematic review had several important limitations. Among the limitations, it included both patients who are at high risk and low risk for stress ulceration. Thus, it is possible that the harmful effects of prophylaxis seen among patients receiving enteral nutrition were due to unnecessary prophylaxis in low risk patients, rather than a more general harmful effect among all patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While such reports are thought provoking and warrant further study, we believe that the evidence is insufficient to justify withholding stress ulcer prophylaxis from patients who are at high risk for gastrointestinal bleeding even if they are receiving enteral nutrition. Putting the evidence together, we suggest that stress ulcer prophylaxis be administered to all critically ill patients who are at high risk for gastrointestinal bleeding. This includes patients with any of the following characteristics:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Coagulopathy, defined as a platelet count &lt;50,000 per m3, an International Normalized Ratio (INR) &gt;1.5, or a partial thromboplastin time (PTT) &gt;2 times the control value",
"     </li>",
"     <li>",
"      Mechanical ventilation for &gt;48 hours",
"     </li>",
"     <li>",
"      History of GI ulceration or bleeding within the past year",
"     </li>",
"     <li>",
"      Traumatic brain injury, traumatic spinal cord injury, or burn injury",
"     </li>",
"     <li>",
"      Two or more of the following: sepsis, an ICU stay &gt;1 week, occult GI bleeding for &ge;6 days, or glucocorticoid therapy (more than 250 mg",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"       hydrocortisone",
"      </a>",
"      or the equivalent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Among patients who are not considered high risk for gastrointestinal bleeding, we believe that stress ulcer prophylaxis should be administered on a case-by-case basis. Among the considerations are whether the patient is receiving enteral nutrition, how long the patient is expected to be without enteral nutrition, the severity of the patient&rsquo;s illness, and the patient&rsquo;s comorbidities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H929392\">",
"    <span class=\"h2\">",
"     Pharmacologic agents",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      H2 blockers &mdash; Histamine-2 receptor antagonists (H2 blockers) antagonize the H2 receptors on the parietal cell, resulting in diminished gastric acid secretion. They can be given orally, via nasogastric tube, or intravenously [",
"      <a class=\"abstract\" href=\"UTD.htm?18/21/18776/abstract/30\">",
"       30",
"      </a>",
"      ]. The dose depends on which H2 blocker is used (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/54/2921?source=see_link\">",
"       cimetidine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/56/42888?source=see_link\">",
"       ranitidine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/45/728?source=see_link\">",
"       famotidine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/16/29958?source=see_link\">",
"       nizatidine",
"      </a>",
"      ). Continuous intravenous infusion is more effective than bolus intravenous infusion at controlling gastric pH [",
"      <a class=\"abstract\" href=\"UTD.htm?18/21/18776/abstract/31,32\">",
"       31,32",
"      </a>",
"      ]. However, there is no moderate or high quality data indicating that it is more effective at preventive clinically significant GI bleeding. H2 blockers are generally well tolerated, but a number of uncommon side effects have been reported. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/47/13049?source=see_link&amp;anchor=H2#H2\">",
"       \"Pharmacology of antiulcer medications\", section on 'H2 receptor antagonists'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Proton pump inhibitors &mdash; Proton pump inhibitors (PPIs) block acid secretion by irreversibly binding to and inhibiting the hydrogen-potassium ATPase pump that resides on the luminal surface of the parietal cell membrane. They can be given orally, via nasogastric tube, or intravenously [",
"      <a class=\"abstract\" href=\"UTD.htm?18/21/18776/abstract/24\">",
"       24",
"      </a>",
"      ]. The dose depends on which PPI is used (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/62/26601?source=see_link\">",
"       omeprazole",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/14/3305?source=see_link\">",
"       lansoprazole",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/18/44327?source=see_link\">",
"       rabeprazole",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/16/32009?source=see_link\">",
"       pantoprazole",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/39/15993?source=see_link\">",
"       esomeprazole",
"      </a>",
"      ). PPIs are an extremely safe class of drugs, although some risks have been described. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/47/13049?source=see_link&amp;anchor=H14#H14\">",
"       \"Pharmacology of antiulcer medications\", section on 'Proton pump inhibitors'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/28/25034?source=see_link&amp;anchor=H59974871#H59974871\">",
"       \"Overview and comparison of the proton pump inhibitors for the treatment of acid-related disorders\", section on 'Safety'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/29/29141?source=see_link\">",
"       Sucralfate",
"      </a>",
"      &mdash; Sucralfate is a sulfated polysaccharide complexed with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/16/27910?source=see_link\">",
"       aluminum hydroxide",
"      </a>",
"      . It exerts its effects by coating and protecting the gastric mucosa, without altering gastric acid secretion or significantly buffering acid [",
"      <a class=\"abstract\" href=\"UTD.htm?18/21/18776/abstract/33,34\">",
"       33,34",
"      </a>",
"      ]. Sucralfate is administered orally or via nasogastric tube at a dose of 1 gram four times per day. It is generally well tolerated, except for infrequent aluminum toxicity. In a prospective cohort study of 11 mechanically ventilated patients who received sucralfate (6 grams per day) for 14 days, none of the patients developed an elevated plasma aluminum concentration, even in the presence of renal impairment [",
"      <a class=\"abstract\" href=\"UTD.htm?18/21/18776/abstract/35\">",
"       35",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/47/13049?source=see_link&amp;anchor=H18#H18\">",
"       \"Pharmacology of antiulcer medications\", section on 'Sucralfate'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/47/13049?source=see_link&amp;anchor=H20#H20\">",
"       \"Pharmacology of antiulcer medications\", section on 'Aluminum toxicity'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Antacids &mdash; Antacids neutralize gastric acid and protect the gastric mucosa. Antacids are generally administered every one to two hours at a dose of 30 to 60 mL either orally or via nasogastric tube. Nasogastric tube obstruction can be problematic. Side effects of antacids include hypermagnesemia, hypercalcemia, hypophosphatemia, constipation, and diarrhea. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/58/13220?source=see_link&amp;anchor=H5#H5\">",
"       \"Causes and treatment of hypermagnesemia\", section on 'Oral ingestion'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/22/28007?source=see_link&amp;anchor=H11#H11\">",
"       \"Etiology of hypercalcemia\", section on 'Milk alkali syndrome'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/25/15767?source=see_link&amp;anchor=H8#H8\">",
"       \"Causes of hypophosphatemia\", section on 'Antacids containing aluminum or magnesium'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/47/13049?source=see_link&amp;anchor=H16#H16\">",
"       \"Pharmacology of antiulcer medications\", section on 'antacids'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Prostanoids &mdash; Prostanoids (ie, prostaglandin analogs), such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"       misoprostol",
"      </a>",
"      , inhibit gastric acid secretion by selectively reducing the ability of the parietal cell to generate cyclic AMP in response to histamine. They also exert a cytoprotective effect by enhancing mucosal defense mechanisms [",
"      <a class=\"abstract\" href=\"UTD.htm?18/21/18776/abstract/36,37\">",
"       36,37",
"      </a>",
"      ]. As an example, prostanoid-induced capillary bed vasodilation may protect against local ischemia. Prostanoids are not commonly used for stress ulcer prophylaxis in ICU patients because there are a paucity of data regarding their impact on clinically important outcomes and they have a propensity to cause diarrhea [",
"      <a class=\"abstract\" href=\"UTD.htm?18/21/18776/abstract/7,19\">",
"       7,19",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/47/13049?source=see_link&amp;anchor=H23#H23\">",
"       \"Pharmacology of antiulcer medications\", section on 'Prostaglandins'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical trials have demonstrated that H2 blockers, PPIs, and antacids reduce the frequency of overt GI bleeding in ICU patients compared to placebo or no prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18776/abstract/4,38-42\">",
"     4,38-42",
"    </a>",
"    ]. Comparative trials have also been performed; despite this, the body of evidence is relatively poor because many of the studies were imprecise or had other significant methodologic flaws. This section describes the moderate to high quality comparative evidence:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      H2 blockers versus PPI &ndash; A meta-analysis of 13 randomized trials (1587 patients) compared stress ulcer prophylaxis with a PPI to prophylaxis with an H2 blocker [",
"      <a class=\"abstract\" href=\"UTD.htm?18/21/18776/abstract/43\">",
"       43",
"      </a>",
"      ]. It found less GI bleeding among those who received a PPI (1.3 versus 6.6 percent, odds ratio 0.30, 95% CI 0.17-0.54). There was no difference in mortality or the incidence of nosocomial pneumonia.",
"     </li>",
"     <li>",
"      H2 blockers versus antacids &ndash; A meta-analysis that compared H2 blockers to antacids in critically ill patients found that the H2 blocker group had a significantly lower rate of overt GI bleeding (odds ratio 0.56, 95% CI, 0.33-0.97) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/21/18776/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      H2 blockers versus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/29/29141?source=see_link\">",
"       sucralfate",
"      </a>",
"      &ndash; A trial randomly assigned 1200 mechanically ventilated patients to receive sucralfate suspension via nasogastric tube plus an intravenous placebo, or an H2 blocker (intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/56/42888?source=see_link\">",
"       ranitidine",
"      </a>",
"      ) plus a placebo suspension via nasogastric tube [",
"      <a class=\"abstract\" href=\"UTD.htm?18/21/18776/abstract/44\">",
"       44",
"      </a>",
"      ]. The H2 blocker decreased overt GI bleeding compared to sucralfate (1.7 versus 3.8 percent).",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/29/29141?source=see_link\">",
"       Sucralfate",
"      </a>",
"      versus antacids &ndash; A meta-analysis that compared sucralfate to antacids in ICU patients found that the antacids group had a lower rate of clinically important GI bleeding, but the difference was not statistically significant [",
"      <a class=\"abstract\" href=\"UTD.htm?18/21/18776/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Other comparisons &ndash; There are a lack of moderate or high quality trials comparing PPIs to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/29/29141?source=see_link\">",
"       sucralfate",
"      </a>",
"      , PPIs to antacids, sucralfate to placebo in critically ill patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Potential harms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Randomized trials and meta-analyses suggest that prophylactic agents that increase gastric pH (eg, PPIs, H2 blockers, and antacids) may increase the frequency of nosocomial pneumonia compared to agents that do not alter gastric pH (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/29/29141?source=see_link\">",
"     sucralfate",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18776/abstract/38,44-47\">",
"     38,44-47",
"    </a>",
"    ]. As an example, a trial that randomly assigned 1200 mechanically ventilated patients to receive either an intravenous H2 blocker (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/56/42888?source=see_link\">",
"     ranitidine",
"    </a>",
"    ) or sucralfate found that ventilator-associated pneumonia was more frequent in the H2 blocker group, although the difference was not statistically significant (19 versus 16 percent, RR 1.18, 95% CI 0.92-1.51).",
"   </p>",
"   <p>",
"    The clinical importance of the evidence that certain prophylactic agents may increase the incidence of nosocomial pneumonia is uncertain because many of the studies did not achieve statistical significance. However, the direction of the effect was the same in most of the studies, indicating that insufficient sample size may be the reason that the results were not statistically significant.",
"   </p>",
"   <p>",
"    The impact of different prophylactic agents on the incidence of nosocomial pneumonia may be variable. This was suggested by an observational study in cardiothoracic surgery patients that found a higher incidence of nosocomial pneumonia among patients who received a PPI than among those who received an H2 blocker [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18776/abstract/48\">",
"     48",
"    </a>",
"    ], as well as a randomized trial that found a higher risk of nosocomial pneumonia among mechanically ventilated patients who received an H2 blocker than among those who received an antacid [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18776/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A potential mechanism for prophylaxis-related nosocomial pneumonia has been proposed. Agents that raise gastric pH promote the growth of bacteria in the stomach, particularly gram-negative bacilli that originate in the duodenum. Esophageal reflux and aspiration of gastric contents along the endotracheal tube may then lead to endobronchial colonization or pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18776/abstract/46,49-52\">",
"     46,49-52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2073692\">",
"    <span class=\"h2\">",
"     Choosing an agent",
"    </span>",
"    &nbsp;&mdash;&nbsp;For ICU patients who are able to receive enteral medications and in whom stress ulcer prophylaxis is indicated, we recommend an oral PPI rather than an alternative prophylactic agent. In contrast, for those who cannot receive enteral medications, we suggest an intravenous H2 blocker rather than an intravenous proton pump inhibitor. Our rationale is that intravenous H2 blockers are substantially less expensive than intravenous PPIs and the lower cost probably outweighs the modest increase in efficacy, especially since the baseline risk of stress ulcer-related gastrointestinal bleeding is low. In situations where cost is not an issue, an intravenous PPI is an appropriate choice. It is important to reiterate and emphasize that this discussion is about prophylaxis; active gastrointestinal bleeding requires a different approach. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28538?source=see_link&amp;anchor=H5079594#H5079594\">",
"     \"Approach to acute upper gastrointestinal bleeding in adults\", section on 'Medications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The major factors on which a prophylactic agent is chosen are the balance between efficacy and potential harm, as well as cost.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Efficacy versus potential harm &mdash; The evidence indicates that those prophylactic agents that reduce the frequency of overt GI bleeding in ICU patients most effectively (H2 blockers and PPIs) might be associated with more frequent nosocomial pneumonia. In contrast, a less effective prophylactic agent (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/29/29141?source=see_link\">",
"       sucralfate",
"      </a>",
"      ) may be associated with fewer nosocomial pneumonias. Thus, clinicians need to consider the following when choosing a prophylactic agent: whether prevention of overt GI bleeding or minimizing the incidence of nosocomial pneumonia is of greater clinical importance and the strength of the nosocomial pneumonia data.",
"      <br/>",
"      <br/>",
"      We believe the prophylactic agent should be chosen on the basis of the more definitive evidence - impact on overt GI bleeding - until the relationship between the type of prophylactic agent and the incidence of nosocomial pneumonia is confirmed by more rigorous clinical trials. For this reason, we typically use H2 blockers or PPIs for stress ulcer prophylaxis in our clinical practice.",
"     </li>",
"     <li>",
"      Cost &mdash; Choosing less expensive prophylactic agents or administering prophylaxis only to patients who are at high risk for stress ulceration can diminish the cost of stress ulcer prophylaxis:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Choosing less expensive prophylactic agents - One analysis found that prophylaxis with oral PPI may be more cost-effective than intravenous H2 blockers [",
"      <a class=\"abstract\" href=\"UTD.htm?18/21/18776/abstract/53\">",
"       53",
"      </a>",
"      ]. This was a consequence of the lower cost of oral medications and fewer treatment failures in the oral PPI group.",
"     </li>",
"     <li>",
"      Administering prophylaxis only to patients who are at high risk for stress ulceration - It is estimated that only 30 patients who are at high risk for stress ulceration need to receive prophylaxis to prevent one GI bleed, compared to nearly 900 low risk patients [",
"      <a class=\"abstract\" href=\"UTD.htm?18/21/18776/abstract/54\">",
"       54",
"      </a>",
"      ]. This approach has the added advantage of decreasing the risk of adverse effects related to stress ulcer prophylaxis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, remembering to discontinue prophylaxis when the patient is no longer at high risk for stress ulceration can reduce the cost of stress ulcer prophylaxis. Such prophylaxis is unnecessary because the reduction in the rate of nosocomial gastrointestinal bleeding among non-critically ill patients is minuscule due to the low baseline risk (prophylaxis decreases the rate of gastrointestinal bleeding from 0.33 to 0.22 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18776/abstract/55\">",
"     55",
"    </a>",
"    ]. Despite this, several studies have demonstrated a high rate of ongoing stress ulcer prophylaxis among patients who are discharged from the ICU [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18776/abstract/56,57\">",
"     56,57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stress ulcerations usually occur in the fundus and body of the stomach, but sometimes develop in the antrum, duodenum, or distal esophagus. They tend to be shallow and cause oozing of blood from superficial capillary beds. Deeper lesions may also occur, which can erode into the submucosa and cause massive hemorrhage, perforation, or both. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Histamine-2 receptor antagonists (H2 blockers), proton pump inhibitors (PPI), and antacids reduce overt GI bleeding in ICU patients compared to placebo or no prophylaxis. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Efficacy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prophylactic agents that increase gastric pH (PPI, H2 blockers, antacids) might increase the frequency of nosocomial pneumonia, compared to prophylactic agents that do not alter gastric pH (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/29/29141?source=see_link\">",
"       sucralfate",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Potential harms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Stress ulcer prophylaxis is indicated for any critically ill patient who has one or more of the following risk factors: mechanically ventilated for more than 48 hours, coagulopathy, GI ulceration or bleeding within the past year, traumatic brain injury, traumatic spinal cord injury, severe burns, or two or more minor risk factors. Coagulopathy is defined as a platelet count &lt;50,000 per m3, an International Normalized Ratio (INR) &gt;1.5, or a partial thromboplastin time (PTT) &gt;2 times the control value. Severe burns are defined as &gt;35 percent of the body surface area. Minor risk factors include sepsis, ICU admission lasting &gt;1 week, occult GI bleeding lasting &ge;6 days, or high-dose glucocorticoid therapy (more than 250 mg",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"       hydrocortisone",
"      </a>",
"      or the equivalent). (See",
"      <a class=\"local\" href=\"#H929814\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Stress ulcer prophylaxis should be considered on a case-by-case basis for patients without any of the above risk factors. Considerations include whether the patient is receiving enteral nutrition, how long the patient is expected to be without enteral nutrition, the severity of the patient&rsquo;s illness, and the patient&rsquo;s comorbidities. (See",
"      <a class=\"local\" href=\"#H929814\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For ICU patients who are able to receive enteral medications and in whom stress ulcer prophylaxis is indicated, we recommend an oral PPI rather than an alternative prophylactic agent (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2073692\">",
"       'Choosing an agent'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For ICU patients who cannot receive enteral medications and in whom stress ulcer prophylaxis is indicated, we suggest an intravenous H2 blocker rather than an intravenous proton pump inhibitor (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Intravenous H2 blockers are usually much less expensive than intravenous PPIs and the lower cost probably outweighs the modest increase in efficacy, especially since the baseline risk of stress ulcer-related gastrointestinal bleeding is low. In situations where cost is not an issue, an intravenous PPI is a reasonable choice. (See",
"      <a class=\"local\" href=\"#H2073692\">",
"       'Choosing an agent'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18776/abstract/1\">",
"      Cook DJ. Stress ulcer prophylaxis: gastrointestinal bleeding and nosocomial pneumonia. Best evidence synthesis. Scand J Gastroenterol Suppl 1995; 210:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18776/abstract/2\">",
"      Cook DJ, Fuller HD, Guyatt GH, et al. Risk factors for gastrointestinal bleeding in critically ill patients. Canadian Critical Care Trials Group. N Engl J Med 1994; 330:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18776/abstract/3\">",
"      Ben-Menachem T, Fogel R, Patel RV, et al. Prophylaxis for stress-related gastric hemorrhage in the medical intensive care unit. A randomized, controlled, single-blind study. Ann Intern Med 1994; 121:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18776/abstract/4\">",
"      Shuman RB, Schuster DP, Zuckerman GR. Prophylactic therapy for stress ulcer bleeding: a reappraisal. Ann Intern Med 1987; 106:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18776/abstract/5\">",
"      Cook DJ, Griffith LE, Walter SD, et al. The attributable mortality and length of intensive care unit stay of clinically important gastrointestinal bleeding in critically ill patients. Crit Care 2001; 5:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18776/abstract/6\">",
"      Tsiotos GG, Mullany CJ, Zietlow S, van Heerden JA. Abdominal complications following cardiac surgery. Am J Surg 1994; 167:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18776/abstract/7\">",
"      DePriest JL. Stress ulcer prophylaxis. Do critically ill patients need it? Postgrad Med 1995; 98:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18776/abstract/8\">",
"      Czaja AJ, McAlhany JC, Pruitt BA Jr. Acute gastroduodenal disease after thermal injury. An endoscopic evaluation of incidence and natural history. N Engl J Med 1974; 291:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18776/abstract/9\">",
"      Terdiman JP, Ostroff JW. Gastrointestinal bleeding in the hospitalized patient: a case-control study to assess risk factors, causes, and outcome. Am J Med 1998; 104:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18776/abstract/10\">",
"      Ritchie WP Jr. Role of bile acid reflux in acute hemorrhagic gastritis. World J Surg 1981; 5:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18776/abstract/11\">",
"      Schindlbeck NE, Lippert M, Heinrich C, M&uuml;ller-Lissner SA. Intragastric bile acid concentrations in critically ill, artificially ventilated patients. Am J Gastroenterol 1989; 84:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18776/abstract/12\">",
"      Navab F, Steingrub J. Stress ulcer: is routine prophylaxis necessary? Am J Gastroenterol 1995; 90:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18776/abstract/13\">",
"      Geus WP, Lamers CB. Prevention of stress ulcer bleeding: a review. Scand J Gastroenterol Suppl 1990; 178:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18776/abstract/14\">",
"      Bowen JC, Fleming WH, Thompson JC. Increased gastrin release following penetrating central nervous system injury. Surgery 1974; 75:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18776/abstract/15\">",
"      Stremple JF, Molot MD, McNamara JJ, et al. Posttraumatic gastric bleeding: prospective gastric secretion composition. Arch Surg 1972; 105:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18776/abstract/16\">",
"      Watts CC, Clark K. Gastric acidity in the comatose patient. J Neurosurg 1969; 30:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18776/abstract/17\">",
"      Maury E, Tankovic J, Ebel A, et al. An observational study of upper gastrointestinal bleeding in intensive care units: is Helicobacter pylori the culprit? Crit Care Med 2005; 33:1513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18776/abstract/18\">",
"      Robertson MS, Cade JF, Clancy RL. Helicobacter pylori infection in intensive care: increased prevalence and a new nosocomial infection. Crit Care Med 1999; 27:1276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18776/abstract/19\">",
"      Martin LF, Booth FV, Reines HD, et al. Stress ulcers and organ failure in intubated patients in surgical intensive care units. Ann Surg 1992; 215:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18776/abstract/20\">",
"      Hatton J, Lu WY, Rhoney DH, et al. A step-wise protocol for stress ulcer prophylaxis in the neurosurgical intensive care unit. Surg Neurol 1996; 46:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18776/abstract/21\">",
"      McBride DQ, Rodts GE. Intensive care of patients with spinal trauma. Neurosurg Clin N Am 1994; 5:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18776/abstract/22\">",
"      Daley RJ, Rebuck JA, Welage LS, Rogers FB. Prevention of stress ulceration: current trends in critical care. Crit Care Med 2004; 32:2008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18776/abstract/23\">",
"      ASHP Therapeutic Guidelines on Stress Ulcer Prophylaxis. ASHP Commission on Therapeutics and approved by the ASHP Board of Directors on November 14, 1998. Am J Health Syst Pharm 1999; 56:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18776/abstract/24\">",
"      Spirt MJ, Stanley S. Update on stress ulcer prophylaxis in critically ill patients. Crit Care Nurse 2006; 26:18.",
"     </a>",
"    </li>",
"    <li>",
"     Guillamondegui, OD, Gunter OL, et al. Practice management guidelines for stress ulcer prophylaxis, Eastern Association for the Surgery of Trauma (EAST), Chicago 2008. p.24.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18776/abstract/26\">",
"      Pingleton SK, Hadzima SK. Enteral alimentation and gastrointestinal bleeding in mechanically ventilated patients. Crit Care Med 1983; 11:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18776/abstract/27\">",
"      Raff T, Germann G, Hartmann B. The value of early enteral nutrition in the prophylaxis of stress ulceration in the severely burned patient. Burns 1997; 23:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18776/abstract/28\">",
"      Cook D, Heyland D, Griffith L, et al. Risk factors for clinically important upper gastrointestinal bleeding in patients requiring mechanical ventilation. Canadian Critical Care Trials Group. Crit Care Med 1999; 27:2812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18776/abstract/29\">",
"      Marik PE, Vasu T, Hirani A, Pachinburavan M. Stress ulcer prophylaxis in the new millennium: a systematic review and meta-analysis. Crit Care Med 2010; 38:2222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18776/abstract/30\">",
"      Pemberton LB, Schaefer N, Goehring L, et al. Oral ranitidine as prophylaxis for gastric stress ulcers in intensive care unit patients: serum concentrations and cost comparisons. Crit Care Med 1993; 21:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18776/abstract/31\">",
"      Baghaie AA, Mojtahedzadeh M, Levine RL, et al. Comparison of the effect of intermittent administration and continuous infusion of famotidine on gastric pH in critically ill patients: results of a prospective, randomized, crossover study. Crit Care Med 1995; 23:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18776/abstract/32\">",
"      Ballesteros MA, Hogan DL, Koss MA, Isenberg JI. Bolus or intravenous infusion of ranitidine: effects on gastric pH and acid secretion. A comparison of relative efficacy and cost. Ann Intern Med 1990; 112:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18776/abstract/33\">",
"      McCarthy DM. Sucralfate. N Engl J Med 1991; 325:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18776/abstract/34\">",
"      Rees WD. Mechanisms of gastroduodenal protection by sucralfate. Am J Med 1991; 91:58S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18776/abstract/35\">",
"      Tryba M, Kurz-M&uuml;ller K, Donner B. Plasma aluminum concentrations in long-term mechanically ventilated patients receiving stress ulcer prophylaxis with sucralfate. Crit Care Med 1994; 22:1769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18776/abstract/36\">",
"      Wilson DE. Antisecretory and mucosal protective actions of misoprostol. Potential role in the treatment of peptic ulcer disease. Am J Med 1987; 83:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18776/abstract/37\">",
"      Dajani EZ. Overview of the mucosal protective effects of misoprostol in man. Prostaglandins 1987; 33 Suppl:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18776/abstract/38\">",
"      Cook DJ, Reeve BK, Guyatt GH, et al. Stress ulcer prophylaxis in critically ill patients. Resolving discordant meta-analyses. JAMA 1996; 275:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18776/abstract/39\">",
"      Cook DJ, Witt LG, Cook RJ, Guyatt GH. Stress ulcer prophylaxis in the critically ill: a meta-analysis. Am J Med 1991; 91:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18776/abstract/40\">",
"      Phillips JO, Metzler MH, Palmieri MT, et al. A prospective study of simplified omeprazole suspension for the prophylaxis of stress-related mucosal damage. Crit Care Med 1996; 24:1793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18776/abstract/41\">",
"      Lasky MR, Metzler MH, Phillips JO. A prospective study of omeprazole suspension to prevent clinically significant gastrointestinal bleeding from stress ulcers in mechanically ventilated trauma patients. J Trauma 1998; 44:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18776/abstract/42\">",
"      Tryba M. Prophylaxis of stress ulcer bleeding. A meta-analysis. J Clin Gastroenterol 1991; 13 Suppl 2:S44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18776/abstract/43\">",
"      Barkun AN, Bardou M, Pham CQ, Martel M. Proton pump inhibitors vs. histamine 2 receptor antagonists for stress-related mucosal bleeding prophylaxis in critically ill patients: a meta-analysis. Am J Gastroenterol 2012; 107:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18776/abstract/44\">",
"      Cook D, Guyatt G, Marshall J, et al. A comparison of sucralfate and ranitidine for the prevention of upper gastrointestinal bleeding in patients requiring mechanical ventilation. Canadian Critical Care Trials Group. N Engl J Med 1998; 338:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18776/abstract/45\">",
"      Messori A, Trippoli S, Vaiani M, et al. Bleeding and pneumonia in intensive care patients given ranitidine and sucralfate for prevention of stress ulcer: meta-analysis of randomised controlled trials. BMJ 2000; 321:1103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18776/abstract/46\">",
"      Prod'hom G, Leuenberger P, Koerfer J, et al. Nosocomial pneumonia in mechanically ventilated patients receiving antacid, ranitidine, or sucralfate as prophylaxis for stress ulcer. A randomized controlled trial. Ann Intern Med 1994; 120:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18776/abstract/47\">",
"      Driks MR, Craven DE, Celli BR, et al. Nosocomial pneumonia in intubated patients given sucralfate as compared with antacids or histamine type 2 blockers. The role of gastric colonization. N Engl J Med 1987; 317:1376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18776/abstract/48\">",
"      Miano TA, Reichert MG, Houle TT, et al. Nosocomial pneumonia risk and stress ulcer prophylaxis: a comparison of pantoprazole vs ranitidine in cardiothoracic surgery patients. Chest 2009; 136:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18776/abstract/49\">",
"      Torres A, El-Ebiary M, Soler N, et al. Stomach as a source of colonization of the respiratory tract during mechanical ventilation: association with ventilator-associated pneumonia. Eur Respir J 1996; 9:1729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18776/abstract/50\">",
"      Ryan P, Dawson J, Teres D, et al. Nosocomial pneumonia during stress ulcer prophylaxis with cimetidine and sucralfate. Arch Surg 1993; 128:1353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18776/abstract/51\">",
"      Bonten MJ, Gaillard CA, de Leeuw PW, Stobberingh EE. Role of colonization of the upper intestinal tract in the pathogenesis of ventilator-associated pneumonia. Clin Infect Dis 1997; 24:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18776/abstract/52\">",
"      Maier RV, Mitchell D, Gentilello L. Optimal therapy for stress gastritis. Ann Surg 1994; 220:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18776/abstract/53\">",
"      Schupp KN, Schrand LM, Mutnick AH. A cost-effectiveness analysis of stress ulcer prophylaxis. Ann Pharmacother 2003; 37:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18776/abstract/54\">",
"      Cash BD. Evidence-based medicine as it applies to acid suppression in the hospitalized patient. Crit Care Med 2002; 30:S373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18776/abstract/55\">",
"      Herzig SJ, Vaughn BP, Howell MD, et al. Acid-suppressive medication use and the risk for nosocomial gastrointestinal tract bleeding. Arch Intern Med 2011; 171:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18776/abstract/56\">",
"      Grube RR, May DB. Stress ulcer prophylaxis in hospitalized patients not in intensive care units. Am J Health Syst Pharm 2007; 64:1396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18776/abstract/57\">",
"      Wohlt PD, Hansen LA, Fish JT. Inappropriate continuation of stress ulcer prophylactic therapy after discharge. Ann Pharmacother 2007; 41:1611.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1611 Version 21.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-41B8DEA544-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_21_18776=[""].join("\n");
var outline_f18_21_18776=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      STRESS ULCERATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Pathophysiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PROPHYLAXIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H929814\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H929392\">",
"      Pharmacologic agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Potential harms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2073692\">",
"      Choosing an agent",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28538?source=related_link\">",
"      Approach to acute upper gastrointestinal bleeding in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/58/13220?source=related_link\">",
"      Causes and treatment of hypermagnesemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/25/15767?source=related_link\">",
"      Causes of hypophosphatemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/22/28007?source=related_link\">",
"      Etiology of hypercalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/28/25034?source=related_link\">",
"      Overview and comparison of the proton pump inhibitors for the treatment of acid-related disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/15/24826?source=related_link\">",
"      Overview of the treatment of bleeding peptic ulcers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/47/13049?source=related_link\">",
"      Pharmacology of antiulcer medications",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_21_18777="Gingivitis and periodontitis in adults: Classification and dental treatment";
var content_f18_21_18777=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Gingivitis and periodontitis in adults: Classification and dental treatment",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/21/18777/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/21/18777/contributors\">",
"     Rebecca S Wilder, BSDH, MS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/21/18777/contributors\">",
"     Antonio J Moretti, DDS, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/21/18777/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/21/18777/contributors\">",
"     Daniel G Deschler, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/21/18777/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/21/18777/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/21/18777/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 7, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Periodontal, or gum disease is a common condition affecting the tissues that comprise the dental supporting structure: gingiva, cementum, periodontal ligament, and the alveolar bone (",
"    <a class=\"graphic graphic_figure graphicRef68403 \" href=\"UTD.htm?5/47/5880\">",
"     figure 1",
"    </a>",
"    ). Periodontal disease is broadly classified as either gingivitis or periodontitis; these conditions are distinguished by the presence of alveolar bone involvement that occurs with periodontitis, and not with gingivitis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18777/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Periodontal disease may be a risk factor for a number of conditions including cardiovascular and pulmonary diseases, and pregnancies resulting in low birth weight [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18777/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. Clinicians should encourage regular dental visits and incorporate oral examination into their office practice, inspecting for inflamed gingiva, bleeding, or suppuration around teeth.",
"   </p>",
"   <p>",
"    This topic will review the classification of gingivitis and conditions associated with gingivitis and periodontitis. The pathogenesis, clinical manifestations, and antibiotic treatment of odontogenic infections are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/30/16873?source=see_link\">",
"     \"Epidemiology, pathogenesis, and clinical manifestations of odontogenic infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/53/20313?source=see_link\">",
"     \"Complications, diagnosis, and treatment of odontogenic infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GINGIVITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Before describing periodontal disease, it is important to define features of periodontal health. Healthy gingival tissues are pink, stippled (similar to an orange peel) and firm (",
"    <a class=\"graphic graphic_picture graphicRef54818 \" href=\"UTD.htm?1/28/1473\">",
"     picture 1",
"    </a>",
"    ). Non inflamed gingival tissue should not bleed or have suppuration during daily flossing and brushing or when professionally probed.",
"   </p>",
"   <p>",
"    Gingivitis is the most common form of periodontal disease; most people have clinical signs of gingival inflammation in one or more sites of their mouth [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18777/abstract/5\">",
"     5",
"    </a>",
"    ]. Gingivitis is an inflammatory process characterized by gingival redness, swelling, and bleeding provoked by a periodontal probe, brushing, or flossing (",
"    <a class=\"graphic graphic_picture graphicRef75902 \" href=\"UTD.htm?23/28/24001\">",
"     picture 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Bacterial biofilm-induced gingivitis is a reversible condition, affecting only the gingival (gum) tissue. However, gingivitis is a precursor to periodontitis; the transition from gingivitis to periodontitis may vary from weeks to years. Periodontitis is associated with attachment loss or alveolar bone loss and treatment for gingivitis can prevent such loss. When the bacterial biofilm is removed on a daily basis, the gingiva returns to health in approximately two weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18777/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Gingivitis can be classified as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18777/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Associated with plaque (ie, bacterial biofilm)",
"     </li>",
"     <li>",
"      Not plaque induced",
"     </li>",
"     <li>",
"      Modified by systemic factors (eg, hormonal changes, HIV)",
"     </li>",
"     <li>",
"      Modified by medications (eg, antihypertensives, immunosuppressors)",
"     </li>",
"     <li>",
"      Modified by malnutrition (vitamin C deficiency)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Associated with plaque",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dental plaque induced gingival disease is the most common form of gingivitis. Dental plaque, also known as bacterial biofilm, is a dense, nonmineralized, complex mass of bacterial colonies living in a gel-like intermicrobial matrix (bacterial biofilm) that forms around the gingival margin (gum line), both supra- and subgingivally [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18777/abstract/5,9\">",
"     5,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Plaque (also referred to as dental plaque biofilm) begins to accumulate within 24 hours without regular removal. The amount of tissue damage related to plaque is dependent on the interaction between the plaque and the host defense mechanisms.",
"   </p>",
"   <p>",
"    The biofilm has an exopolysaccharide that surrounds and protects it from",
"    <span class=\"nowrap\">",
"     antibiotic/drug",
"    </span>",
"    penetration [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18777/abstract/10\">",
"     10",
"    </a>",
"    ]. Mechanical debridement (regular toothbrushing, dental flossing, supplemented by instrumentation by a dental professional) is the only effective way to remove dental biofilms. The goal of daily hygiene is to reduce both supra and subgingival bacteria below a threshold level capable of initiating",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    perpetuating clinical inflammation.",
"   </p>",
"   <p>",
"    Plaque build-up may be promoted by dental restorations that are ill fitting, have overhanging margins, or open margins. Such conditions increase inflammation and may lead to loss of both clinical attachment and alveolar [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18777/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Calculus (\"tartar\") is essentially mineralized plaque. Calculus promotes the retention of bacterial biofilm and must be removed to promote resolution of inflammation. Calculus cannot be removed by toothbrushing, flossing or polishing, and requires intervention by a dentist or dental hygienist for scaling and root planing procedures, using hand or ultrasonic instrumentation.",
"   </p>",
"   <p>",
"    Personal plaque control involves improved home care to reduce bacterial load via brushing (manual or power brush) twice daily, flossing once daily, and rinsing with an",
"    <span class=\"nowrap\">",
"     antimicrobial/antiseptic",
"    </span>",
"    mouthrinse or dentifrice (eg toothpaste, powder or gel) twice daily. A meta-analysis of randomized trials found that flossing, in addition to toothbrushing, reduced gingivitis compared to toothbrushing alone at one-, three-, and six-month follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18777/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Non-plaque induced",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dental plaque does not have an etiologic role in all gingivitis. Non-plaque induced gingivitis represents a small percentage of gingivitis cases and diagnosis may be difficult. The gingival inflammation may be due to one or more of several factors: infectious (specific bacteria, viruses or fungi); dermatologic; allergic; genetic; trauma-related; or a manifestation of systemic conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18777/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Modified by systemic factors",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Pregnancy gingivitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hormonal shifts during pregnancy may cause the gingiva to become inflamed and overgrown (",
"    <a class=\"graphic graphic_picture graphicRef82278 \" href=\"UTD.htm?27/6/27744\">",
"     picture 3",
"    </a>",
"    ). Gingival inflammation tends to increase during pregnancy and diminishes postpartum [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18777/abstract/14\">",
"     14",
"    </a>",
"    ]. Pregnancy-related gingivitis may be unrelated to the amount of plaque biofilm and usually does not increase rates of bone or attachment loss (periodontitis) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18777/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients should be instructed to perform meticulous oral hygiene procedures to keep the plaque biofilm levels to a minimum [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18777/abstract/15\">",
"     15",
"    </a>",
"    ]. Therapy for pregnancy gingivitis may consist of debridement and adjunctive antibiotics. In one randomized trial of 800 pregnant women with gingivitis, there were no differences in pregnancy outcomes between women who received periodontal treatment during gestational weeks 13 to 17 and those who were treated postpartum [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18777/abstract/16\">",
"     16",
"    </a>",
"    ]. Dental professionals commonly schedule periodontal treatments for the early part of the second trimester [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18777/abstract/17\">",
"     17",
"    </a>",
"    ], and defer additional treatment of nonurgent periodontal needs until the postpartum period, although there is no evidence to support this practice. Acute infection, abscess, or potential sources of sepsis need prompt intervention, regardless of the pregnancy stage.",
"   </p>",
"   <p>",
"    Another condition, pregnancy associated pyogenic granuloma (pregnancy tumor), occurs in approximately 0.5 to 5 percent of pregnant women (",
"    <a class=\"graphic graphic_picture graphicRef66965 \" href=\"UTD.htm?19/60/20422\">",
"     picture 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18777/abstract/18\">",
"     18",
"    </a>",
"    ]. This is an exaggerated inflammatory response to local irritants (plaque and calculus) that occur during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18777/abstract/5\">",
"     5",
"    </a>",
"    ]. Pyogenic granuloma is painless and usually occurs in the anterior mandibular or maxillary gingiva [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18777/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Plaque and calculus should be removed, but the pregnancy granuloma should not be excised during pregnancy, as it may resolve after parturition; excision is necessary if it does not resolve [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18777/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hormonal changes outside of pregnancy may also influence gingival health. Some women experience an increase in gingival inflammation with ovulation (menstrual cycle-associated gingivitis) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18777/abstract/18\">",
"     18",
"    </a>",
"    ]. Gingival inflammation also increases with puberty-related hormonal changes [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18777/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Linear gingival erythema",
"    </span>",
"    &nbsp;&mdash;&nbsp;Linear gingival erythema, previously called HIV-gingivitis, presents as a brightly inflamed and well-defined band of marginal gingiva (",
"    <a class=\"graphic graphic_picture graphicRef62628 \" href=\"UTD.htm?23/1/23571\">",
"     picture 5",
"    </a>",
"    ). The soft tissues can be painful, bleed easily, and there may be rapid periodontal destruction. The microbiologic pattern is dominated by Gram negative anaerobes, enteric strains, and yeast (Candida albicans); these organisms are not found in routine cases of gingivitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/30/16873?source=see_link\">",
"     \"Epidemiology, pathogenesis, and clinical manifestations of odontogenic infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment consists of debridement plus antibiotic administration. Antibacterial rinses (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/36/12870?source=see_link\">",
"     chlorhexidine",
"    </a>",
"    , fluoride) and antifungal",
"    <span class=\"nowrap\">",
"     rinses/troches",
"    </span>",
"    (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/53/32592?source=see_link\">",
"     nystatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    , etc) may also be used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Drug-induced gingival overgrowth",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain medications may affect the periodontium, by causing gingival (gum) overgrowth or enlargement (",
"    <a class=\"graphic graphic_picture graphicRef56248 \" href=\"UTD.htm?18/30/18917\">",
"     picture 6",
"    </a>",
"    ). Common drugs that cause this reaction include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"       Phenytoin",
"      </a>",
"     </li>",
"     <li>",
"      Calcium channel blockers (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"       nifedipine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"       diltiazem",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/18/296?source=see_link\">",
"       amlodipine",
"      </a>",
"      ; case reports have also implicated",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/45/2775?source=see_link\">",
"       felodipine",
"      </a>",
"      , nitrendipine, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/61/42969?source=see_link\">",
"       nicardipine",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/21/18777/abstract/23,24\">",
"       23,24",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       Cyclosporine",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The term &ldquo;gingival hyperplasia,&rdquo; still used by some clinicians, describes a histologic rather than a clinical presentation. The gingiva affected by these drugs can have hyperplasia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hypertrophy. The currently preferred clinical diagnostic terminologies are either &ldquo;drug-induced gingival overgrowth&rdquo; or &ldquo;drug-induced gingival enlargement.&rdquo;",
"   </p>",
"   <p>",
"    The clinical manifestations of gingival overgrowth are the same, regardless of which drug caused the reaction. The gingival tissues can grow disproportionally by several millimeters, covering one-third or more of the teeth crowns. The overgrown tissues form pseudo-gum pockets that easily harbor and protect the bacterial biofilm. Consequently, there are significant inflammatory changes leading to gingival bleeding and discomfort when eating and",
"    <span class=\"nowrap\">",
"     brushing/flossing,",
"    </span>",
"    perpetuating the problem.",
"   </p>",
"   <p>",
"    The severity and distribution of the overgrowth is dose- and case-specific. The overgrown tissues may create deep pockets that interfere with appropriate oral hygiene. In addition, gingival overgrowth can become a significant aesthetic and functional (chewing) problem for the affected patient.",
"   </p>",
"   <p>",
"    Gingival overgrowth (hyperplasia and hypertrophy) may be due to a direct effect of the drug. One case report has demonstrated that regression of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    -induced gingival overgrowth is possible upon interruption of drug therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18777/abstract/25\">",
"     25",
"    </a>",
"    ]. However, it is generally accepted that the inflammatory changes caused by the bacteria biofilm synergize with the drug effect to cause overgrowth of the soft tissues.",
"   </p>",
"   <p>",
"    Treatment of gingival overgrowth includes conscientious mechanical and chemical plaque (bacterial biofilm) control (ie, brushing, flossing, and use of dentifrices and rinses with antimicrobial properties). Even with conscientious oral toilet, surgical removal of the overgrown tissue is frequently inevitable. Gingivectomy (excision of excessive gingival tissue) is indicated for severe cases that affect oral hygiene, function (chewing), or cosmetic (esthetic) issues. Gingivectomy can be performed by scalpel, electrosurgery, high-speed dental handpiece with a diamond burr, or laser therapy. Successful outcome depends on restoration of normal gingival contours and careful postoperative care.",
"   </p>",
"   <p>",
"    Long term, when possible, the drug responsible for gingival overgrowth should be discontinued and another substituted. Recurrence of overgrown gingival tissues is likely if the medication cannot be changed. Clinicians may consider",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    in lieu of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , another antihypertensive drug class for calcium channel blockers, or another anticonvulsant for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    . If these drugs cannot be replaced, dental prophylaxes (dental cleaning) at three-month intervals is recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Modified by malnutrition",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Acute necrotizing ulcerative gingivitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute necrotizing ulcerative gingivitis (ANUG), also called Vincent's angina or \"trench mouth,\" is characterized by the acute onset of fetid breath, blunting of the interdental papilla, and an ulcerative necrotic slough of the gingiva. Pain is the hallmark of necrotizing periodontal diseases. The sloughed material, or film, consists of fibrin, necrotic tissue, leukocytes, erythrocytes, and bacteria. Removal of this film causes bleeding and exposure of ulcerated and erythematous tissue.",
"   </p>",
"   <p>",
"    It is unclear if ANUG is an entity distinct from necrotizing ulcerative periodontitis (NUP). For this reason, these conditions have been designated as a single category and renamed \"necrotizing periodontal disease\" (NPD) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18777/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The patient may be febrile with lymphadenopathy. The disease classically inflicts individuals in their 20s. Etiologic factors for ANUG are poor oral care, existing gingivitis, stress, smoking, impaired host immune response, and malnutrition [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18777/abstract/26-30\">",
"     26-30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with NPD experience severe pain. If no systemic involvement is present, patients may be managed in a dental or periodontal office with thorough debridement (scaling and root planing) under local anesthesia. Adjunctive antibiotics and antimicrobial rinses (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/36/12870?source=see_link\">",
"     chlorhexidine gluconate",
"    </a>",
"    mouthrinse) are often indicated in addition to intraoral debridement. Commonly used antibiotics are penicillin or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    , given for 7 to 10 days [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18777/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Vitamin deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gingival diseases modified by malnutrition occur rarely in areas of adequate food supply. Scurvy is the disease process caused by ascorbic acid (vitamin C) deficiency, and may become symptomatic as early as three months after deficient intake. The gingival component of scurvy may be difficult to distinguish from bacterial biofilm-induced gingivitis (",
"    <a class=\"graphic graphic_picture graphicRef76282 \" href=\"UTD.htm?38/51/39728\">",
"     picture 7",
"    </a>",
"    ). However, scurvy is also associated with other clinical manifestations due to disordered connective tissues resulting from impaired collagen synthesis. Systemic symptoms include ecchymoses, petechiae, coiled hairs, and hyperkeratosis. Treatment is vitamin C replacement (300 to 1000 mg of ascorbic acid daily for adults). Gingival disease generally responds in a few weeks. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/62/28650?source=see_link\">",
"     \"Overview of water-soluble vitamins\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other than vitamin C deficiency, the precise role of nutrition in the initiation or progression of periodontal diseases remains unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     PERIODONTITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Periodontitis is characterized by gingival inflammation accompanied by loss of supportive connective tissues, including alveolar bone. This results in loss of attachment of the periodontal ligament to the cementum.",
"   </p>",
"   <p>",
"    Clinical findings include increased probing depth, bleeding on probing, and tooth mobility. Bone loss is seen on radiographs (",
"    <a class=\"graphic graphic_picture graphicRef62167 \" href=\"UTD.htm?11/2/11303\">",
"     picture 8",
"    </a>",
"    ). Progression of the disease will cause increased mobility and eventual tooth loss. Additionally, systemic disease may result from pathogenic bacterial strains included among the &gt;500 bacterial species harbored in periodontal pockets [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18777/abstract/32,33\">",
"     32,33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Moderate periodontitis affects a majority of adults [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18777/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. It is estimated that 5 to 15 percent of the population in the United States suffers from severe generalized periodontitis, defined as a loss of attachment exceeding 6 mm.",
"   </p>",
"   <p>",
"    Periodontitis may be classified as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18777/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic periodontitis (most commonly seen in adults)",
"     </li>",
"     <li>",
"      Aggressive periodontitis (previously known as early onset periodontitis, localized periodontitis, rapid periodontitis, prepubertal periodontitis, most commonly seen in young individuals)",
"     </li>",
"     <li>",
"      Periodontitis as a manifestation of systemic disease (eg, leukemia, cyclic neutropenia, Ehlers-Danlos syndrome)",
"     </li>",
"     <li>",
"      Periodontitis associated with pulpal (endodontic) infection",
"     </li>",
"     <li>",
"      Necrotizing ulcerative periodontitis",
"     </li>",
"     <li>",
"      Developmental or acquired deformities (eg, gingival recession)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Chronic periodontitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic periodontitis (once called adult periodontitis, although it may occur in children or adolescents) is the most common form of periodontitis. It is plaque-induced and a major cause of tooth loss throughout the world [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18777/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The disease usually occurs as a slowly progressive condition, with unpredictable brief episodic periods of rapid progression and attachment loss [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18777/abstract/36-42\">",
"     36-42",
"    </a>",
"    ]. The triggering mechanism for active bone loss has not been clearly elucidated, but appears to be associated with a shift from a predominantly Gram positive flora to a predominance of anaerobic Gram negative rods. It has been hypothesized that supragingival plaque serves as a reservoir for the pathogenic Gram negative bacteria [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18777/abstract/43-45\">",
"     43-45",
"    </a>",
"    ]. When the host is overwhelmed, the pathogenic supragingival bacteria migrate subgingivally and form a subgingival biofilm that can be highly detrimental to surrounding periodontal structures.",
"   </p>",
"   <p>",
"    Host response to the pathogenic flora is variable. Factors contributing to disease progression include cigarette smoking, diabetes mellitus, and emotional stress [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18777/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. Disease activity and tissue destruction are modulated through production of inflammatory factors, including interleukins, prostaglandins, and matrix metalloproteinases [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18777/abstract/48,49\">",
"     48,49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chronic (common) periodontitis is graded by increasing severity ranging from slight to severe involvement (",
"    <a class=\"graphic graphic_table graphicRef50857 \" href=\"UTD.htm?43/37/44635\">",
"     table 1",
"    </a>",
"    ). Untreated disease causes architectural defects (craters) in the bone and increased gingival pocket depth.",
"   </p>",
"   <p>",
"    Treatment includes debridement, scaling and root planing of subgingival biofilm and calculus by a periodontist, general dentist or dental hygienist. This should be accompanied by improved oral hygiene: brushing two times daily, flossing or interdental cleaning, and adjunctive therapies or host modulating therapies.",
"   </p>",
"   <p>",
"    Adjunctive therapies to the mechanical removal of calculus and plaque may include the use of topical antibiotic (Atridox&reg; or Arestin&reg;) or antimicrobial (PerioChip&reg;) agents. Systemic antibiotics, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    , may be prescribed for severe and generalized cases. Periostat&reg;, also available in the United States in a generic tablet formulation, is a low dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    (20 mg) which may be taken twice a day for up to nine months. Systemic levels do not reach inhibitory concentrations against bacteria. The drug inhibits collagenase activity in vitro and may prevent further breakdown of connective tissue and alveolar bone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Aggressive periodontitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aggressive periodontitis (AP, which includes conditions formerly termed early onset periodontitis, localized periodontitis, rapid periodontitis, and prepubertal periodontitis) is much less common than chronic periodontitis, accounting for only 1 to 2 percent of cases of periodontitis.",
"   </p>",
"   <p>",
"    Aggressive periodontitis occurs in both localized (affecting the periodontal tissues of first molars and incisors) or generalized (affecting additional teeth) forms. Both conditions affect otherwise healthy patients, although abnormalities in phagocyte function can be identified. Rapid loss of attachment and bone destruction occur, but the condition may be self-arresting [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18777/abstract/50\">",
"     50",
"    </a>",
"    ]. Severity of disease is not related to the amount of bacterial biofilm present, and there is a strong genetic predisposition [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18777/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Localized aggressive periodontitis usually affects prepubescent individuals, predominantly African-American females [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18777/abstract/52\">",
"     52",
"    </a>",
"    ]. Bone loss around the first permanent molars, mandibular, and maxillary central incisors is seen on radiographs (",
"    <a class=\"graphic graphic_picture graphicRef52689 \" href=\"UTD.htm?29/61/30676\">",
"     picture 9",
"    </a>",
"    ). The bone loss may be rapid and severe with few overt clinical signs of inflammation. Untreated lesions will develop into adult periodontitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/45/32471?source=see_link&amp;anchor=H14#H14\">",
"     \"Overview of gingivitis and periodontitis in children and adolescents\", section on 'Localized aggressive'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Generalized aggressive periodontitis (GAP) may affect adolescents and younger adults (ages 25 to 35 years). GAP affects the entire dentition, including teeth other than molars or incisors [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18777/abstract/50\">",
"     50",
"    </a>",
"    ]; heavy accumulations of plaque and calculus may be present. Inflammation may be severe and bone loss is rapid, with a pronounced episodic nature of the destruction. GAP must be treated aggressively with local therapy and systemic antibiotics. Surgery may be required and referral to a periodontist is advised when the diagnosis is made.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Manifestation of systemic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic diseases associated with periodontitis include hematologic disorders (leukemia and acquired neutropenia), and genetic disorders (Down syndrome, cyclic neutropenia, Chediak-Higashi syndrome) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18777/abstract/53\">",
"     53",
"    </a>",
"    ]. Bacterial biofilm is also an important etiologic factor in this category. However, periodontal condition is considered a manifestation of the systemic disease because the underlying host impairment is a major determinant in the development and severity of the periodontitis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18777/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Periodontal disease in patients with diabetes mellitus is not described as a distinct disease entity, but the prevalence and overall severity of periodontal disease is increased, particularly when diabetes is not well controlled. Patients with poorly controlled type 2 diabetes have three times the risk of periodontitis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18777/abstract/54\">",
"     54",
"    </a>",
"    ] and 11 times the risk of progressive alveolar bone loss [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18777/abstract/55\">",
"     55",
"    </a>",
"    ] than patients with diabetes; periodontal morbidity is not increased in patients with well controlled diabetes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Necrotizing ulcerative periodontitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Necrotizing ulcerative periodontitis (NUP) involves severe loss of periodontal attachment and alveolar bone. This condition was previously termed \"HIV periodontitis\", but it is not limited to patients with HIV. It affects patients with HIV infection and CD4 counts less than 400, as well as patients with severe immunosuppression related to cancer chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18777/abstract/56\">",
"     56",
"    </a>",
"    ] or advanced protein-energy malnutrition [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18777/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The condition manifests as rapid painful soft tissue and bone loss that may appear as necrotic clefts (",
"    <a class=\"graphic graphic_picture graphicRef58606 \" href=\"UTD.htm?22/59/23478\">",
"     picture 10",
"    </a>",
"    ). Destruction may be so rapid that denuded bone is visible followed by sequestration.",
"   </p>",
"   <p>",
"    The microbiologic flora composition is unique; in addition to the Gram negative rods associated with chronic periodontitis, enteric organisms and yeast can be cultured.",
"   </p>",
"   <p>",
"    Treatment consists of scaling and",
"    <span class=\"nowrap\">",
"     root/planing",
"    </span>",
"    (debridement) along with antibiotics and pain medication. Antifungals (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/53/32592?source=see_link\">",
"     nystatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    ) and antibacterial rinses (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/36/12870?source=see_link\">",
"     chlorhexidine",
"    </a>",
"    ) may also be incorporated into the treatment regimen (",
"    <a class=\"graphic graphic_picture graphicRef54957 \" href=\"UTD.htm?30/58/31655\">",
"     picture 11",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Associated with pulpal infection",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Periodontal and gingival abscesses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Periodontal and gingival abscess are commonly occurring acute infections of the supporting structures. Patients may be predisposed to abscess formation due to the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Deep periodontal pockets [",
"      <a class=\"abstract\" href=\"UTD.htm?18/21/18777/abstract/58,59\">",
"       58,59",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Incomplete removal of subgingival calculus after a professional scaling and root planing [",
"      <a class=\"abstract\" href=\"UTD.htm?18/21/18777/abstract/59,60\">",
"       59,60",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Occlusion of the pocket orifice by foreign bodies (ie, popcorn kernel) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/21/18777/abstract/59,61\">",
"       59,61",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Inadequate treatment of periodontitis (eg, administration of antibiotics in the absence of scaling or planing mechanical therapy) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/21/18777/abstract/62\">",
"       62",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Poorly controlled diabetes",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Dental abscesses are classified in one of three categories [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18777/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Periodontal abscess &mdash; Localized within the tissues adjacent to the periodontal pocket. These are the most common.",
"     </li>",
"     <li>",
"      Gingival abscess &mdash; Confined to the marginal gingival and interdental papilla.",
"     </li>",
"     <li>",
"      Pericoronal abscess &mdash; Develop within tissue surrounding the crown of a partially erupted tooth (ie, third molars, also known as wisdom teeth).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The abscess usually presents as a painful swelling of the buccal or",
"    <span class=\"nowrap\">",
"     lingual/palatal",
"    </span>",
"    <span class=\"nowrap\">",
"     gingiva/mucosa,",
"    </span>",
"    but may be asymptomatic. Teeth in the affected region may be painful and sensitive to mastication. The patient may have lymphadenopathy and fever. A productive sinus tract fistula may be evident when palpating the fluctuant area.",
"   </p>",
"   <p>",
"    Abscesses cause rapid alveolar bone resorption, which can be confirmed radiographically. However, prompt treatment often leads to repair. The prognosis is dependent upon the presence of other endodontic complications. Treatment consists of incision and drainage followed by antibiotic therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/53/20313?source=see_link\">",
"     \"Complications, diagnosis, and treatment of odontogenic infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Associated with endodontic lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;An existing periapical infection may spread to a periodontal pocket or an infection from the periodontal pocket may spread to the apex of the tooth and join a periapical lesion. The existence of endodontic and periodontal infections has been named combined periodontal-endodontic lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18777/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Developmental or acquired deformities",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Periimplantitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Periimplantitis refers to bone infection secondary to dental implants. The tissues surrounding the implant may become painful and the implant itself may loosen. Dental radiographs display periimplant radiolucency (bone destruction). The bacteria associated with periimplantitis are similar to those in chronic periodontitis. Treatment ranges from antibiotic therapy and bone grafting to surgical removal of the implant [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18777/abstract/66,67\">",
"     66,67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     MEDICAL EFFECTS OF PERIODONTAL DISEASE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Anesthesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Teeth with associated periodontal disease can present a significant problem for the anesthesiologist. Intubation and extubation may dislodge teeth, calculus, and prostheses. All have the potential to act as a source of infection",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    obstruction. Careful presurgical screening and dental consultation may prevent many of these complications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Hematogenous seeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Odontogenic infections in any individual may disseminate hematogenously to seed native or prosthetic heart valves, joint replacements, or other prosthetic devices. Antibiotic prophylaxis is essential prior to any invasive dental procedure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/36/585?source=see_link\">",
"     \"Antimicrobial prophylaxis for bacterial endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Routine examination of the oral cavity should be considered prior to elective prosthetic heart valve implantation or artificial joint replacement [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18777/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Diabetes mellitus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Poorly controlled diabetes may be a risk factor for increased severity of periodontitis and poor response to periodontal treatment. Patients may present with xerostomia, candidiasis, and caries as well as periodontal disease. Consensus guidelines for dental and medical providers have been developed by an expert panel to aid in recognizing diabetes and providing appropriate attention to dental and gingival health in patients with diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18777/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with poor control of diabetes and severe periodontitis may show improvement in their A1c levels, as well as decrease in periodontal inflammation, with treatment of the periodontitis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18777/abstract/69,70\">",
"     69,70",
"    </a>",
"    ]; not all studies confirm improvement in glycemic control, however [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18777/abstract/71-73\">",
"     71-73",
"    </a>",
"    ]. To date, there is no strong scientific evidence on the effects of periodontal treatment on glycemic control and systemic inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18777/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Cardiovascular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relationship between periodontal disease and cardiovascular disease is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/30/16873?source=see_link\">",
"     \"Epidemiology, pathogenesis, and clinical manifestations of odontogenic infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Periodontal disease, classified as gingivitis or periodontitis (involving alveolar bone loss), is the major cause of tooth loss in adults. Prevalence is associated with oral hygiene, as well as age and multiple host factors. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Gingivitis is most commonly associated with plaque (dental biofilm). Tissue damage results for the interaction between plaque and host defense mechanisms; plaque buildup is reduced by regular dental hygiene. Calculus, mineralized plaque, can only be removed by scaling and planing. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Associated with plaque'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hormonal shifts in pregnancy may cause gingival inflammation and, less commonly, pyogenic granuloma, which may resolve after parturition. Gingivitis may occur with HIV infection (linear gingival erythema) and medications. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Modified by systemic factors'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Drug-induced gingival overgrowth'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Necrotizing ulcerative gingivitis, or trench mouth, causes systemic symptoms, pain, and ulcerated necrotic gingiva, and is associated with immune disorders and malnutrition. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Acute necrotizing ulcerative gingivitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Chronic periodontitis is plaque-induced and characterized by slow bone loss with periods of rapid progression. Treatment includes debridement, scaling, and root planing by a periodontist, dentist, or dental hygienist, accompanied by improved oral hygiene. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Chronic periodontitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Aggressive periodontitis may be localized or generalized, is familial, and affects younger people. Localized disease occurs in prepubescent African American girls. Other periodontal conditions include periodontal abscess, necrotizing ulcerative periodontitis, and periimplantitis. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Periodontitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Periodontal bacteria can spread hematogenously and damage heart valves or joint prostheses; can cause problems for intubation when general anesthesia is required; and can contribute to poor glycemic control in patients with diabetes. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Medical effects of periodontal disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18777/abstract/1\">",
"      Williams RC. Periodontal disease. N Engl J Med 1990; 322:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18777/abstract/2\">",
"      Beck JD, Offenbacher S. The association between periodontal diseases and cardiovascular diseases: a state-of-the-science review. Ann Periodontol 2001; 6:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18777/abstract/3\">",
"      Offenbacher S, Katz V, Fertik G, et al. Periodontal infection as a possible risk factor for preterm low birth weight. J Periodontol 1996; 67:1103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18777/abstract/4\">",
"      Hayes C, Sparrow D, Cohen M, et al. The association between alveolar bone loss and pulmonary function: the VA Dental Longitudinal Study. Ann Periodontol 1998; 3:257.",
"     </a>",
"    </li>",
"    <li>",
"     Ronderos M, Michalowicz B. Epidemiology of Periodontal Diseases and Risk Factors. In: Periodontics Medicine, Surgery, and Implants, Mealey B, Genco R, Cohen W (Eds), Elsevier Mosby, St Louis 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18777/abstract/6\">",
"      Burt B, Research, Science and Therapy Committee of the American Academy of Periodontology. Position paper: epidemiology of periodontal diseases. J Periodontol 2005; 76:1406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18777/abstract/7\">",
"      LOE H, THEILADE E, JENSEN SB. EXPERIMENTAL GINGIVITIS IN MAN. J Periodontol 1965; 36:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18777/abstract/8\">",
"      Armitage GC. Development of a classification system for periodontal diseases and conditions. Ann Periodontol 1999; 4:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18777/abstract/9\">",
"      Socransky SS, Haffajee AD. Dental biofilms: difficult therapeutic targets. Periodontol 2000 2002; 28:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18777/abstract/10\">",
"      Costerton JW, Lewandowski Z, Caldwell DE, et al. Microbial biofilms. Annu Rev Microbiol 1995; 49:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18777/abstract/11\">",
"      Gilmore N, Sheiham A. Overhanging dental restorations and periodontal disease. J Periodontol 1971; 42:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18777/abstract/12\">",
"      Sambunjak D, Nickerson JW, Poklepovic T, et al. Flossing for the management of periodontal diseases and dental caries in adults. Cochrane Database Syst Rev 2011; :CD008829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18777/abstract/13\">",
"      Holmstrup P. Non-plaque-induced gingival lesions. Ann Periodontol 1999; 4:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18777/abstract/14\">",
"      LOE H, SILNESS J. PERIODONTAL DISEASE IN PREGNANCY. I. PREVALENCE AND SEVERITY. Acta Odontol Scand 1963; 21:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18777/abstract/15\">",
"      Boggess KA, Society for Maternal-Fetal Medicine Publications Committee. Maternal oral health in pregnancy. Obstet Gynecol 2008; 111:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18777/abstract/16\">",
"      Michalowicz BS, Hodges JS, DiAngelis AJ, et al. Treatment of periodontal disease and the risk of preterm birth. N Engl J Med 2006; 355:1885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18777/abstract/17\">",
"      Task Force on Periodontal Treatment of Pregnant Women, American Academy of Periodontology. American Academy of Periodontology statement regarding periodontal management of the pregnant patient. J Periodontol 2004; 75:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18777/abstract/18\">",
"      Mariotti A. Dental plaque-induced gingival diseases. Ann Periodontol 1999; 4:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18777/abstract/19\">",
"      Vilmann A, Vilmann P, Vilmann H. Pyogenic granuloma: evaluation of oral conditions. Br J Oral Maxillofac Surg 1986; 24:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18777/abstract/20\">",
"      Eversole LR, Rovin S. Reactive lesions of the gingiva. J Oral Pathol 1972; 1:30.",
"     </a>",
"    </li>",
"    <li>",
"     Aguirre A, Tapia J. Selected soft and hard tissue lesions with periodontal relevance. In: Periodontics Medicine, Surgery, and Implants, 1st ed., Rose L, Mealey B, Genco R, Cohen W (Eds), Elsevier Mosby, St. Louis 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18777/abstract/22\">",
"      Albandar JM, Kingman A. Gingival recession, gingival bleeding, and dental calculus in adults 30 years of age and older in the United States, 1988-1994. J Periodontol 1999; 70:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18777/abstract/23\">",
"      Steele RM, Schuna AA, Schreiber RT. Calcium antagonist-induced gingival hyperplasia. Ann Intern Med 1994; 120:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18777/abstract/24\">",
"      Ellis JS, Seymour RA, Thomason JM, et al. Gingival sequestration of amlodipine and amlodipine-induced gingival overgrowth. Lancet 1993; 341:1102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18777/abstract/25\">",
"      Mathur H, Moretti AJ, Flaitz CM. Regression of cyclosporia-induced gingival overgrowth upon interruption of drug therapy. Gen Dent 2003; 51:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18777/abstract/26\">",
"      Melnick SL, Roseman JM, Engel D, Cogen RB. Epidemiology of acute necrotizing ulcerative gingivitis. Epidemiol Rev 1988; 10:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18777/abstract/27\">",
"      Shannon IL, Kilgore WG, O'Leary TJ. Stres as a predisposing factor in necrotizing ulcerative gingivitis. J Periodontol 1969; 40:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18777/abstract/28\">",
"      Shields WD. Acute necrotizing ulcerative gingivitis. A study of some of the contributing factors and their validity in an Army population. J Periodontol 1977; 48:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18777/abstract/29\">",
"      Emslie, RD. Cancrum oris. Dent Prac 1963; 69:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18777/abstract/30\">",
"      Pindborg, JJ. The epidemiology of ulceromembranous gingivitis showing the influence of service in the Armed Forces. Paradontology 1956; 10:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18777/abstract/31\">",
"      Pihlstrom BL, Ammons WF. Treatment of gingivitis and periodontitis. Research, Science and Therapy Committee of the American Academy of Periodontology. J Periodontol 1997; 68:1246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18777/abstract/32\">",
"      Genco RJ. Current view of risk factors for periodontal diseases. J Periodontol 1996; 67:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18777/abstract/33\">",
"      Terezhalmy GT, Safadi TJ, Longworth DL, Muehrcke DD. Oral disease burden in patients undergoing prosthetic heart valve implantation. Ann Thorac Surg 1997; 63:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18777/abstract/34\">",
"      Oliver RC, Brown LJ, L&ouml;e H. Periodontal diseases in the United States population. J Periodontol 1998; 69:269.",
"     </a>",
"    </li>",
"    <li>",
"     Third National Health and Nutrition Examination Survey, 1998-94. Hyattsville, MD: Centers for Disease Control; 1997. Public use data file no. 7-0627.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18777/abstract/36\">",
"      Reddy MS, Geurs NC, Jeffcoat RL, et al. Periodontal disease progression. J Periodontol 2000; 71:1583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18777/abstract/37\">",
"      Greenstein G, Caton J. Periodontal disease activity: a critical assessment. J Periodontol 1990; 61:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18777/abstract/38\">",
"      Brown LJ, L&ouml;e H. Prevalence, extent, severity and progression of periodontal disease. Periodontol 2000 1993; 2:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18777/abstract/39\">",
"      Papapanou PN, Wennstr&ouml;m JL, Gr&ouml;ndahl K. A 10-year retrospective study of periodontal disease progression. J Clin Periodontol 1989; 16:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18777/abstract/40\">",
"      L&ouml;e H, Anerud A, Boysen H, Morrison E. Natural history of periodontal disease in man. Rapid, moderate and no loss of attachment in Sri Lankan laborers 14 to 46 years of age. J Clin Periodontol 1986; 13:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18777/abstract/41\">",
"      Socransky SS, Haffajee AD, Goodson JM, Lindhe J. New concepts of destructive periodontal disease. J Clin Periodontol 1984; 11:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18777/abstract/42\">",
"      Jeffcoat MK, Reddy MS. Progression of probing attachment loss in adult periodontitis. J Periodontol 1991; 62:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18777/abstract/43\">",
"      Grossi SG, Zambon JJ, Ho AW, et al. Assessment of risk for periodontal disease. I. Risk indicators for attachment loss. J Periodontol 1994; 65:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18777/abstract/44\">",
"      MacGregor ID, Sheiham A. Patterns of periodontal pocketing in Western Nigerian populations. J Periodontol 1974; 45:402.",
"     </a>",
"    </li>",
"    <li>",
"     Miyazaki H. A global overview of periodontal epidemiology. In: Periodontal needs of developing nations, International Academy of Periodontology, Pack ARC, Newman HN (Eds), Sciences Reviews Limited, Middlesex, NJ 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18777/abstract/46\">",
"      Taylor GW. Bidirectional interrelationships between diabetes and periodontal diseases: an epidemiologic perspective. Ann Periodontol 2001; 6:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18777/abstract/47\">",
"      Salvi GE, Lawrence HP, Offenbacher S, Beck JD. Influence of risk factors on the pathogenesis of periodontitis. Periodontol 2000 1997; 14:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18777/abstract/48\">",
"      Caton JG, Ciancio SG, Blieden TM, et al. Treatment with subantimicrobial dose doxycycline improves the efficacy of scaling and root planing in patients with adult periodontitis. J Periodontol 2000; 71:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18777/abstract/49\">",
"      Novak MJ, Johns LP, Miller RC, Bradshaw MH. Adjunctive benefits of subantimicrobial dose doxycycline in the management of severe, generalized, chronic periodontitis. J Periodontol 2002; 73:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18777/abstract/50\">",
"      Lang, N, Bartold, PM, Cullinan, M, et al. Consensus Report: Aggressive Periodontitis. Ann Periodontol 1999; 4:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18777/abstract/51\">",
"      Tonetti MS, Mombelli A. Early-onset periodontitis. Ann Periodontol 1999; 4:39.",
"     </a>",
"    </li>",
"    <li>",
"     Armitage G. Diagnosis and classification of periodontal diseases. In: Periodontics Medicine, Surgery, and Implants, 1st ed., Rose L, Mealey B, Genco R, Cohen W (Eds), Elsevier Mosby, St. Louis 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18777/abstract/53\">",
"      Kinane DF. Periodontitis modified by systemic factors. Ann Periodontol 1999; 4:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18777/abstract/54\">",
"      Tsai C, Hayes C, Taylor GW. Glycemic control of type 2 diabetes and severe periodontal disease in the US adult population. Community Dent Oral Epidemiol 2002; 30:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18777/abstract/55\">",
"      Taylor GW, Burt BA, Becker MP, et al. Non-insulin dependent diabetes mellitus and alveolar bone loss progression over 2 years. J Periodontol 1998; 69:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18777/abstract/56\">",
"      Armitage GC. Clinical evaluation of periodontal diseases. Periodontol 2000 1995; 7:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18777/abstract/57\">",
"      Enwonwu CO. Cellular and molecular effects of malnutrition and their relevance to periodontal diseases. J Clin Periodontol 1994; 21:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18777/abstract/58\">",
"      Kaldahl WB, Kalkwarf KL, Patil KD, et al. Long-term evaluation of periodontal therapy: I. Response to 4 therapeutic modalities. J Periodontol 1996; 67:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18777/abstract/59\">",
"      Meng HX. Periodontal abscess. Ann Periodontol 1999; 4:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18777/abstract/60\">",
"      Dello Russo NM. The post-prophylaxis periodontal abscess: etiology and treatment. Int J Periodontics Restorative Dent 1985; 5:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18777/abstract/61\">",
"      Abrams H, Kopczyk RA. Gingival sequela from a retained piece of dental floss. J Am Dent Assoc 1983; 106:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18777/abstract/62\">",
"      Helovuo H, Hakkarainen K, Paunio K. Changes in the prevalence of subgingival enteric rods, staphylococci and yeasts after treatment with penicillin and erythromycin. Oral Microbiol Immunol 1993; 8:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18777/abstract/63\">",
"      Lang, N, Soskolne, WA, Greenstein, G, et al. Consensus report: Abscesses of the periodontium. Ann Periodontol 1999; 4:83.",
"     </a>",
"    </li>",
"    <li>",
"     Kerns D. Acute Periodontal Conditions. In: Periodontics Medicine, Surgery, and Implants, 1st ed., Rose L, Mealey B, Genco R, Cohen W (Eds), Elsevier Mosby, St. Louis 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18777/abstract/65\">",
"      Lang, N, Soskolne, WA, Greenstein, G, et al. Consensus report: periodontic-endodontic lesions. Ann Periodontol 1999; 4:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18777/abstract/66\">",
"      Lang NP, Wilson TG, Corbet EF. Biological complications with dental implants: their prevention, diagnosis and treatment. Clin Oral Implants Res 2000; 11 Suppl 1:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18777/abstract/67\">",
"      Esposito M, Grusovin MG, Worthington HV. Interventions for replacing missing teeth: treatment of peri-implantitis. Cochrane Database Syst Rev 2012; 1:CD004970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18777/abstract/68\">",
"      Hein, C. Scottsdale Revisted. The role of dental practitioners in screening for undiagnosed diabetes and the medical comanagement of patients with diabetes or those at risk for diabetes. Compend Contin Educ Dent 2008; 29:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18777/abstract/69\">",
"      Stewart JE, Wager KA, Friedlander AH, Zadeh HH. The effect of periodontal treatment on glycemic control in patients with type 2 diabetes mellitus. J Clin Periodontol 2001; 28:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18777/abstract/70\">",
"      Kiran M, Arpak N, Unsal E, Erdo��an MF. The effect of improved periodontal health on metabolic control in type 2 diabetes mellitus. J Clin Periodontol 2005; 32:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18777/abstract/71\">",
"      Aldridge JP, Lester V, Watts TL, et al. Single-blind studies of the effects of improved periodontal health on metabolic control in type 1 diabetes mellitus. J Clin Periodontol 1995; 22:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18777/abstract/72\">",
"      Christgau M, Palitzsch KD, Schmalz G, et al. Healing response to non-surgical periodontal therapy in patients with diabetes mellitus: clinical, microbiological, and immunologic results. J Clin Periodontol 1998; 25:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18777/abstract/73\">",
"      Promsudthi A, Pimapansri S, Deerochanawong C, Kanchanavasita W. The effect of periodontal therapy on uncontrolled type 2 diabetes mellitus in older subjects. Oral Dis 2005; 11:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18777/abstract/74\">",
"      Salvi, GE, Carollo-Bittel, B, Lang, NP. Effects of diabetes mellitus on periodontal and peri-implant conditions. Update on associations and risks. J Clin Periodontol 2008; 35 (Suppl 8):349.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6858 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-69ABC6F150-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_21_18777=[""].join("\n");
var outline_f18_21_18777=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GINGIVITIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Associated with plaque",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Non-plaque induced",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Modified by systemic factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Pregnancy gingivitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Linear gingival erythema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Drug-induced gingival overgrowth",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Modified by malnutrition",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Acute necrotizing ulcerative gingivitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Vitamin deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      PERIODONTITIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Chronic periodontitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Aggressive periodontitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Manifestation of systemic disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Necrotizing ulcerative periodontitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Associated with pulpal infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Periodontal and gingival abscesses",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Associated with endodontic lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Developmental or acquired deformities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Periimplantitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      MEDICAL EFFECTS OF PERIODONTAL DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Anesthesia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Hematogenous seeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/6858\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/6858|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?5/47/5880\" title=\"figure 1\">",
"      Structure of tooth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/6858|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/28/1473\" title=\"picture 1\">",
"      Healthy gingiva",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/28/24001\" title=\"picture 2\">",
"      Swollen gingival tissues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/6/27744\" title=\"picture 3\">",
"      Pregnancy gingivitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/60/20422\" title=\"picture 4\">",
"      Pyogenic granuloma gingival mucosa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/1/23571\" title=\"picture 5\">",
"      Linear gingival erythema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/30/18917\" title=\"picture 6\">",
"      Gingival enlargement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/51/39728\" title=\"picture 7\">",
"      Gingival abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/2/11303\" title=\"picture 8\">",
"      Chronic periodontitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/61/30676\" title=\"picture 9\">",
"      Aggressive periodontitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/59/23478\" title=\"picture 10\">",
"      Necrotizing periodontal dis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/58/31655\" title=\"picture 11\">",
"      Periodontal destruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/6858|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?43/37/44635\" title=\"table 1\">",
"      Dx gingivitis periodontitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/36/585?source=related_link\">",
"      Antimicrobial prophylaxis for bacterial endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/53/20313?source=related_link\">",
"      Complications, diagnosis, and treatment of odontogenic infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/30/16873?source=related_link\">",
"      Epidemiology, pathogenesis, and clinical manifestations of odontogenic infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/45/32471?source=related_link\">",
"      Overview of gingivitis and periodontitis in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/62/28650?source=related_link\">",
"      Overview of water-soluble vitamins",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_21_18778="Pathophysiology of anaphylaxis";
var content_f18_21_18778=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathophysiology of anaphylaxis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/21/18778/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/21/18778/contributors\">",
"     Stephen F Kemp, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/21/18778/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/21/18778/contributors\">",
"     F Estelle R Simons, MD, FRCPC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/21/18778/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/21/18778/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/21/18778/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anaphylaxis is an acute, potentially lethal, multisystem syndrome resulting from the sudden release of mast cell- and basophil-derived mediators into the circulation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18778/abstract/1\">",
"     1",
"    </a>",
"    ]. It most often results from immunologic reactions to foods, medications, and insect stings, although it can also be induced through nonimmunologic mechanisms by any agent capable of producing a sudden, systemic degranulation of mast cells or basophils [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18778/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The phenomenon of anaphylaxis was first described in the modern medical literature in 1902 in a study involving protocols for immunizing dogs with jellyfish toxin. The injection of small amounts of toxin in some animals, rather than generating protection, precipitated the rapid onset of fatal or near-fatal symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18778/abstract/3\">",
"     3",
"    </a>",
"    ]. The authors named this response \"l'anaphylaxie,\" which is derived from the Greek words a- (against) and phylaxis (immunity or protection).",
"   </p>",
"   <p>",
"    The pathophysiology of anaphylaxis will be reviewed here. The clinical manifestations, diagnosis and management of anaphylaxis, and the epidemiology and etiology of fatal anaphylaxis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=see_link\">",
"     \"Anaphylaxis: Rapid recognition and treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/13/1241?source=see_link\">",
"     \"Fatal anaphylaxis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PROPOSED IMMUNOPATHOLOGIC MECHANISMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanism responsible for most cases of human anaphylaxis involves immunoglobulin E. Possible alternative mechanisms remain incompletely understood. Environmental exposures and complex genetic factors may also have important roles, although these are not explored in this review.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Terminology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term anaphylaxis has traditionally been reserved for IgE-dependent events, and the term \"anaphylactoid reaction\" has been used to describe IgE-independent events, although the two reactions are often clinically indistinguishable. The World Allergy Organization (WAO), an international umbrella organization representing a large number of regional and national professional societies dedicated to allergy and clinical immunology, has proposed discarding this nomenclature. The WAO categorizes anaphylaxis as either immunologic or nonimmunologic, and this is the terminology used in this review [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18778/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Immunologic anaphylaxis - Immunologic anaphylaxis includes the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      IgE-mediated reactions",
"     </li>",
"     <li>",
"      IgG-mediated reactions (which have not been identified in humans, as discussed below)",
"     </li>",
"     <li>",
"      Immune",
"      <span class=\"nowrap\">",
"       complex/complement-mediated",
"      </span>",
"      reactions",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nonimmunologic anaphylaxis - Nonimmunologic anaphylaxis is caused by agents or events that induce sudden, massive mast cell or basophil degranulation in the absence of immunoglobulins. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Nonimmunologic anaphylaxis'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Immunologic anaphylaxis",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     IgE-mediated",
"    </span>",
"    &nbsp;&mdash;&nbsp;The classical mechanism associated with human allergic disease is initiated by an antigen (allergen) interacting with allergen-specific IgE bound to the receptor Fc epsilon RI (Fc&epsilon;RI) on mast cells",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    basophils.",
"   </p>",
"   <p>",
"    The events leading to allergen-specific IgE production in an atopic individual are complex. In brief, B cells are driven to differentiate into IgE-producing cells via the activity of the type 2 subset of CD4-bearing helper T cells (Th2 cells). This process largely takes place in the peripheral lymphoid tissues. The cytokines interleukin-4 (IL-4) and its receptors",
"    <span class=\"nowrap\">",
"     (IL-4R&alpha;/&gamma;c",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     IL-4R&alpha;/IL-13R&alpha;1)",
"    </span>",
"    and IL-13 and its receptor",
"    <span class=\"nowrap\">",
"     (IL-4R&alpha;/IL-13R&alpha;1)",
"    </span>",
"    contribute to IgE responses in humans.",
"   </p>",
"   <p>",
"    Once produced, allergen-specific IgE diffuses through the tissues and vasculature and constitutively occupies high-affinity IgE receptors (Fc&epsilon;RI) on mast cells and basophils (",
"    <a class=\"graphic graphic_figure graphicRef55328 \" href=\"UTD.htm?41/30/42469\">",
"     figure 1",
"    </a>",
"    ). The generation of allergen-specific IgE is reviewed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/6/31848?source=see_link\">",
"     \"The biology of IgE\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When allergen diffuses into the proximity of a mast cell or basophil, it interacts with any surface-bound IgE that is specific for that allergen. Certain allergens are able to interact with IgE molecules on two or more receptors of the cell surface to cause cross-linking, which in turn causes the receptors to become aggregated and initiate intracellular signaling. Allergens that are capable of cross-linking are either multivalent allergens (which have multiple identical sites for antibody binding), or univalent allergens that have multiple different epitopes to which IgE molecules can bind. If signaling is sufficiently robust, the mast cell (or basophil) becomes activated and degranulates, releasing preformed mediators, enzymes, and cytokines (such as histamine, tryptase, and TNF, respectively) and initiating additional mediator, cytokine, and enzyme production.",
"   </p>",
"   <p>",
"    These mediators either act directly on tissues to cause allergic symptoms, or recruit and activate additional inflammatory cells, particularly eosinophils [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18778/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. The recruited cells, in turn, release more mediators and propagate a fulminant \"chain-reaction\" of allergic inflammation. The various mediators and cytokines involved are reviewed below. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Chemical mediators of anaphylaxis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     IgG-mediated (in animal models)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Animal models that appear analogous to human anaphylaxis have been established in mice, pigs, and dogs [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18778/abstract/1\">",
"     1",
"    </a>",
"    ]. Clinically, each has some distinctive signs and symptoms. As an example, murine anaphylaxis is characterized by dramatic reductions in core body temperature and subtle cardiopulmonary differences, compared with human anaphylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18778/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In mouse models, at least two IgG-mediated pathways have been identified:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one model, allergen interacts with allergen-specific IgG bound to Fc gamma RIII (Fc&gamma;RIII) on macrophages and basophils (",
"      <a class=\"graphic graphic_figure graphicRef81752 \" href=\"UTD.htm?16/48/17153\">",
"       figure 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/21/18778/abstract/5-7,9-11\">",
"       5-7,9-11",
"      </a>",
"      ]. This IgG-dependent pathway requires proportionately more antibody and antigen than the murine IgE-mediated pathway, and macrophage activation results primarily in the release of platelet activating factor (PAF), rather than histamine [",
"      <a class=\"abstract\" href=\"UTD.htm?18/21/18778/abstract/5,6\">",
"       5,6",
"      </a>",
"      ]. PAF causes platelet aggregation and the release of the potent vasoconstrictors thromboxane A2 and serotonin, and can act directly on vascular endothelial cells to increase vascular permeability [",
"      <a class=\"abstract\" href=\"UTD.htm?18/21/18778/abstract/12\">",
"       12",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      There is evidence in mice that pathways of IgG- and IgE-mediated anaphylaxis are interrelated. When low doses of allergen are administered, IgG antibody can block IgE-dependent anaphylaxis by intercepting the antigen before it can cross-link mast cell- and basophil-associated IgE, and by activating the inhibitory receptor, Fc&gamma;RIIb. Low doses of IgG are insufficient to induce IgG-mediated anaphylaxis, presumably because Fc&gamma;RIII has a much lower affinity than Fc&epsilon;RI [",
"      <a class=\"abstract\" href=\"UTD.htm?18/21/18778/abstract/5,6\">",
"       5,6",
"      </a>",
"      ]. In comparison, high doses of allergen can precipitate IgG-dependent anaphylaxis by forming complexes with antigen that activate macrophages and basophils through Fc&gamma;RIII.",
"     </li>",
"     <li>",
"      Another mouse model found evidence of the above mechanism, in concert with activation of neutrophils resulting from the interaction of allergen-specific IgG2 with Fc gamma RIV (Fc&gamma;RIV) on those cells [",
"      <a class=\"abstract\" href=\"UTD.htm?18/21/18778/abstract/13\">",
"       13",
"      </a>",
"      ]. PAF was the predominant mediator in this model also.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    IgG-dependent anaphylaxis has not been demonstrated in humans. However, human IgG receptors are capable of activating macrophages and neutrophils to secrete PAF [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18778/abstract/5,14\">",
"     5,14",
"    </a>",
"    ], and PAF can activate mast cells in vitro [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18778/abstract/15\">",
"     15",
"    </a>",
"    ], so PAF potentially may contribute to human anaphylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18778/abstract/16\">",
"     16",
"    </a>",
"    ]. Additionally, anaphylaxis has been reported to be more severe in individuals who catabolize PAF slowly.",
"   </p>",
"   <p>",
"    Rare individuals have experienced anaphylaxis after receiving therapeutic preparations of IgG anti-IgE antibodies (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38629?source=see_link\">",
"     omalizumab",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18778/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. Omalizumab blocks the binding of IgE to Fc&epsilon;RI receptors and does not bind Fc&epsilon;RI-associated IgE (",
"    <a class=\"graphic graphic_figure graphicRef59320 \" href=\"UTD.htm?32/26/33191\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18778/abstract/5,19\">",
"     5,19",
"    </a>",
"    ]. These anaphylactic reactions could conceivably be IgG-mediated, with the patient's IgE acting as the antigen, and the IgG of the drug acting as the causative antibody [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18778/abstract/5\">",
"     5",
"    </a>",
"    ]. IgE-independent anaphylaxis has also been reported in some patients receiving another monoclonal antibody preparation,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18778/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. More human data are needed to clarify the mechanism underlying these clinical events. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/46/17130?source=see_link&amp;anchor=H16#H16\">",
"     \"Anti-IgE therapy\", section on 'Adverse effects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Immune complex/complement mediated",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several drugs have been implicated in immediate life-threatening reactions that are clinically similar to anaphylaxis except that drug-specific IgE could not be identified. Activation of complement by immune complexes, composed of the culprit drug and IgG or other isotypes, has been proposed for some of these drugs, such as protamine [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18778/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Other proposed mechanisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of non IgE-mediated mechanisms have been proposed to explain anaphylaxis caused by radiocontrast media (RCM). One of these involves the interaction of RCM molecules with the Fc portions of IgE or IgG already bound to the mast cell or basophil surface, causing crosslinking and activation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/36/31305?source=see_link\">",
"     \"Immediate hypersensitivity reactions to radiocontrast media: Clinical manifestations, diagnosis, and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Nonimmunologic anaphylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anaphylactic reactions to various drugs have revealed potential mechanisms by which mast cells and basophils could be activated without evidence of involvement of IgE, other antibodies, or immune complexes.",
"   </p>",
"   <p>",
"    These potential mechanisms include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Activation of complement, in the absence of immune complex formation, has been proposed to account for reactions to drugs that were solubilized in the diluent Cremophor EL&reg;, such as older preparations of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17816?source=see_link\">",
"       propofol",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?18/21/18778/abstract/24-26\">",
"       24-26",
"      </a>",
"      ]. It has been proposed that under physiologic conditions, Cremophor formed large micelles with serum lipids and cholesterol, stimulating complement activation. Some human mast cells express receptors for the \"anaphylatoxins\" C3a and C5a, and release histamine in response to exposure to these complement fragments. Macrophages and basophils also have C3a receptors and can produce PAF in response to their activation. This mechanism has been implicated in peanut-induced anaphylaxis in mice, although the significance of this in human anaphylaxis has not been demonstrated. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/22/44393?source=see_link\">",
"       \"Mast cells: Development, identification, and physiologic roles\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/59/11190?source=see_link\">",
"       \"Complement pathways\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/57/43930?source=see_link\">",
"       \"Infusion reactions to systemic chemotherapy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Direct activation of mast cells",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      basophils by",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      , leading to histamine release, has been implicated in \"red man syndrome.\" This reaction can involve hypotension and present similarly to anaphylaxis in up to 15 percent of patients. The mechanism is unknown. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/59/1978?source=see_link\">",
"       \"Vancomycin hypersensitivity\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Opiate medications, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/44/11976?source=see_link\">",
"       meperidine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/0/35848?source=see_link\">",
"       codeine",
"      </a>",
"      , can cause nonimmunologic histamine release via direct mast cell degranulation [",
"      <a class=\"abstract\" href=\"UTD.htm?18/21/18778/abstract/27\">",
"       27",
"      </a>",
"      ]. Mild reactions, such as urticaria, are common, although anaphylactic reactions are occasionally reported [",
"      <a class=\"abstract\" href=\"UTD.htm?18/21/18778/abstract/28\">",
"       28",
"      </a>",
"      ]. In the past, some allergy specialists used opiates as positive controls in skin testing, because these agents induce a characteristic wheal-and-flare response due to the direct degranulation of mast cells in the skin.",
"     </li>",
"     <li>",
"      Cold urticaria is a reproducible disorder that is characterized by the rapid onset of erythema, pruritus, and edema after exposure to cold (eg, water, air,",
"      <span class=\"nowrap\">",
"       food/beverage,",
"      </span>",
"      or other source of cold temperature). Systemic cold exposure, as might occur with swimming or total body exposure to cold air, can cause massive release of histamine and other mediators, leading to hypotension. Some episodes are characterized by the presence of abnormal proteins (ie, cryoglobulins or cryofibrinogens), which may agglutinate or precipitate at lower temperatures. However, most instances of cold",
"      <span class=\"nowrap\">",
"       urticaria/anaphylaxis",
"      </span>",
"      are idiopathic and lack abnormal circulating proteins [",
"      <a class=\"abstract\" href=\"UTD.htm?18/21/18778/abstract/29\">",
"       29",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/63/22522?source=see_link\">",
"       \"Overview of cryoglobulins and cryoglobulinemia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/25/7576?source=see_link\">",
"       \"Cryofibrinogenemia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Angiotensin converting enzyme (ACE) inhibitors cause rare anaphylactic reactions, although isolated angioedema is common. Both reactions are believed to be caused by excessive production",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      accumulation of bradykinin. These mechanisms are reviewed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38391?source=see_link&amp;anchor=H11#H11\">",
"       \"An overview of angioedema: Pathogenesis and causes\", section on 'ACE inhibitors'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Oversulfated chondroitin sulfate (OSCS), a compound contaminating worldwide",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      supplies in 2007 to 2008, caused anaphylaxis by directly activating the kinin-kallikrein pathway, which generated bradykinin, C3a, and C5a. Anaphylactic reactions consisted of hypotension and abdominal pain and variably included dyspnea, diarrhea, flushing, and angioedema. However, these reactions consistently lacked urticaria or pruritus [",
"      <a class=\"abstract\" href=\"UTD.htm?18/21/18778/abstract/30,31\">",
"       30,31",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33930?source=see_link&amp;anchor=H28#H28\">",
"       \"Therapeutic use of heparin and low molecular weight heparin\", section on 'Heparin contamination'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Regulation of mast cell activation in anaphylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple additional protein motifs, receptors, channels, and molecular signals act at various levels to modulate the reactivity and responsiveness of mast cells [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18778/abstract/5\">",
"     5",
"    </a>",
"    ]. These are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/28/20936?source=see_link\">",
"     \"Mast cells: Surface receptors and signal transduction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     CHEMICAL MEDIATORS OF ANAPHYLAXIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The chemical mediators of IgE-mediated anaphylaxis in humans include biologically active products of mast cells, basophils, and eosinophils, as well as serum components of the complement, coagulation, and kallikrein-kinin pathways. In addition, cytokines that alter the sensitivity of various target cells to these mediators are believed to influence the severity of anaphylaxis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Mast cells and basophils",
"    </span>",
"    &nbsp;&mdash;&nbsp;The degranulation of mast cells and basophils results in the systemic release of various biochemical mediators and chemotactic substances, including the following [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18778/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Histamine, tryptase, chymase, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      , which are preformed substances associated with intracellular granules",
"     </li>",
"     <li>",
"      Histamine-releasing factor and other cytokines (TNF, IL-4, IL-13)",
"     </li>",
"     <li>",
"      Newly generated lipid-derived mediators such as prostaglandin D2, leukotriene B4, platelet activating factor (PAF), and the cysteinyl leukotrienes, LTC4, LTD4, and LTE4",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The functions of these mediators specifically in anaphylaxis have not been extensively studied, although the available data are reviewed here. A more complete description of the mediators, cytokines, and chemokines produced by mast cells is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/22/44393?source=see_link\">",
"     \"Mast cells: Development, identification, and physiologic roles\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A mutation of c-kit, a tyrosine kinase receptor expressed on the membrane surfaces of all mast cells has been associated with anaphylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18778/abstract/32\">",
"     32",
"    </a>",
"    ]. Subjects with the D816V c-kit mutation present with normal numbers of mast cells in the bone marrow but abnormal expression of CD25 and symptoms of severe anaphylaxis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/28/20937?source=see_link\">",
"     \"Mast cell activation disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Histamine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Localized histamine release in the skin causes urticaria. Systemic release of histamine, however, causes hemodynamic and cardiovascular changes, and is not associated with the presence of urticaria. Serum histamine levels correlated with the severity and persistence of cardiopulmonary manifestations in studies of human anaphylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18778/abstract/33,34\">",
"     33,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The systemic effects of histamine are dose-dependent. Histamine was administered to normal volunteers over 30 minutes at doses ranging from 0.05 to 1.0",
"    <span class=\"nowrap\">",
"     micrograms/kg/min,",
"    </span>",
"    to determine the plasma levels required to elicit symptoms of anaphylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18778/abstract/35\">",
"     35",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At low plasma levels, histamine was associated with a 30 percent increase in heart rate",
"     </li>",
"     <li>",
"      At moderate plasma levels, histamine precipitated flushing and headache",
"     </li>",
"     <li>",
"      Higher plasma histamine levels elicited a 30 percent increase in pulse pressure (ie, systolic pressure minus diastolic pressure)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The actions of histamine in anaphylaxis are mediated by binding to H1 and H2 receptors on target cells. In the study above, pretreatment with H1 antihistamines, H2 antihistamines, or both, suggested that both H1 and H2 receptors mediated flushing, hypotension, and headache, whereas H1 receptors alone mediated tachycardia, pruritus, rhinorrhea, and bronchospasm [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18778/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    H3 receptors have been implicated in the canine model of anaphylaxis, and appear to influence cardiovascular responses to norepinephrine, although this has not been studied in human anaphylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18778/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Murine models suggest H4 receptors might be involved in chemotaxis and mast cell cytokine release and they might also help to mediate pruritus [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18778/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. Their role (if any) in human anaphylaxis has not been studied.",
"   </p>",
"   <p>",
"    The specific effects of histamine on the cardiovascular system are discussed below. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Cardiovascular system'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Tryptase",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tryptase is a protease that is abundant in human mast cells. Tryptase is relatively specific for mast cells, although basophils and myeloid precursors contain a small amount. There are different forms of tryptases. Beta-tryptase (mature tryptase) is enzymatically active, concentrated in mast cell secretory granules, and released upon degranulation.",
"   </p>",
"   <p>",
"    Tryptase can activate the complement and coagulation pathways, as well as the kallikrein-kinin contact system [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18778/abstract/39\">",
"     39",
"    </a>",
"    ]. Potential clinical consequences include hypotension, angioedema, clotting, and clot lysis, respectively, with the latter two explaining the variable development of disseminated intravascular coagulation in severe anaphylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18778/abstract/40\">",
"     40",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Serum factors and other inflammatory pathways'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The route of allergen exposure appears to influence the resultant tryptase levels for reasons that have not been fully explained. Specifically, anaphylaxis triggered by ingested food may have minimal or no elevation in serum tryptase [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18778/abstract/39,41\">",
"     39,41",
"    </a>",
"    ]. In an analysis of anaphylaxis fatalities, parenterally-administered triggers (injected medications, insect venoms) were associated with higher serum levels of tryptase and lower levels of antigen-specific IgE, whereas orally-administered allergens were associated with low tryptase levels and comparatively high levels of antigen-specific IgE [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18778/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. This difference in tryptase levels may be related to the subtype of mast cell first encountered by the culprit antigen. Mast cells that predominate in the mucosa of the small intestine and lung contain much less tryptase per cell than those in the connective tissues [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18778/abstract/42\">",
"     42",
"    </a>",
"    ]. Overall, tryptase levels generally correlate with the clinical severity of anaphylaxis, with the notable exception of food allergens previously described.",
"   </p>",
"   <p>",
"    Post-mortem measurements of serum tryptase may be useful in establishing anaphylaxis as the cause of death:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The measurement of tryptase in anaphylaxis and the differential diagnosis of an elevated tryptase level are presented in more detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/54/40809?source=see_link\">",
"       \"Laboratory tests to support the clinical diagnosis of anaphylaxis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Technical aspects of collecting and measuring tryptase in the post-mortem setting are reviewed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/13/1241?source=see_link&amp;anchor=H31#H31\">",
"       \"Fatal anaphylaxis\", section on 'Postmortem diagnosis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is mounting evidence to suggest that closer scrutiny to baseline total tryptase levels might be appropriate, especially in patients who experienced hypotension during anaphylaxis. Most studies have evaluated patients with severe anaphylaxis to insect stings [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18778/abstract/44-46\">",
"     44-46",
"    </a>",
"    ]. Higher baseline tryptase concentrations (greater than 11.4",
"    <span class=\"nowrap\">",
"     &micro;g/L)",
"    </span>",
"    might indicate mastocytosis or a monoclonal mast cell disorder (eg, c-kit mutation) and require bone marrow biopsy and cytogenetic analysis for further evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18778/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/28/20937?source=see_link\">",
"     \"Mast cell activation disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Platelet activating factor",
"    </span>",
"    &nbsp;&mdash;&nbsp;PAF-receptor antagonists are effective in rodent models of anaphylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18778/abstract/5,47\">",
"     5,47",
"    </a>",
"    ]. In contrast, the roles of PAF and PAF acetylhydrolase, the enzyme that inactivates PAF, are not well defined in human anaphylaxis, although available data suggest that PAF may be important. PAF receptors have been identified in some subsets of human mast cells [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18778/abstract/15\">",
"     15",
"    </a>",
"    ]. In addition, in a prospective study of 41 subjects (ages 15 to 74 years) and 23 non-allergic adult controls, serum PAF levels correlated directly and PAF acetylhydrolase levels correlated inversely with the severity of anaphylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18778/abstract/16\">",
"     16",
"    </a>",
"    ]. In a companion retrospective analysis, PAF acetylhydrolase activity was significantly lower in nine individuals who experienced fatal peanut-induced anaphylaxis, compared with patients in five different control groups. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/28/20936?source=see_link\">",
"     \"Mast cells: Surface receptors and signal transduction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Nitric oxide",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nitric oxide (NO), a molecular gas, acts as a messenger molecule in most human organ systems. Within blood vessel walls, it has potent vasodilator activity, and accounts for the bioactivity of endothelium-derived relaxing factor [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18778/abstract/48\">",
"     48",
"    </a>",
"    ]. Under normal circumstances, NO participates in the homeostatic control of vascular tone and regional blood pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18778/abstract/49\">",
"     49",
"    </a>",
"    ]. NO is also involved in the complex interaction of regulatory and counter-regulatory mediators in mast cell activation, and has been implicated in the hypotension of sepsis and anaphylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18778/abstract/50,51\">",
"     50,51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    NO promotes protective responses, such as bronchodilation, coronary artery vasodilation, and decreased histamine release, as evidenced by experiments with NO inhibitors in mice, rabbits, and dogs. However, its net effects in anaphylaxis appear to be detrimental through vascular smooth muscle relaxation and enhanced vascular permeability [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18778/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The binding of histamine to H1-receptors initiates phospholipase-C-dependent calcium mobilization, converting L-arginine to NO through the activity of nitric oxide synthase (NOS). Various isoforms of NOS have been identified, depending on the tissue in which they were first isolated. Constitutively expressed isoforms, ie, endothelial NOS (eNOS) and neuronal NOS (nNOS), are presumed to produce low amounts of NO for physiologic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    anti-inflammatory functions. In contrast, inducible NOS (iNOS) expression is associated with inflammation. Increased expression of iNOS results in overproduction of NO and activation of guanylate cyclase. This mechanism may be responsible for the cardiovascular morbidity and mortality associated with septic shock, and has widely been presumed also to apply to anaphylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18778/abstract/52\">",
"     52",
"    </a>",
"    ]. However, subsequent studies in knockout mice have demonstrated that anaphylaxis can occur in the absence of iNOS, and that in PAF-associated anaphylaxis, eNOS is the critical mediator [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18778/abstract/53\">",
"     53",
"    </a>",
"    ]. Similar data in humans are not available, although these murine findings suggest that NOS involvement in anaphylaxis may be more complex than previously thought.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Arachidonic acid metabolites",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arachidonic acid is a fatty acid derived from membrane phospholipids that can be metabolized via the lipoxygenase and cyclooxygenase pathways to generate proinflammatory mediators, such as leukotrienes, prostaglandins, and PAF. Effects of these arachidonic acid metabolites include bronchospasm, hypotension, and erythema [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18778/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Leukotriene B4 is a chemotactic agent that theoretically may contribute to biphasic and protracted reactions.",
"     </li>",
"     <li>",
"      Overproduction of leukotriene C4 enhances mast cell degranulation [",
"      <a class=\"abstract\" href=\"UTD.htm?18/21/18778/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Leukotrienes D4 and E4 increase microvascular permeability and are potent bronchoconstrictors [",
"      <a class=\"abstract\" href=\"UTD.htm?18/21/18778/abstract/54-56\">",
"       54-56",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Prostaglandin D2 (PGD2) causes vasodilation, increased vasopermeability, and airway smooth muscle bronchoconstriction in various experimental models [",
"      <a class=\"abstract\" href=\"UTD.htm?18/21/18778/abstract/57-59\">",
"       57-59",
"      </a>",
"      ]. It is also chemotactic for neutrophils and activates eosinophils [",
"      <a class=\"abstract\" href=\"UTD.htm?18/21/18778/abstract/60,61\">",
"       60,61",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Modulatory mediators",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other mediators may have anti-inflammatory and modulatory effects that limit anaphylaxis. As examples, chymase may facilitate the conversion of angiotensin I to angiotensin II, theoretically helping to counteract hypotension during anaphylaxis.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     Heparin",
"    </a>",
"    opposes complement activation, modulates tryptase activity, and inhibits clotting, plasmin, and kallikrein [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18778/abstract/34,39\">",
"     34,39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Eosinophils",
"    </span>",
"    &nbsp;&mdash;&nbsp;Eosinophils may be pro-inflammatory (eg, through release of cytotoxic granule-associated proteins) or anti-inflammatory (eg, through metabolism of vasoactive mediators) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18778/abstract/39,62\">",
"     39,62",
"    </a>",
"    ]. A guinea-pig anaphylaxis model suggests that eosinophils already present in chronically inflamed airways may participate in the immediate phase response to allergen exposure, as well as their traditional role in the late-phase allergic response [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18778/abstract/63\">",
"     63",
"    </a>",
"    ]. These mechanisms have not been studied in human anaphylaxis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Serum factors and other inflammatory pathways",
"    </span>",
"    &nbsp;&mdash;&nbsp;During severe episodes of anaphylaxis, there is concomitant activation of complement, coagulation pathways, and the kallikrein-kinin contact system. Much of the evidence for this was obtained during experimental insect sting challenges. Decreases in C4 and C3 and generation of C3a have been observed in anaphylaxis. Demonstrable evidence for coagulation pathway activation during severe anaphylaxis includes decreases in factor V, factor VIII, and fibrinogen, and fatal disseminated intravascular coagulation (DIC) in some instances [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18778/abstract/34,64\">",
"     34,64",
"    </a>",
"    ]. An analysis of 202 anaphylaxis fatalities over a 10-year period in the United Kingdom determined that 8 percent of deaths were attributable to disseminated intravascular coagulation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18778/abstract/64\">",
"     64",
"    </a>",
"    ]. Successful treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/58/14248?source=see_link\">",
"     tranexamic acid",
"    </a>",
"    has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18778/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Decreased high molecular weight kininogen and the formation of kallikrein-C1 inhibitor and factor XIIa-C1 inhibitor complexes indicate contact system activation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18778/abstract/34,66\">",
"     34,66",
"    </a>",
"    ]. Kallikrein activation not only generates bradykinin but also activates factor XII. Factor XII itself can cause clotting and clot lysis via plasmin formation, leading to complement activation. In mouse models of anaphylaxis, PAF appears to be an important mediator in the development of DIC [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18778/abstract/67\">",
"     67",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/59/11190?source=see_link\">",
"     \"Complement pathways\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/35/27194?source=see_link\">",
"     \"Overview of hemostasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Changes in target cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development and severity of anaphylaxis also depend upon the responsiveness of cells targeted by these mediators. As an example, IL-4 and IL-13 are cytokines important in the initial generation of antibody and inflammatory cell responses to anaphylaxis in both mice and humans. In murine anaphylaxis, however, IL-4 also induces a three- to six-fold increase in responsiveness of target cells to inflammatory and vasoactive mediators, including histamine, cysteinyl leukotrienes, serotonin, and PAF [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18778/abstract/5\">",
"     5",
"    </a>",
"    ]. This action of IL-4 appears to take place through the alpha chain of the IL-4 receptor, resulting in the activation of the transcription factor signal transducer and activator of transcription 6 (STAT-6). Comparable mechanisms have not been demonstrated in humans.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     ORGAN SYSTEMS IN ANAPHYLAXIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Organ system involvement in anaphylaxis varies from species to species and determines the clinical manifestations observed. Factors that determine a specific \"shock organ\" include variations in the immune response, the location of smooth muscle, and the distribution, rate of degradation, and responsiveness to chemical mediators [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18778/abstract/2,68\">",
"     2,68",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the human, the predominant shock organs are the heart, vasculature, and lungs, and fatalities are divided between circulatory collapse and respiratory arrest [",
"      <a class=\"abstract\" href=\"UTD.htm?18/21/18778/abstract/64\">",
"       64",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Anaphylaxis in rabbits produces fatal pulmonary artery vasoconstriction with right ventricular failure [",
"      <a class=\"abstract\" href=\"UTD.htm?18/21/18778/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the guinea pig, there is bronchial smooth muscle constriction, which leads to bronchospasm, hypoxemia, and death [",
"      <a class=\"abstract\" href=\"UTD.htm?18/21/18778/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The primary shock organ in the dog is the hepatic venous system, which contracts and produces severe hepatic congestion [",
"      <a class=\"abstract\" href=\"UTD.htm?18/21/18778/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Human anaphylaxis was traditionally considered a form of distributive shock characterized by a profound reduction in venous tone, with similarities to septic shock and toxic shock syndrome. An emerging view, however, is that anaphylaxis has features of hypovolemic shock also, with fluid extravasation causing reduced venous return, as well as depressed myocardial function [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18778/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Cardiovascular system",
"    </span>",
"    &nbsp;&mdash;&nbsp;The human heart may be profoundly affected during anaphylaxis, independently of the effects of pharmacologic agents administered during treatment. One report described two previously healthy patients without apparent underlying heart disease, who developed profound myocardial depression during anaphylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18778/abstract/70\">",
"     70",
"    </a>",
"    ]. Echocardiography, nuclear imaging, and hemodynamic measurements confirmed myocardial dysfunction. Intra-aortic balloon counter-pulsation was used to provide hemodynamic support, in addition to standard anaphylaxis treatment. This intervention was required for up to 72 hours because of persistent myocardial depression, even though other clinical signs of anaphylaxis had resolved. Both patients recovered with no subsequent evidence of myocardial dysfunction.",
"   </p>",
"   <p>",
"    Anaphylaxis has been associated clinically with myocardial ischemia, as well as conduction defects, including atrial and ventricular arrhythmias and T-wave abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18778/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is unclear whether such changes are related to direct mediator effects on the myocardium, exacerbation of preexisting myocardial insufficiency by the hemodynamic stress of anaphylaxis, endogenous epinephrine released from the adrenal medulla in response to stress, or exogenously injected epinephrine [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18778/abstract/34,70-72\">",
"     34,70-72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Effects of mediators",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cardiac effects of some of the mediators of anaphylaxis have been studied:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Histamine, acting at H1 receptors, mediates coronary artery vasoconstriction and possibly vasospasm and increases vascular permeability [",
"      <a class=\"abstract\" href=\"UTD.htm?18/21/18778/abstract/73-75\">",
"       73-75",
"      </a>",
"      ]. H2 receptors increase atrial and ventricular inotropy, atrial chronotropy, and coronary artery vasodilation, as previously mentioned. The interaction of H1 and H2 receptor stimulation results in decreased diastolic pressure and increased pulse pressure [",
"      <a class=\"abstract\" href=\"UTD.htm?18/21/18778/abstract/76\">",
"       76",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Histamine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      PAF decreases coronary blood flow, delays atrioventricular conduction, and has negative inotropic effects on the heart [",
"      <a class=\"abstract\" href=\"UTD.htm?18/21/18778/abstract/71\">",
"       71",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Calcitonin gene-related peptide (CGRP), a sensory neurotransmitter widely distributed in cardiovascular tissues and released during anaphylaxis, may help to counteract coronary artery vasoconstriction during anaphylaxis [",
"      <a class=\"abstract\" href=\"UTD.htm?18/21/18778/abstract/77,78\">",
"       77,78",
"      </a>",
"      ]. CGRP relaxed vascular smooth muscle and had cardioprotective effects in animal models of anaphylaxis [",
"      <a class=\"abstract\" href=\"UTD.htm?18/21/18778/abstract/79\">",
"       79",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Levels of enzymes involved in bradykinin metabolism, serum angiotensin-converting enzyme (ACE) and aminopeptidase P (APP) were measured in 122 patients with peanut and tree nut allergy who presented to a regional allergy center with acute allergic reactions after ingestion of these agents [",
"      <a class=\"abstract\" href=\"UTD.htm?18/21/18778/abstract/80\">",
"       80",
"      </a>",
"      ]. Of these 122, 46 had moderate to severe pharyngeal edema, 36 had moderate to severe bronchospasm, and the rest lacked these symptoms. Patients clinically deemed to have severe pharyngeal edema had significantly lower serum ACE levels than those with no pharyngeal edema. Multivariate analysis indicated that patients with serum ACE concentrations in the lowest quartile were almost ten times more likely to have severe pharyngeal edema than those with higher ACE concentrations. However, patients with serum ACE levels in the lowest quartile were no more likely than others to have reduced consciousness, bronchospasm, or urticaria. Serum APP levels did not correlate with clinical severity or show any statistical trends. More studies are needed, but these findings suggest a clinical scenario in which some patients who experience angioedema during anaphylaxis might be more resistant to treatment with epinephrine and second-line therapeutic agents (eg, antihistamines, glucocorticoids) commonly recommended for use after epinephrine.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Responses to fluid shifts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Massive fluid shifts occur during anaphylaxis due to increased vascular permeability. Up to 35 percent of intravascular volume can shift to the extravascular space within 10 minutes during anaphylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18778/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Compensatory responses include release of endogenous catecholamines, angiotensin II, and endothelins. When adequate, these responses may be life-saving, independent of any medical intervention. Some patients, however, experience abnormal elevations of peripheral vascular resistance (maximal vasoconstriction), yet shock persists due to reduced intravascular volume [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18778/abstract/2\">",
"     2",
"    </a>",
"    ]. Others have decreased systemic vascular resistance despite elevated levels of catecholamines. These differences have important clinical implications, since the latter scenario may respond to treatment with vasoconstrictor agents, while the former is vasoconstrictor-unresponsive and requires large-volume fluid resuscitation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=see_link\">",
"     \"Anaphylaxis: Rapid recognition and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Body posture",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient's posture during anaphylaxis may impact the clinical outcome. In a retrospective review of 10 prehospital anaphylactic fatalities in the United Kingdom, 4 of the 10 fatalities were associated with the assumption of an upright or sitting posture [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18778/abstract/82\">",
"     82",
"    </a>",
"    ]. Postmortem findings were consistent with pulseless electrical activity and an \"empty ventricle,\" attributed to inadequate venous return secondary to vasodilation and loss of intravascular volume.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Bradycardia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tachycardia is the most common arrhythmia observed during anaphylaxis and is believed to develop in response to decreasing blood pressure, intravascular depletion, and endogenous catecholamines, as in other forms of shock. However, some patients present with bradycardia or with relative bradycardia (ie, initial tachycardia followed by a reduction in heart rate despite worsening hypotension). This has been reported in the setting of experimentally induced insect sting anaphylaxis, as well as in trauma patients [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18778/abstract/34,83-85\">",
"     34,83-85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The etiology of this bradycardia has been studied in animal models of hypovolemia. Two distinct phases of physiologic response are apparent [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18778/abstract/86\">",
"     86",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The initial response to hypovolemia is a baroreceptor-mediated increase in cardiac sympathetic drive and concomitant withdrawal of resting vagal drive, which together produce tachycardia and peripheral vasoconstriction.",
"     </li>",
"     <li>",
"      A second phase follows when the effective arterial blood volume falls by 20 to 30 percent, which is characterized by withdrawal of vasoconstrictor drive, relative or absolute bradycardia, increased vasopressin, further catecholamine release as the adrenal axis becomes more active, and hypotension. Hypotension in this setting is independent of the bradycardia, since it persists even if the bradycardia is reversed with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/23/11640?source=see_link\">",
"       atropine",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Bradycardia has also been observed in porcine anaphylaxis precipitated experimentally by various liposomal medications [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18778/abstract/87\">",
"     87",
"    </a>",
"    ]. In this setting, release of the anaphylatoxin, C5a, and adenosine acting via A1 adenosine receptors are believed responsible.",
"   </p>",
"   <p>",
"    Conduction defects and sympatholytic medications, such as beta-blockers, may also produce bradycardia in patients with anaphylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18778/abstract/2\">",
"     2",
"    </a>",
"    ]. Excessive venous pooling with decreased venous return (also seen in vasodepressor reactions) may activate tension-sensitive sensory receptors in the inferoposterior portions of the left ventricle, thus resulting in a cardioinhibitory (Bezold-Jarisch) reflex that stimulates the vagus nerve and causes bradycardia [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18778/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The implications of relative or absolute bradycardia in human anaphylaxis and hypovolemic shock have not been studied, although one retrospective review of approximately 11,000 trauma patients found that 29 percent of hypotensive patients were bradycardic, and mortality was lower in this group, compared with those who were tachycardic, after adjustment for other mortality factors [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18778/abstract/85\">",
"     85",
"    </a>",
"    ]. Thus, there may be a specific compensatory role of bradycardia in these settings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Exacerbation of underlying cardiac disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The concurrence of acute coronary events and anaphylaxis has been noted, although the causal relationship between them is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18778/abstract/73\">",
"     73",
"    </a>",
"    ]. Mast cells accumulate at sites of coronary atherosclerotic plaques, and mast cell degranulation may promote plaque rupture during both acute myocardial events and anaphylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18778/abstract/73,88\">",
"     73,88",
"    </a>",
"    ]. Coronary artery vasoconstriction and decreased intravascular volume could conceivably also precipitate an acute coronary syndrome in a patient who already had atherosclerotic cardiovascular disease. PAF induction of platelet aggregation and activation of coagulation pathways might additionally predispose to coronary artery thrombosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Respiratory system",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anaphylaxis may have adverse effects on any part of the respiratory tract. Upper airway symptoms include sneezing, rhinorrhea, dysphonia, laryngeal edema, laryngeal obstruction, or oropharyngeal angioedema. Lower airway manifestations of anaphylaxis include cough, wheeze, pulmonary hyperinflation, edema, hemorrhage, petechiae, mucus plugging, respiratory failure, or respiratory arrest (",
"    <a class=\"graphic graphic_table graphicRef66333 \" href=\"UTD.htm?20/36/21068\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In retrospective series of acute nonfatal anaphylaxis, respiratory signs and symptoms were observed in 40 to 60 percent of subjects, with rhinitis,",
"    <span class=\"nowrap\">",
"     dyspnea/wheeze,",
"    </span>",
"    and upper airway angioedema in up to 20, 50, and 60 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18778/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar observations have been made in cases of fatal anaphylaxis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One report examined 214 anaphylactic fatalities, among which the mode of death could be surmised in 196 [",
"      <a class=\"abstract\" href=\"UTD.htm?18/21/18778/abstract/64\">",
"       64",
"      </a>",
"      ]. Asphyxia was the cause of death in approximately one-half (98 cases), with involvement of the lower airways (bronchospasm) in 49, upper airway angioedema in 23, and both upper and lower airway involvement in 26. The fatalities from acute bronchospasm during anaphylaxis occurred almost exclusively in those with preexisting asthma.",
"     </li>",
"     <li>",
"      Another postmortem analysis of 23 unselected cases of fatal anaphylaxis determined that 16 of 20 \"immediate\" deaths (deaths occurring within one hour of symptom onset) were due to upper airway edema [",
"      <a class=\"abstract\" href=\"UTD.htm?18/21/18778/abstract/89\">",
"       89",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Autopsy findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Victims of fatal anaphylaxis may show no distinguishing gross pathologic features at autopsy, possibly because anaphylaxis can progress to death so rapidly. A retrospective review included 56 cases of fatal anaphylaxis in which autopsy information was available; death occurred within one hour in 39 cases [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18778/abstract/90\">",
"     90",
"    </a>",
"    ]. This is in keeping with the clinical observation that in patients in whom shock develops rapidly, there may be essentially no other physical signs or symptoms.",
"   </p>",
"   <p>",
"    When present however, other findings include upper airway edema and petechial hemorrhages in airway mucosa, mucus plugging and hyperinflation of the lungs, and cerebral edema. Cutaneous findings, such as urticaria or angioedema, are present in only a minority of fatal cases. Autopsy findings are described in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/13/1241?source=see_link\">",
"     \"Fatal anaphylaxis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     ANAEROBIC METABOLISM COMPLICATES ANAPHYLAXIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blood flow to the periphery is decreased during shock, to preserve perfusion of central organs, such as the brain, heart, and kidneys. In septic shock, the paradigm of distributive shock, hypotension results from decreased systemic vascular resistance. Oxygen consumption by skeletal muscle is impaired, despite an increased partial pressure of oxygen, leading to anaerobic metabolism. This impairment in cellular respiration has been attributed to an unregulated inflammatory process called \"cytopathic hypoxia\" [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18778/abstract/91\">",
"     91",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Preliminary evidence suggests that anaerobic metabolism also occurs within the peripheral tissues during anaphylaxis, although the mechanism may be distinct. One study compared rats with ovalbumin-induced anaphylaxis to a parallel group with severe hypotension induced experimentally by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/61/42969?source=see_link\">",
"     nicardipine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18778/abstract/92\">",
"     92",
"    </a>",
"    ]. The time course and magnitude of hypotension were similar, and both groups experienced decreased perfusion of skeletal muscle. There were metabolic differences, however:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The anaphylactic animals showed greater activation of the sympathetic nervous system, with higher plasma catecholamine levels beginning at 20 minutes, which were maintained throughout the 60 minute protocol. Plasma epinephrine levels increased 15-fold and norepinephrine levels increased 10-fold over baseline values in the anaphylactic animals.",
"     </li>",
"     <li>",
"      Skeletal muscle blood flow was decreased in both",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/61/42969?source=see_link\">",
"       nicardipine",
"      </a>",
"      - and anaphylaxis-induced hypotensive rats initially, which was followed by a further decrease in the anaphylaxis group beginning at 20 minutes and persisting for the duration of the observation period.",
"     </li>",
"     <li>",
"      A higher gradient between plasma and interstitial epinephrine indicated more impaired skeletal muscle blood flow in the anaphylactic animals, possibly due to greater skeletal muscle vasoconstriction.",
"     </li>",
"     <li>",
"      The anaphylactic animals experienced a more rapid increase in interstitial lactate levels, and a corresponding decrease in interstitial pyruvate levels, indicating depletion of cellular energy stores. This latter finding was not observed in the rats with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/61/42969?source=see_link\">",
"       nicardipine",
"      </a>",
"      -induced hypotension.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These findings suggest that skeletal muscle maintains high rates of oxygen utilization during anaphylaxis compared with other forms of distributive shock, and that this, combined with decreased perfusion, leads rapidly to anaerobic metabolism [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18778/abstract/92\">",
"     92",
"    </a>",
"    ]. This may partly explain why end organ injury and irreversible shock can develop so quickly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     TEMPORAL COURSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anaphylaxis is usually characterized by the rapid onset of symptoms over a period of minutes to hours following exposure to a trigger [",
"    <a class=\"abstract\" href=\"UTD.htm?18/21/18778/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=see_link&amp;anchor=H8#H8\">",
"     \"Anaphylaxis: Rapid recognition and treatment\", section on 'Time course'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5688518\">",
"    <span class=\"h2\">",
"     Factors affecting the time course",
"    </span>",
"    &nbsp;&mdash;&nbsp;The variables that determine the temporal course of anaphylaxis are not entirely defined. However, several factors appear to be involved:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The route through which the allergen enters the body is one factor in determining the rapidity of onset of symptoms. Specifically, injected or intravenously administered allergens tend to precipitate symptoms in seconds to minutes, while ingested allergens cause symptoms in minutes to an hour or two. However, these are generalizations to which exceptions are well-reported.",
"     </li>",
"     <li>",
"      The type of allergen responsible for the reaction also affects the timing of symptom onset. In IgE-mediated anaphylaxis triggered by protein allergens (the best-characterized type of allergen), symptoms usually begin within two hours of trigger exposure. In contrast, IgE-mediated anaphylaxis to carbohydrate allergens, such as those responsible for some anaphylaxis to mammalian meats and to the monoclonal drug",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/58/10151?source=see_link\">",
"       cetuximab",
"      </a>",
"      , results in symptoms that typically appear four to six hours after exposure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These factors have been examined in cases of fatal and near-fatal anaphylaxis, and are reviewed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/13/1241?source=see_link&amp;anchor=H16#H16\">",
"     \"Fatal anaphylaxis\", section on 'Clinical characteristics of fatal reactions'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/13/1241?source=see_link&amp;anchor=H21#H21\">",
"     \"Fatal anaphylaxis\", section on 'Possible risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5688532\">",
"    <span class=\"h2\">",
"     Temporal patterns",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anaphylaxis symptoms most commonly appear, build, peak and subside in a unimodal manner, although biphasic and protracted anaphylaxis are other recognized patterns of anaphylaxis. The other patterns are mentioned briefly here and reviewed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/24/19847?source=see_link\">",
"     \"Biphasic and protracted anaphylaxis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5688397\">",
"    <span class=\"h3\">",
"     Biphasic anaphylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biphasic anaphylaxis is defined as a recurrence of symptoms that develops following the apparent resolution of the initial anaphylactic event without additional exposure to the trigger. Biphasic anaphylaxis occurs up to one-fifth of anaphylaxis cases and the mechanisms underlying the recurrence of symptoms is unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5688404\">",
"    <span class=\"h3\">",
"     Protracted anaphylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Protracted anaphylaxis is defined as an anaphylactic reaction that lasts for hours, days, or even weeks in extreme cases. Biphasic anaphylaxis occurs up to one-fifth of anaphylaxis cases and the mechanisms underlying the recurrence of symptoms is unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?14/57/15250?source=see_link\">",
"       \"Patient information: Anaphylaxis symptoms and diagnosis (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?40/14/41186?source=see_link\">",
"       \"Patient information: Anaphylaxis treatment and prevention (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anaphylaxis is an acute, potentially lethal, multi-system syndrome resulting from the sudden release of mast cell-, basophil- and macrophage-derived mediators into the circulation.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anaphylaxis can be classified as \"immunologic\" or \"non-immunologic.\" Immunologic anaphylaxis includes both IgE-mediated and IgG-mediated reactions (which have not been identified in humans), as well as immune",
"      <span class=\"nowrap\">",
"       complex/complement-mediated",
"      </span>",
"      mechanisms. Non-immunologic anaphylaxis is caused by agents or events that induce sudden, massive mast cell or basophil degranulation, without the involvement of antibodies. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Proposed Immunopathologic mechanisms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In IgE-mediated anaphylaxis, the activation of mast cells, basophils, and eosinophils results in the release of preformed inflammatory mediators, including histamine, tryptase, chymase,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      , histamine-releasing factor, and PAF. Cellular activation also stimulates the production of lipid-derived mediators such as prostaglandins and cysteinyl leukotrienes. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Chemical mediators of anaphylaxis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The cytokines IL-4 and IL-13 are released during anaphylaxis and increase the sensitivity of target cells to inflammatory mediators. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Changes in target cells'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In humans, the predominant shock organs are the heart, lung, and vasculature, and fatalities are divided between circulatory collapse and respiratory arrest [",
"      <a class=\"abstract\" href=\"UTD.htm?18/21/18778/abstract/64\">",
"       64",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Organ systems in anaphylaxis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Anaphylaxis is associated with myocardial depression, arrhythmias, and myocardial ischemia. Contributing factors include direct mediator effects on the myocardium, exacerbation of preexisting myocardial insufficiency by the hemodynamic stress of anaphylaxis, and exogenous or endogenous epinephrine. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Cardiovascular system'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Anaphylaxis may affect any part of the respiratory tract, causing bronchospasm and mucus plugging in the smaller airways, and laryngeal edema and asphyxiation in the upper airway. Asphyxiation typically occurs rapidly after allergen exposure, with death occurring within one hour in many cases. Severe bronchospasm during anaphylaxis characteristically develops in individuals with preexisting asthma. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Respiratory system'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Preliminary evidence suggests that during anaphylaxis, peripheral tissues continue to consume oxygen at relatively high rates, and that this, in combination with peripheral vasoconstriction and decreased perfusion, leads rapidly to anaerobic metabolism and end organ damage. (See",
"      <a class=\"local\" href=\"#H31\">",
"       'Anaerobic metabolism complicates anaphylaxis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18778/abstract/1\">",
"      Sampson HA, Mu&ntilde;oz-Furlong A, Campbell RL, et al. Second symposium on the definition and management of anaphylaxis: summary report--Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol 2006; 117:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18778/abstract/2\">",
"      Kemp SF, Lockey RF. Anaphylaxis: a review of causes and mechanisms. J Allergy Clin Immunol 2002; 110:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18778/abstract/3\">",
"      Portier P, Richet C. De L'action anaphylactique de certain venins. CR Soc Biol (Paris) 1902; 54:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18778/abstract/4\">",
"      Johansson SG, Bieber T, Dahl R, et al. Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol 2004; 113:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18778/abstract/5\">",
"      Finkelman FD. Anaphylaxis: lessons from mouse models. J Allergy Clin Immunol 2007; 120:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18778/abstract/6\">",
"      Strait RT, Morris SC, Finkelman FD. IgG-blocking antibodies inhibit IgE-mediated anaphylaxis in vivo through both antigen interception and Fc gamma RIIb cross-linking. J Clin Invest 2006; 116:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18778/abstract/7\">",
"      Strait RT, Morris SC, Yang M, et al. Pathways of anaphylaxis in the mouse. J Allergy Clin Immunol 2002; 109:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18778/abstract/8\">",
"      Takeishi T, Martin TR, Katona IM, et al. Differences in the expression of the cardiopulmonary alterations associated with anti-immunoglobulin E-induced or active anaphylaxis in mast cell-deficient and normal mice. Mast cells are not required for the cardiopulmonary changes associated with certain fatal anaphylactic responses. J Clin Invest 1991; 88:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18778/abstract/9\">",
"      Oettgen HC, Martin TR, Wynshaw-Boris A, et al. Active anaphylaxis in IgE-deficient mice. Nature 1994; 370:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18778/abstract/10\">",
"      Miyajima I, Dombrowicz D, Martin TR, et al. Systemic anaphylaxis in the mouse can be mediated largely through IgG1 and Fc gammaRIII. Assessment of the cardiopulmonary changes, mast cell degranulation, and death associated with active or IgE- or IgG1-dependent passive anaphylaxis. J Clin Invest 1997; 99:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18778/abstract/11\">",
"      Bruschi F, Pozio E, Watanabe N, et al. Anaphylactic response to parasite antigens: IgE and IgG1 independently induce death in Trichinella-infected mice. Int Arch Allergy Immunol 1999; 119:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18778/abstract/12\">",
"      Kinn JW, Bache RJ. Effect of platelet activation on coronary collateral blood flow. Circulation 1998; 98:1431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18778/abstract/13\">",
"      J&ouml;nsson F, Mancardi DA, Kita Y, et al. Mouse and human neutrophils induce anaphylaxis. J Clin Invest 2011; 121:1484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18778/abstract/14\">",
"      J&ouml;nsson F, Mancardi DA, Zhao W, et al. Human Fc&gamma;RIIA induces anaphylactic and allergic reactions. Blood 2012; 119:2533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18778/abstract/15\">",
"      Kajiwara N, Sasaki T, Bradding P, et al. Activation of human mast cells through the platelet-activating factor receptor. J Allergy Clin Immunol 2010; 125:1137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18778/abstract/16\">",
"      Vadas P, Gold M, Perelman B, et al. Platelet-activating factor, PAF acetylhydrolase, and severe anaphylaxis. N Engl J Med 2008; 358:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18778/abstract/17\">",
"      Cox L, Platts-Mills TA, Finegold I, et al. American Academy of Allergy, Asthma &amp; Immunology/American College of Allergy, Asthma and Immunology Joint Task Force Report on omalizumab-associated anaphylaxis. J Allergy Clin Immunol 2007; 120:1373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18778/abstract/18\">",
"      Limb SL, Starke PR, Lee CE, Chowdhury BA. Delayed onset and protracted progression of anaphylaxis after omalizumab administration in patients with asthma. J Allergy Clin Immunol 2007; 120:1378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18778/abstract/19\">",
"      Dreyfus DH, Randolph CC. Characterization of an anaphylactoid reaction to omalizumab. Ann Allergy Asthma Immunol 2006; 96:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18778/abstract/20\">",
"      Cheifetz A, Smedley M, Martin S, et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol 2003; 98:1315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18778/abstract/21\">",
"      Stallmach A, Giese T, Schmidt C, et al. Severe anaphylactic reaction to infliximab: successful treatment with adalimumab - report of a case. Eur J Gastroenterol Hepatol 2004; 16:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18778/abstract/22\">",
"      Lakin JD, Blocker TJ, Strong DM, Yocum MW. Anaphylaxis to protamine sulfate mediated by a complement-dependent IgG antibody. J Allergy Clin Immunol 1978; 61:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18778/abstract/23\">",
"      Weiss ME, Nyhan D, Peng ZK, et al. Association of protamine IgE and IgG antibodies with life-threatening reactions to intravenous protamine. N Engl J Med 1989; 320:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18778/abstract/24\">",
"      Laxenaire MC, Mata-Bermejo E, Moneret-Vautrin DA, Gueant JL. Life-threatening anaphylactoid reactions to propofol (Diprivan). Anesthesiology 1992; 77:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18778/abstract/25\">",
"      H&uuml;ttel MS, Schou Olesen A, Stoffersen E. Complement-mediated reactions to diazepam with Cremophor as solvent (Stesolid MR). Br J Anaesth 1980; 52:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18778/abstract/26\">",
"      Szebeni J, Alving CR, Savay S, et al. Formation of complement-activating particles in aqueous solutions of Taxol: possible role in hypersensitivity reactions. Int Immunopharmacol 2001; 1:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18778/abstract/27\">",
"      Blunk JA, Schmelz M, Zeck S, et al. Opioid-induced mast cell activation and vascular responses is not mediated by mu-opioid receptors: an in vivo microdialysis study in human skin. Anesth Analg 2004; 98:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18778/abstract/28\">",
"      Levy JH, Rockoff MA. Anaphylaxis to meperidine. Anesth Analg 1982; 61:301.",
"     </a>",
"    </li>",
"    <li>",
"     Kaplan AP. Urticaria and angioedema. In: Middleton's allergy: Principles and practice, 7th ed, Adkinson NF, Bochner BS, Busse WW, et AL (Eds), Mosby, St. Louis 2009. p.1063.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18778/abstract/30\">",
"      Kishimoto TK, Viswanathan K, Ganguly T, et al. Contaminated heparin associated with adverse clinical events and activation of the contact system. N Engl J Med 2008; 358:2457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18778/abstract/31\">",
"      Schwartz LB. Heparin comes clean. N Engl J Med 2008; 358:2505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18778/abstract/32\">",
"      Akin C, Scott LM, Kocabas CN, et al. Demonstration of an aberrant mast-cell population with clonal markers in a subset of patients with \"idiopathic\" anaphylaxis. Blood 2007; 110:2331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18778/abstract/33\">",
"      Lin RY, Schwartz LB, Curry A, et al. Histamine and tryptase levels in patients with acute allergic reactions: An emergency department-based study. J Allergy Clin Immunol 2000; 106:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18778/abstract/34\">",
"      Smith PL, Kagey-Sobotka A, Bleecker ER, et al. Physiologic manifestations of human anaphylaxis. J Clin Invest 1980; 66:1072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18778/abstract/35\">",
"      Kaliner M, Sigler R, Summers R, Shelhamer JH. Effects of infused histamine: analysis of the effects of H-1 and H-2 histamine receptor antagonists on cardiovascular and pulmonary responses. J Allergy Clin Immunol 1981; 68:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18778/abstract/36\">",
"      Chrusch C, Sharma S, Unruh H, et al. Histamine H3 receptor blockade improves cardiac function in canine anaphylaxis. Am J Respir Crit Care Med 1999; 160:1142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18778/abstract/37\">",
"      Godot V, Arock M, Garcia G, et al. H4 histamine receptor mediates optimal migration of mast cell precursors to CXCL12. J Allergy Clin Immunol 2007; 120:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18778/abstract/38\">",
"      Dunford PJ, Williams KN, Desai PJ, et al. Histamine H4 receptor antagonists are superior to traditional antihistamines in the attenuation of experimental pruritus. J Allergy Clin Immunol 2007; 119:176.",
"     </a>",
"    </li>",
"    <li>",
"     Lieberman PL. Anaphylaxis. In: Middleton's allergy: Principles and practice, 7th ed, Adkinson NF, Bochner BS, Busse WW, et AL (Eds), Mosby, St. Louis 2009. p.1027.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18778/abstract/40\">",
"      Pumphrey RS. Fatal anaphylaxis in the UK, 1992-2001. Novartis Found Symp 2004; 257:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18778/abstract/41\">",
"      Sampson HA, Mendelson L, Rosen JP. Fatal and near-fatal anaphylactic reactions to food in children and adolescents. N Engl J Med 1992; 327:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18778/abstract/42\">",
"      Schwartz LB. Effector cells of anaphylaxis: mast cells and basophils. Novartis Found Symp 2004; 257:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18778/abstract/43\">",
"      Mertes PM, Laxenaire MC, Alla F, Groupe d'Etudes des R&eacute;actions Anaphylacto&iuml;des Peranesth&eacute;siques. Anaphylactic and anaphylactoid reactions occurring during anesthesia in France in 1999-2000. Anesthesiology 2003; 99:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18778/abstract/44\">",
"      Akin C. Anaphylaxis and mast cell disease: what is the risk? Curr Allergy Asthma Rep 2010; 10:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18778/abstract/45\">",
"      Bonadonna P, Perbellini O, Passalacqua G, et al. Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels. J Allergy Clin Immunol 2009; 123:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18778/abstract/46\">",
"      Ru&euml;ff F, Przybilla B, Bil&oacute; MB, et al. Predictors of severe systemic anaphylactic reactions in patients with Hymenoptera venom allergy: importance of baseline serum tryptase-a study of the European Academy of Allergology and Clinical Immunology Interest Group on Insect Venom Hypersensitivity. J Allergy Clin Immunol 2009; 124:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18778/abstract/47\">",
"      Arias K, Baig M, Colangelo M, et al. Concurrent blockade of platelet-activating factor and histamine prevents life-threatening peanut-induced anaphylactic reactions. J Allergy Clin Immunol 2009; 124:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18778/abstract/48\">",
"      Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987; 327:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18778/abstract/49\">",
"      Marsden PA, Brenner BM. Nitric oxide and endothelins: novel autocrine/paracrine regulators of the circulation. Semin Nephrol 1991; 11:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18778/abstract/50\">",
"      Coleman JW. Nitric oxide: a regulator of mast cell activation and mast cell-mediated inflammation. Clin Exp Immunol 2002; 129:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18778/abstract/51\">",
"      Mitsuhata H, Shimizu R, Yokoyama MM. Role of nitric oxide in anaphylactic shock. J Clin Immunol 1995; 15:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18778/abstract/52\">",
"      Lowenstein CJ, Michel T. What's in a name? eNOS and anaphylactic shock. J Clin Invest 2006; 116:2075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18778/abstract/53\">",
"      Cauwels A, Janssen B, Buys E, et al. Anaphylactic shock depends on PI3K and eNOS-derived NO. J Clin Invest 2006; 116:2244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18778/abstract/54\">",
"      Juhlin L, Hammarstr&ouml;m S. Effects of intradermally injected leukotriene C4 and histamine in patients with urticaria, psoriasis and atopic dermatitis. Br J Dermatol 1982; 107 Suppl 23:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18778/abstract/55\">",
"      Arm JP, Lee TH. Sulphidopeptide leukotrienes in asthma. Clin Sci (Lond) 1993; 84:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18778/abstract/56\">",
"      Austen KF. The Paul Kall&oacute;s Memorial Lecture. From slow-reacting substance of anaphylaxis to leukotriene C4 synthase. Int Arch Allergy Immunol 1995; 107:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18778/abstract/57\">",
"      Flower RJ, Harvey EA, Kingston WP. Inflammatory effects of prostaglandin D2 in rat and human skin. Br J Pharmacol 1976; 56:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18778/abstract/58\">",
"      Hardy CC, Robinson C, Tattersfield AE, Holgate ST. The bronchoconstrictor effect of inhaled prostaglandin D2 in normal and asthmatic men. N Engl J Med 1984; 311:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18778/abstract/59\">",
"      Pugliese G, Spokas EG, Marcinkiewicz E, Wong PY. Hepatic transformation of prostaglandin D2 to a new prostanoid, 9 alpha,11 beta-prostaglandin F2, that inhibits platelet aggregation and constricts blood vessels. J Biol Chem 1985; 260:14621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18778/abstract/60\">",
"      Goetzl EJ. Oxygenation products of arachidonic acid as mediators of hypersensitivity and inflammation. Med Clin North Am 1981; 65:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18778/abstract/61\">",
"      Raible DG, Schulman ES, DiMuzio J, et al. Mast cell mediators prostaglandin-D2 and histamine activate human eosinophils. J Immunol 1992; 148:3536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18778/abstract/62\">",
"      Goetzl EJ, Wasserman SI, Austen F. Eosinophil polymorphonuclear leukocyte function in immediate hypersensitivity. Arch Pathol 1975; 99:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18778/abstract/63\">",
"      Erjefalt JS, Korsgren M, Malm-Erjefalt M, et al. Acute allergic responses induce a prompt luminal entry of airway tissue eosinophils. Am J Respir Cell Mol Biol 2003; 29:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18778/abstract/64\">",
"      Pumphrey R. Anaphylaxis: can we tell who is at risk of a fatal reaction? Curr Opin Allergy Clin Immunol 2004; 4:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18778/abstract/65\">",
"      De Souza RL, Short T, Warman GR, et al. Anaphylaxis with associated fibrinolysis, reversed with tranexamic acid and demonstrated by thrombelastography. Anaesth Intensive Care 2004; 32:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18778/abstract/66\">",
"      Anne' S, Middleton E Jr, Reisman RE. Vancomycin anaphylaxis and successful desensitization. Ann Allergy 1994; 73:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18778/abstract/67\">",
"      Choi IH, Ha TY, Lee DG, et al. Occurrence of disseminated intravascular coagulation (DIC) in active systemic anaphylaxis: role of platelet-activating factor. Clin Exp Immunol 1995; 100:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18778/abstract/68\">",
"      JAMES LP Jr, AUSTEN KF. FATAL SYSTEMIC ANAPHYLAXIS IN MAN. N Engl J Med 1964; 270:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18778/abstract/69\">",
"      Brown SG. The pathophysiology of shock in anaphylaxis. Immunol Allergy Clin North Am 2007; 27:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18778/abstract/70\">",
"      Raper RF, Fisher MM. Profound reversible myocardial depression after anaphylaxis. Lancet 1988; 1:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18778/abstract/71\">",
"      Marone G, Bova M, Detoraki A, et al. The human heart as a shock organ in anaphylaxis. Novartis Found Symp 2004; 257:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18778/abstract/72\">",
"      Wittstein IS, Thiemann DR, Lima JA, et al. Neurohumoral features of myocardial stunning due to sudden emotional stress. N Engl J Med 2005; 352:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18778/abstract/73\">",
"      Kounis NG. Kounis syndrome (allergic angina and allergic myocardial infarction): a natural paradigm? Int J Cardiol 2006; 110:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18778/abstract/74\">",
"      Abela GS, Picon PD, Friedl SE, et al. Triggering of plaque disruption and arterial thrombosis in an atherosclerotic rabbit model. Circulation 1995; 91:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18778/abstract/75\">",
"      Steffel J, Akhmedov A, Greutert H, et al. Histamine induces tissue factor expression: implications for acute coronary syndromes. Circulation 2005; 112:341.",
"     </a>",
"    </li>",
"    <li>",
"     Lieberman P. Anaphylaxis and anaphylactoid reactions. In: Middleton's allergy: Principles and practice, Adkinson NF, Yunginger JW, Busse WW (Eds), Mosby, St. Louis, MO 2003. p.1497.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18778/abstract/77\">",
"      Rubin LE, Levi R. Protective role of bradykinin in cardiac anaphylaxis. Coronary-vasodilating and antiarrhythmic activities mediated by autocrine/paracrine mechanisms. Circ Res 1995; 76:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18778/abstract/78\">",
"      Schuligoi R, Amann R, Donnerer J, Peskar BA. Release of calcitonin gene-related peptide in cardiac anaphylaxis. Naunyn Schmiedebergs Arch Pharmacol 1997; 355:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18778/abstract/79\">",
"      Rang WQ, Du YH, Hu CP, et al. Protective effects of calcitonin gene-related peptide-mediated evodiamine on guinea-pig cardiac anaphylaxis. Naunyn Schmiedebergs Arch Pharmacol 2003; 367:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18778/abstract/80\">",
"      Summers CW, Pumphrey RS, Woods CN, et al. Factors predicting anaphylaxis to peanuts and tree nuts in patients referred to a specialist center. J Allergy Clin Immunol 2008; 121:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18778/abstract/81\">",
"      Fisher MM. Clinical observations on the pathophysiology and treatment of anaphylactic cardiovascular collapse. Anaesth Intensive Care 1986; 14:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18778/abstract/82\">",
"      Pumphrey RS. Fatal posture in anaphylactic shock. J Allergy Clin Immunol 2003; 112:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18778/abstract/83\">",
"      van der Linden PW, Struyvenberg A, Kraaijenhagen RJ, et al. Anaphylactic shock after insect-sting challenge in 138 persons with a previous insect-sting reaction. Ann Intern Med 1993; 118:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18778/abstract/84\">",
"      Brown SG, Blackman KE, Stenlake V, Heddle RJ. Insect sting anaphylaxis; prospective evaluation of treatment with intravenous adrenaline and volume resuscitation. Emerg Med J 2004; 21:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18778/abstract/85\">",
"      Demetriades D, Chan LS, Bhasin P, et al. Relative bradycardia in patients with traumatic hypotension. J Trauma 1998; 45:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18778/abstract/86\">",
"      Schadt JC, Ludbrook J. Hemodynamic and neurohumoral responses to acute hypovolemia in conscious mammals. Am J Physiol 1991; 260:H305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18778/abstract/87\">",
"      Szebeni J, Baranyi L, S&aacute;vay S, et al. Complement activation-related cardiac anaphylaxis in pigs: role of C5a anaphylatoxin and adenosine in liposome-induced abnormalities in ECG and heart function. Am J Physiol Heart Circ Physiol 2006; 290:H1050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18778/abstract/88\">",
"      Kovanen PT, Kaartinen M, Paavonen T. Infiltrates of activated mast cells at the site of coronary atheromatous erosion or rupture in myocardial infarction. Circulation 1995; 92:1084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18778/abstract/89\">",
"      Greenberger PA, Rotskoff BD, Lifschultz B. Fatal anaphylaxis: postmortem findings and associated comorbid diseases. Ann Allergy Asthma Immunol 2007; 98:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18778/abstract/90\">",
"      Pumphrey RS, Roberts IS. Postmortem findings after fatal anaphylactic reactions. J Clin Pathol 2000; 53:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18778/abstract/91\">",
"      Fink MP. Bench-to-bedside review: Cytopathic hypoxia. Crit Care 2002; 6:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/21/18778/abstract/92\">",
"      Dewachter P, Jouan-Hureaux V, Franck P, et al. Anaphylactic shock: a form of distributive shock without inhibition of oxygen consumption. Anesthesiology 2005; 103:40.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 386 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-197.136.42.3-BBD4CCF919-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_21_18778=[""].join("\n");
var outline_f18_21_18778=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H34\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PROPOSED IMMUNOPATHOLOGIC MECHANISMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Terminology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Immunologic anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - IgE-mediated",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - IgG-mediated (in animal models)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Immune complex/complement mediated",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Other proposed mechanisms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Nonimmunologic anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Regulation of mast cell activation in anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      CHEMICAL MEDIATORS OF ANAPHYLAXIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Mast cells and basophils",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Histamine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Tryptase",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Platelet activating factor",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Nitric oxide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Arachidonic acid metabolites",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Modulatory mediators",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Eosinophils",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Serum factors and other inflammatory pathways",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Changes in target cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      ORGAN SYSTEMS IN ANAPHYLAXIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Cardiovascular system",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Effects of mediators",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Responses to fluid shifts",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Body posture",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Bradycardia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Exacerbation of underlying cardiac disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Respiratory system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Autopsy findings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      ANAEROBIC METABOLISM COMPLICATES ANAPHYLAXIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      TEMPORAL COURSE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5688518\">",
"      Factors affecting the time course",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5688532\">",
"      Temporal patterns",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5688397\">",
"      - Biphasic anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5688404\">",
"      - Protracted anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/386\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/386|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/30/42469\" title=\"figure 1\">",
"      Allergen sensitization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/48/17153\" title=\"figure 2\">",
"      IgG anaphylaxis mice",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/26/33191\" title=\"figure 3\">",
"      Omalizumab mechansim",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/386|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/36/21068\" title=\"table 1\">",
"      Symptoms and signs of anaphylaxis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38391?source=related_link\">",
"      An overview of angioedema: Pathogenesis and causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=related_link\">",
"      Anaphylaxis: Rapid recognition and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/46/17130?source=related_link\">",
"      Anti-IgE therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/24/19847?source=related_link\">",
"      Biphasic and protracted anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/59/11190?source=related_link\">",
"      Complement pathways",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/25/7576?source=related_link\">",
"      Cryofibrinogenemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/13/1241?source=related_link\">",
"      Fatal anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/36/31305?source=related_link\">",
"      Immediate hypersensitivity reactions to radiocontrast media: Clinical manifestations, diagnosis, and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/57/43930?source=related_link\">",
"      Infusion reactions to systemic chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/54/40809?source=related_link\">",
"      Laboratory tests to support the clinical diagnosis of anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/28/20937?source=related_link\">",
"      Mast cell activation disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/22/44393?source=related_link\">",
"      Mast cells: Development, identification, and physiologic roles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/28/20936?source=related_link\">",
"      Mast cells: Surface receptors and signal transduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/63/22522?source=related_link\">",
"      Overview of cryoglobulins and cryoglobulinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/35/27194?source=related_link\">",
"      Overview of hemostasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/57/15250?source=related_link\">",
"      Patient information: Anaphylaxis symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?40/14/41186?source=related_link\">",
"      Patient information: Anaphylaxis treatment and prevention (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/6/31848?source=related_link\">",
"      The biology of IgE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33930?source=related_link\">",
"      Therapeutic use of heparin and low molecular weight heparin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/59/1978?source=related_link\">",
"      Vancomycin hypersensitivity",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_21_18779="Poisons and drugs amenable to hemodialysis";
var content_f18_21_18779=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F82353&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F82353&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Common agents for which hemodialysis enhances elimination",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Barbiturates",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bromides",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Alcohols",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Ethanol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Isopropanol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Acetone&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Methanol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Ethylene glycol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lithium",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Procainamide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Theophylline",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Salicylates",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Heavy metals (possible)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Trichloroethanol/Chloral hydrate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Atenolol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sotalol",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_21_18779=[""].join("\n");
var outline_f18_21_18779=null;
var title_f18_21_18780="Causes cardiogenic shock";
var content_f18_21_18780=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F69673&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F69673&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of cardiogenic shock",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Acute myocardial infarction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Pump failure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Large infarction, generally involving &ge;40 percent of the left ventricle",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Smaller infarction with preexisting left ventricular dysfunction or a prior infarction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Infarction extension or expansion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Reinfarction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Mechanical complications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Acute mitral regurgitation caused by rupture of a papillary muscle or chordae tendinae or severe papillary muscle dysfunction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Ventricular septal defect caused by rupture of the interventricular septum",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Left ventricular free wall rupture",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Pericardial tamponade due to rupture of the left ventricular free wall or hemorrhagic pericardial effusion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Right ventricular infarction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Other conditions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        End-stage cardiomyopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Myocarditis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Septic shock with severe myocardial depression",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Left ventricular outflow tract obstruction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Aortic stenosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Hypertrophic obstructive cardiomyopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Obstruction to left ventricular filling",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Mitral stenosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Left atrial myxoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute mitral regurgitation (chordal rupture)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute aortic insufficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Myocardial contusion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prolonged cardiopulmonary bypass",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Hollenberg SM, Kavinsky CJ, Parrillo JE. Ann Intern Med 1999; 131:47.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_21_18780=[""].join("\n");
var outline_f18_21_18780=null;
var title_f18_21_18781="Nephropathy and control";
var content_f18_21_18781=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F73143&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F73143&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Strict glycemic control prevents moderately increased albuminuria (formerly called microalbuminuria) in patients with type 1 diabetes mellitus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 369px; height: 213px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cumulative incidence of moderately increased albuminuria (formerly called microalbuminuria) in patients with type 1 diabetes treated with either conventional or intensive insulin therapy for up to nine years. There was an increasing benefit of intensive therapy over time (p &lt;0.04).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from The Diabetes Control and Complications Trial Research Group, N Engl J Med 1993; 329:977.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_21_18781=[""].join("\n");
var outline_f18_21_18781=null;
var title_f18_21_18782="Approach to the child with pseudovertigo";
var content_f18_21_18782=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F77547&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F77547&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 500px\">",
"   <div class=\"ttl\">",
"    Approach to the child with pseudovertigo",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 480px; height: 454px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     EKG: electrocardiogram.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Teach SJ. Dizziness. In: Textbook of Pediatric Emergency Medicine, 6th ed, Fleisher GR, Ludwig S (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_21_18782=[""].join("\n");
var outline_f18_21_18782=null;
var title_f18_21_18783="Capillary loop PI";
var content_f18_21_18783=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F61209&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F61209&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Swelling of the blood vessels in the nail fold in a person with dermatomyositis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 334px; height: 295px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of John H. Stone, MD, MPH.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_21_18783=[""].join("\n");
var outline_f18_21_18783=null;
